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Abstract
Background
Androgen deprivation therapy (ADT) is associated with numerous adverse effects
that impact on quality of life and contribute further to the cost burden of prostate cancer
(PCa) via treatment and supportive care. Exercise medicine is effective in slowing PCa
progression, reversing treatment adverse effects and improving quality of life and
survival of patients, however, no economic analyses have been conducted to
determine whether exercise is cost-effective in this population.

Objectives
Firstly, to examine the adverse effects of ADT for PCa and the evidence supporting
the use of exercise medicine in their management. Secondly, to conduct the first
economic evaluations of exercise medicine in the management of the adverse effects
of ADT for PCa to strengthen the evidence base for the development of effective health
policy around exercise and PCa survivorship.

Methods
A systematic review was conducted to determine the incidence of the adverse
effects of ADT for PCa. A rapid review examined the role of exercise in managing
these adverse effects. Three economic evaluations were then conducted to determine
the cost-effectiveness of supervised exercise for men with PCa receiving ADT. Two
trial-based cost-effectiveness analyses (CEAs) compared exercise training and usual
care (a suggestion to exercise). The first involved a preliminary randomised controlled
trial (RCT) of exercise for 20 men with metastatic PCa. A value of information (VOI)
analysis was also conducted to examine the need for and value of a larger trial. The
second CEA involved a RCT of exercise for men previously treated with radiation
therapy and ADT. For the third economic evaluation, a decision analytic Markov model
was constructed to evaluate the cost-effectiveness of an exercise intervention in
preventing falls and fractures for men with localised or locally advanced PCa receiving
ADT. All economic analyses were conducted from a healthcare payer perspective and
the primary outcome measure was quality adjusted life years (QALYs) gained.
Uncertainty in the results was explored using deterministic univariate and probabilistic
sensitivity analysis where appropriate.

Results
The systematic review generated incidence evidence for nine adverse effect groups
and 19 sub-groups, with statistically significant increased risks in 17 sub-groups. The
iii

rapid review revealed that exercise was effective in improving body composition,
physical function and fatigue, as well as mitigating the bone loss, sexual dysfunction
and psychosocial effects associated with ADT. The first within-trial CEA of exercise for
men with metastatic PCa resulted in an incremental cost-effectiveness ratio (ICER) of
$133,509 and a 30% probability of being cost-effective after three months at a
willingness-to-pay of AU$50,000. VOI analysis suggested further research is likely to
be cost-effective to conduct. The second within-trial CEA of exercise for men who
received radiation therapy and adjuvant ADT for localised PCa resulted in an ICER of
$64,235 and a 41 per cent probability of cost-effectiveness after six months at a
willingness-to-pay of AU$50,000. For the modelled cost-utility analysis, the exercise
intervention dominated usual care (a suggestion to exercise), as it was less costly and
more effective. Net monetary benefit (NMB) was $102,112 and probabilistic sensitivity
analysis showed a 58% probability of cost-effectiveness at a willingness-to-pay of
AU$50,000.

Conclusion
This research is the first to examine the cost-effectiveness of exercise for men
with PCa receiving ADT. Supervised exercise is effective in managing many adverse
effects of PCa treatment and cost saving in preventing falls and fractures. Future
efforts need to focus on strengthening the evidence base in exercise for ADT adverse
effect management. Uncertainty in economic evaluation can be reduced with more
comprehensive cost and outcome data, longer follow up and larger sample sizes. This
research has the potential to translate into changes in clinical practice, better informed
policy decisions, cost savings for healthcare payers, and ultimately, better health and
quality of life for PCa patients, survivors and their families.
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Chapter 1 General Introduction
Cancers are a major contributor to the burden of disease in Australia and have a
considerable effect on the physical and emotional wellbeing of patients and their
families. There is also a substantial social and economic impact, representing
significant costs to the individual, family, community and the economy in terms of
healthcare provision, absence from work, quality of life and premature mortality.
Cancer accounts for about one-fifth (19%) of the total disease burden in Australia,
making it the leading cause(1). An ageing population, lifestyle, environmental factors
and diagnostic testing have resulted in an increasing number of cancer diagnoses in
Australia in recent years. In 2020, it is estimated that almost 145,000 new cases of
cancer will be diagnosed and there will be around 48,000 deaths from cancer(2). New
developments in cancer therapy, a more personalised approach to medicine and new
technologies contribute to the increasing costs of care. In addition, more people now
survive a cancer diagnosis and require supportive care(3). In 2008-2009, according to
the latest available data, cancer was responsible for $4.5 billion in allocated health
expenditure, amounting to 4% of all government health expenditure(4).

1.1 Prostate cancer
Prostate cancer (PCa) is an increasingly significant public health issue. It is a
heterogeneous disease with a high incidence and the cause of significant morbidity
and mortality. In Australian men, it is the most commonly diagnosed cancer and the
second most common cause of cancer death after lung cancer(2). In 2020, it is
estimated 16,741 new cases of cancer will be diagnosed; in age-standardised rates,
that is an estimated incidence of 110 cases per 100,000 males(2). Australia and New
Zealand have the highest incidence rate in the GLOBOCAN database, which includes
estimates of the incidence, mortality and prevalence for 36 types of cancer and for all
cancers combined in 185 countries in the world(5). An estimated 3,152 Australian
males are expected to die from PCa in 2020, corresponding to an age-standardised
mortality rate of 21 deaths per 100,000 males(2).
PCa is an age-related disease and the incidence rate is expected to increase with
age, peaking between 70 and 74 years of age, before decreasing with age. In 2020,
there were an estimated 3498 cases of prostate cancer diagnosed in the 70-74 year
age group(2). To age 75, the risk of PCa is one in seven men and by age 85, the risk
increases to one in six, however less than 10% of men die from PCa(2). In 2020, the 51

year survival rate was estimated to be 95%(2). Stage of PCa is a major contributor to
survival. Men with local (organ confined) or regional disease (in the region of the
prostate) have a 5-year survival rate of almost 100%, whereas men with distant
metastatic disease have a 5-year survival rate of 36%(2). In Australia, over 80% of
men are diagnosed with Stage I or II PCa(2). With the advent of increased testing,
incidence of local and regional disease is increasing and metastatic disease is
decreasing(6). The staging of PCa, the grading system used to determine prognosis,
and ultimately inform the treatment pathway, are explicated below (Tables 3, 4 & 5).
The specific causes of PCa remain unknown; the only established risk factors are
age, race or ethnicity and family history(7). The prostate is known to undergo structural
changes as a result of diet, and hormonal changes that take place with ageing, which
leads to alterations in genetic expression(7). While diet and lifestyle cannot be
conclusively associated with an increased risk of prostate cancer, smoking does
increase risk of mortality due to PCa, and obesity is associated with cases of higher
grade and fatal disease(6). Insulin growth factor-1 (IGF-1), which is responsible for
promoting cell proliferation and inhibiting programmed cell death, has been associated
with PCa progression which provides a potential link with westernised diet, obesity and
metabolic factors like insulin resistance(8). However, it is androgens and the androgen
receptor that play a fundamental role in the development and progression of PCa(9).
1.11 Androgen deprivation therapy
In 1941, Huggins and Hodges(10) demonstrated that androgens fuel cancer growth
and that androgen suppression, in the form of surgical (bilateral orchiectomy) or
medical castration (oestrogen treatment), resulted in prostate cancer regression. This
discovery heralded the beginning of hormone therapy as a treatment for advanced
PCa. Two retrospective studies in the late 1940’s and early 1950’s concluded that
patients treated with hormonal therapy (either oestrogens or orchiectomy) enjoyed a
survival and quality-of-life advantage over patients in the pre-hormonal therapy era(11,
12).
While surgical castration is not associated with the same increases in myocardial
infarction, coronary heart disease and cardiac death as some medications, it has
largely been replaced by medical castration for reasons including reversibility, ease of
administration, and cosmetic and psychological concerns(13, 14). Medical castration
was initially carried out using oestrogen. However, oestrogens were associated with
significant adverse effects such as thromboembolic and cardiovascular risk, as well as
2

feminisation(13-15). Since the development of luteinizing hormone-releasing hormones
(LHRH) agonists and antagonists in the 1980’s, oestrogen therapy fell largely out of
favour. Since that time, medical means of androgen deprivation therapy (ADT) other
than oestrogen have been the standard first-line therapy for metastatic prostate cancer.
ADT has also been shown to have survival benefits for men with locally advanced or
high-risk localised disease. Its use, however, has increased across the spectrum of
disease(16). The use of ADT to treat many stages and grades of tumour among men of
all ages has the potential to generate considerable costs to the individual, healthcare
providers, and society. The types of ADT currently available in Australia and their
modes of action are shown in Table 1 below.
Table 1 Androgen deprivation medications currently used in Australia
Type
GnRH/LHRH agonist

Androgen receptor
blockers (anti-androgens)
Steroidal

What it does
Inhibits GnRH release from the testes
with continuous delivery to suppress
testosterone production
Inhibits GnRH release from the testes
by binding to pituitary GnRH receptors
decreasing circulating levels of
testosterone

Format
injection

GnRH/LHRH antagonist

Technical name
goserelin
leuprorelin
triptorelin
degarelix

cyproterone acetate

Inhibits androgen receptor (AR) &
central nervous system effects
Inhibits AR, thereby reducing the
stimulation of PCa cells

tablet

Blocks several steps in the AR
signalling pathway: binding to the AR;
nuclear translocation of activates
receptor; and association of the
translocated receptor with DNA
Inhibits androgen production at all
sources: adrenal glands, testes, tumour

tablet

Non-steroidal -1st generation
Non-steroidal - 2nd generation

Adrenal androgen
inhibitors

bicalutamide
flutamide
nilutamide
enzalutamide
apalutamide

abiraterone acetate +
prednisone/
methylprednisolone

injection

tablet

tablet

Abbreviations: GnRH gonadotrophin releasing hormones; LHRH luteinizing hormone-releasing hormones

Use of ADT is associated with significant adverse effects. These are numerous and
can be particularly debilitating, even life threatening, so are a fundamental
consideration in choice of treatment modality(14). As shown in Table 2, the range of
adverse effects is broad and can be categorised into nine different groups according to
the Common Terminology Criteria for Adverse Events (CTCAE) Version 5(17). A
detailed discussion of the adverse effects associated with ADT, including their
incidence/risk is presented in Chapter 2.
3

Table 2 Adverse effects of androgen deprivation therapy
Adverse effect group (CTCAE)

Sub-group

1

Musculoskeletal changes

Bone loss, osteoporosis, fracture

2

Metabolic changes

3

Cardiac disorders

4

Nervous system disorders

Body composition changes (increased fat mass, decreased
muscle mass and strength), metabolic syndrome, diabetes
Cardiovascular events (myocardial infarction, cardiac arrest,
cardiovascular mortality)
Cognitive impairment, stroke, dementia

5

Vascular disorders

Hypertension, thromboembolic events, hot flashes

6

Hepatobiliary disorders

Hepatic disorders

7

Reproductive system disorders

Gynaecomastia, breast pain, sexual dysfunction

8

Psychiatric disorders

Depression

9

General disorders

Fatigue, Gait disturbance

Abbreviations: CTCAE Common terminology criteria for adverse events

Adverse effects and their treatment are an important consideration in terms of the
economic impact of ADT for PCa. For example, Lee et al.(18) found significant utility
decrements for patients experiencing adverse events (fracture, musculoskeletal event,
joint related symptoms, serious cardiovascular events) across all algorithms mapped to
four health related quality of life questionnaires. The following section is an
examination of the treatment of PCa and highlights the importance of ADT within
treatment algorithms.

1.2 Prostate cancer treatment
Current treatment guidelines for PCa take a number of factors into
consideration(16). A key determinant of primary treatment is estimated life expectancy
which uses age and current quartile of health. Risk assessment involves consideration
of serum PSA level, biopsy result, clinical tumour stage (size of tumour and how far it
has spread) and Gleason score (abnormality of cancer tissue). The Gleason score is
used to assign a histologic Grade group from 1 – 5 to express the aggressiveness of
the cancer (Table 3) and the Tumour-Node-Metastasis staging system is used to
determine the stage of the cancer (Table 4) (16, 19). How these systems are combined
to determine prognostic groups and treatment is shown in Table 5. Other factors that
impact on the risk of PCa and inform treatment decision making are family and
personal history, as well as patient preferences(16).

4

Table 3 Prostate cancer grade groups
Grade group
1
2
3
4
5

Gleason score1
≤6
7
7
8
9 or 10

Gleason pattern2
≤3+3
3+4
4+3
4+4, 3+5, 5+3
4+5, 5+4, 5+5

Notes: 1Gleason score is the grading system used to score PCa aggressiveness (healthy cells-lower; unhealthy cells-higher). 2Gleason
pattern refers to a composite score comprising the primary grade (cells that make up the largest area) and the secondary grade (cells
that make up the next largest area).

Table 4 Prostate cancer staging system
Prostate cancer stage
Definition
Clinical tumour (cT) descriptors
T
Primary tumour
TX
Primary tumour cannot be assessed
T0
No evidence of primary tumour
T1
Clinically inapparent tumour that is not palpable
T1a
Tumour in 5% or less of biopsy tissue
T1b
Tumour in more than 5% of biopsy tissue
T1c
Tumour identified by needle biopsy found in one or both sides, not palpable
T2
Tumour is palpable and confined within prostate
T2a
Tumour involves one-half of one side or less
T2b
Tumour involves more than one-half of one side but not both sides
T2c
Tumour involves both sides
T3
Extra prostatic tumour that is not fixed or does not invade adjacent structures
T3a
Extra-prostatic extension (unilateral or bilateral)
T3b
Tumour invades seminal vesicle(s)
T4
Tumour is fixed or invades adjacent structures other than seminal vesicles
such as external sphincter, rectum, bladder, levator muscles, and/or pelvic wall
Lymph Node descriptors
N
Regional lymph nodes
NX
Regional lymph nodes cannot be assessed
N0
No positive regional nodes
N1
Metastases in regional node(s)
Metastases descriptors
M
Distant metastases
M0
No distant metastases
M1
Distant metastases
M1a
Non-regional lymph nodes
M1b
Bone(s)
M1c
Other site(s) with or without bone disease
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Table 5 Prostate cancer prognostic groups
Group

T

N

M

PSA (ng/mL)

Grade Group

Stage I

cT1a-c
cT2a
pT2
cT1a-c
cT2a
pT2
cT2b
cT2c
T1-2
T1-2
T1-2
T1-2
T3-4
Any T
Any T
Any T

N0
N0
N0
N0
N0
N0
N0
N0
N0
N0
N0
N0
N0
N0
N1
Any N

M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M0
M1

PSA <10
PSA <10
PSA <10
PSA ≥10 <20
PSA ≥10 <20
PSA ≥10 <20
PSA <20
PSA <20
PSA <20
PSA <20
PSA <20
PSA <20
Any PSA
Any PSA
Any PSA
Any PSA

1
1
1
1
1
1
1
1
2
3
4
1-4
1-4
5
Any
Any

Stage IIA

Stage IIB
Stage IIC
Stage IIIA
Stage IIIB
Stage IIIC
Stage IVA
Stage IVB

Abbreviations: PSA prostate specific antigen; ng/mL nanograms per milliliter; cT clinical tumour; pT pathological tumour
Notes: see Table 4 for tumour (T), lymph node (N), Metastases (M) descriptors

1.2.1 Treatment options
In order to address the potential for overtreatment of PCa, it is recommended that
men with a life expectancy of five years or less with very low, low or intermediate risk
disease and no symptoms receive no workup or treatment until symptoms develop.
Those with high or very high-risk PCa should undergo bone imaging and, if regional or
metastatic disease is found, receive ADT. Observation is also an option if the risks and
complications associated with treatment are considered greater than the benefits in
terms of prolonged life or improved quality of life. Where there is no nodal involvement
or metastases but high risk, external beam radiotherapy (EBRT) may be recommended
(16).
For men with life expectancy of five years or more, treatment determination is
based on assessment of risk guided by the prognostic groupings in Table 5. However,
PCa is a complex disease with much controversy surrounding its management. A
number of different primary treatment modalities are used for PCa such as observation,
active surveillance, EBRT, radical prostatectomy or brachytherapy and ADT. Low risk,
early stage disease tends to be treated with curative therapies such as prostatectomy,
EBRT or brachytherapy, whereas ADT (LHRH agonist or orchiectomy) tends to be
used for more unfavourable or high-risk disease, where there is regional or lymph node
involvement (N1) or high risk of metastasis (M0). Androgen deprivation (LHRH agonist
or LHRH agonist + antiandrogen) may also be used as a neoadjuvant, concurrent
and/or adjuvant therapy with radiation therapy in such cases, with or without
6

abiraterone and prednisone or methylprednisolone. If the tumour is metastatic,
orchiectomy or ADT of varied forms (i. LHRH agonist; ii. LHRH agonist + antiandrogen;
iii. LHRH antagonist or iv. - i. or iii. + abiraterone with prednisone or
methylprednisolone) are the treatments of choice (sometimes with the addition of
chemotherapy-docetaxel)(16).
Once the tumour becomes resistant to the initial ADT, referred to as castrate
resistant prostate cancer (CRPCa), ADT should be maintained to keep testosterone
levels low and additional therapies applied. For non-metastatic CRPCa, additional
therapies include addition of or switching to a different antiandrogen, (flutamide,
bicalutamide, nilutamide, enzalutamide or apalutamide). For metastatic CRPCa,
additional therapies include a different antiandrogen (as above, with the exception of
apalutamide), an adrenal androgen inhibitor (abiraterone acetate + prednisone or
methylprednisolone), docetaxel, palliative radiation therapy for bone metastases,
immunotherapy (sipuleucel-T). Visceral metastases (liver, lung, adrenal, peritoneal,
and brain) can be treated with the addition of all of the above (with the exception of
sipuleucel-T), as well as chemotherapy (mitoxantrone + prednisone). With progression,
subsequent therapy depends on prior therapy (whether docetaxel, enzalutamide or
abiraterone + prednisone or methylprednisolone), but includes various forms of
chemotherapy, secondary hormone therapy or immunotherapy (pembrolizumab)(16). It
is evident from the above treatment guidelines that ADT is used broadly across the
PCa disease spectrum, with the exception, in most circumstances, of lower risk,
localised cancer.

1.3 Economic impact of ADT medications
The economic impact of ADT in Australia is significant. Based on Medicare
services listed in the Medicare Benefits Schedule (MBS) and medicines listed on the
Pharmaceutical Benefits Scheme (PBS), government expenditure for PCa treatment in
2012 (from initial appointment prior to diagnosis to 12 months post diagnosis) was
highest for men receiving ADT ($16,883 per person) compared to other treatments
such as EBRT ($13,310), orchiectomy ($13,282) and radical prostatectomy (RP)
($7,653)(AUD 2012)(20). Mean out-of-pocket (OOP) costs (AUD 2012) were also
highest for men receiving ADT ($11,471) compared to watchful waiting ($5,492), active
surveillance ($10,302) and RP ($10,996)(21). The broader application of ADT over
time has resulted in a marked increase in the number of men receiving ADT for PCa in
Australia. One study estimated an increase from 16,000 patients in 2003-2004 to
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23,500 in 2008-2009(22, 23). Allan et al.(24) reported a steady increase of over 300%
from 6,500 men using ADT in 1999-2000 to 21,800 in 2009-2010.
A number of ADT medications are currently available in Australia, however, GnRH
agonists are most commonly used (Table 1)(25, 26). Medicare Australia(27), through
the PBS, records the use and cost of ADT medications. The volume and cost of many
ADT medications are still high and increasing, despite the reductions in cost associated
with medications transitioning out of patent and being produced as multibranded/generic pharmaceuticals(28). Cost figures are thus conservative indications of
the real cost. For example, the cost of some generic medications fall below the copayment, so do not register in any PBS cost or volume data(29).
Trends in PBS expenditure show that while prescriptions for generic medicines are
becoming more popular than in the past, contributing to over 60% of prescription
volumes in 2010/11, single patented medications account for 60% of government
expenditure for the same period(29). This trend can be explained by some medicines
coming out of patent, adding to volumes but not much to expenditure, while new,
patented and costly medicines are also being released. This trend is demonstrated in
Figure 1, where more recently released and costly single patented ADT drugs, like
abiraterone acetate and degarelix, are rising more markedly in use, in contrast to
generic drugs like leuprorelin and goserelin. It is these changes in practices that are
also contributing to the rising cost of ADT medication.
It is important to note from Figure 1 that these estimates of ADT cost do not include
the cost of the GP consult, patient co-payments or the cost associated with script
dispensing. Nor do they include the cost of associated clinical treatments such as
prostatectomy, radiotherapy or chemotherapy or the costs of supportive care. Some of
these treatments could also have been provided in public hospitals and therefore not
appear as MBS and PBS costs. In addition, not all ADT related costs could be
included. One form of goserelin is used to treat breast cancer and endometriosis as
well as PCa, so this cost was not included. Similarly, in the case of abiraterone acetate,
which must be administered with a corticosteroid, it was not possible to distinguish
administration of the corticosteroid for PCa purposes from other purposes, so this cost
was also excluded. Over the period 2010 – 2018 (results January 2010 to November
30, 2018), the cost of ADT to the PBS has been $1.5 billion(30). This cost has
increased each year and in 2018 the cost of ADT stood at $247 million(30). Goserelin,
the most commonly used drug for the 2010-2018 period accounted for 34% of total
costs ($492 million), followed by leuprorelin at 22% of total costs ($318 million),
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enzalutamide at 20% of total costs ($285 million) after less than 5 years on the PBS,
and abiraterone acetate at 16% of total costs ($227 million) after less than 6 years on
the PBS. Other ADT drugs, comprising triptorelin, bicalutamide, flutamide, nilutamide
and degarelix together had a 10% share of total costs ($76 million)(30). With the
advent of new generation drugs like abiraterone acetate in 2013 and enzalutamide in
2014, costs for ADT have escalated, increasing over 1.5 times between 2013 and 2014
and by almost 2.5 times between 2013 and 2018. The share of total cost has also
changed over the last five years. Enzalutamide holds a 27% share equal to goserelin,
abiraterone acetate a 21% share and leuprorelin,18%. While the cost of ADT
medications is significant, one cost that is often not considered is that of the adverse
effects associated with treatment. ADT adverse effects and their consequent treatment,
as well as the supportive care often needed, have the potential to add further costs to
the considerable expense of ADT medication in the treatment of PCa. How much extra
cost depends on how prevalent and how debilitating the adverse effects are, in addition
to the cost of treating or managing them.
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Figure 1 Cost of androgen deprivation therapy Australia 2000-2018 PBS (30)

ADT, in one form or another, is the only treatment used across the spectrum of
PCa disease and therefore has the potential to generate considerable costs to the
individual and society. The incidence of PCa increases with age, so with the
demographic transition towards an ageing population and a greater uptake of PSA
testing, the burden and cost of PCa is only likely to increase(31). This emphasises the
importance of finding a cost-effective way of managing the adverse effects of ADT for
PCa.

1.4 Exercise and the management of the side effects of ADT
It has been extensively demonstrated that physical exercise is an effective therapy
that slows PCa progression, reverses treatment adverse effects and improves the
wellbeing and quality of life of cancer patients(32-37). An early review of exercise
interventions for cancer patients revealed evidence of benefits such as reduced
fatigue, improved muscle function and physical performance, increased aerobic
capacity, improved body composition and quality of life(38). Researchers focusing on
PCa noted the impact of ADT adverse effects, reporting clinically significant decreases
in lean muscle mass and strength as well as impaired physical functioning. Patients
receiving ADT also had lower bone mineral density and increased fat mass compared
to controls(39, 40). Research identifying further ADT adverse effects such as metabolic
syndrome, heightened risk of diabetes and cardiovascular disease (CVD), prompted
exercise physiologists to research the impact of exercise on preventing or reversing
these adverse effects(41). Resistance exercise improved muscle strength, functional
performance and balance, as well as maintaining body composition and reducing ADT
adverse effects such as fatigue and levels of C-reactive protein(42). In addition, high
intensity exercise was found not to impact on ADT efficacy(43). Further studies showed
that exercise was beneficial for patients receiving both short term and long term
ADT(44). As some of the adverse effects of ADT required a longer exercise
intervention to demonstrate any benefits (bone loss, diabetes and CVD risk), a
comprehensive randomized controlled trial (RCT) was conducted to determine the
impact of exercise over 12 months(45). A significant finding from this RCT was that
different modes of exercise address different aspects of ADT toxicity(46).
This growing body of evidence led to the publication, in 2009, of the Australian
position statement on exercise and cancer that participating in exercise during and
after cancer treatment is associated with benefits such as improvements in physical
and psychosocial outcomes, reduced impact of disease symptoms and treatment
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related side effects and better survival. The exercise prescription was moderate
intensity exercise for at least 20 minutes 3-5 times per week, involving aerobic,
resistance or mixed exercise(47). In 2010, a roundtable of experts was convened by
the American College of Sports Medicine to develop exercise guidelines for cancer
survivors(48). Their review of RCTs concluded that exercise for PCa survivors was
safe, reduced fatigue and improved aerobic fitness, body composition, muscle
strength, physical function and quality of life. The guidelines recommended that PCa
survivors should aim to achieve a minimum of 150 minutes of moderate aerobic
exercise a week, including at least two sessions of resistance exercises.
It wasn’t until 2011, however, that a health professionals follow-up study examined
physical activity and survival after PCa diagnosis(37). This study demonstrated a 49%
lower risk of all-cause mortality and a 61% lower risk of PCa death in a sample of
2,705 men diagnosed with non-metastatic disease. A recent systematic review of the
literature around the effects of exercise on the treatment related effects of ADT for PCa
demonstrated improvements in lean body mass, muscular strength, physical function,
cardiorespiratory fitness and fatigue with varied effects for adiposity(49). Exercise has
thus been shown to be critical to health and quality of life, as well as survival, for PCa
survivors.
In 2019, the Exercise and Sports Science Australia (ESSA) position statement and
the American College of Sports Medicine (ACSM) guidelines were updated with current
scientific evidence, clinical experience and exercise science principles. They
emphasise the importance of an appropriate exercise prescription for cancer patients,
which is individualised and targeted for the specific health issues most impacting the
patient (50, 51). The ACSM guidelines for cancer survivors recommend moderate
intensity aerobic training at least three times per week, for at least 30 minutes. The
addition of resistance exercise to aerobic training, at least twice a week, using at least
two sets of eight to 15 repetitions, results in similar benefits, though evidence suggests
resistance training alone may not be enough (51). The ESSA guidelines recommend a
more tailored approach with exercise mode and dosage prescribed specifically to
ameliorate, in priority order, the health issues and mortality risks of greatest concern for
the patient. Both these documents were based on extensive research reviews to
ascertain the strength of evidence supporting the use of exercise for cancer patients
and survivors. Strong evidence was available for a number of cancer-related
outcomes: anxiety and depression, fatigue, health related quality of life (HRQoL) and
physical function. Moderate evidence was also available for bone health and sleep.
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While organisations such as the American Society of Clinical Oncology (ASCO)
(52), the National Comprehensive Cancer Network (53) and the National Institute for
Care and Excellence(54) have PCa survivorship guidelines that support exercise for
adverse effect management, few cancer patients are able to meet these guidelines due
to reasons of access to the level of care required, time constraints, physical,
psychological and financial capacity, as well as concerns regarding the risk of
inappropriate and potentially detrimental types and doses of exercise(55). More
targeted and tailored guidelines alongside implementation strategies and policy support
are needed to contribute to increased uptake of these evidence based guidelines(55).
Aside from the effectiveness of exercise in PCa adverse effect management,
exercise is emerging not only as a targeted medicine delaying progression, reducing
the risk of recurrence or improving survival(51, 56), but also as a synergistic medicine,
increasing the effectiveness of other concomitant therapies such as chemotherapy or
radiation therapy(56). While considerable evidence exists to support the use of
exercise as an essential part of a cancer treatment and care plan, there has been
limited uptake of this approach(57). Exercise has the potential to generate significant
cost savings as well as improve quality of life for this population. It is expected that the
use of exercise in cancer management may translate into health and economic
benefits in improved quality of life and fewer complications, resulting in savings to the
health care system through potential reductions in adverse effects and chronic
diseases, enhanced productivity and reduced patient and carer burden.

1.5 Purpose
ADT is the standard first-line therapy for metastatic prostate cancer but also
improves survival in men with non-metastatic, locally advanced or high-risk localised
prostate cancer. It thus represents a significant cost in the treatment of PCa. In
addition, ADT is associated with debilitating adverse effects with the potential to
generate further costs from their subsequent treatment. Some adverse effects
contribute to the development of chronic disease and long-term health utilisation and
reduced quality of life. There is, therefore, a need for management strategies that
minimise the burden of PCa treatment. A growing body of research has shown that
exercise is effective at reducing and even preventing the adverse effects of ADT for PC
survivors. Exercise also has the potential to manage the side effects of ADT in a costeffective manner. To date, there has been no attempt to quantify the economic impact
of exercise programs on PCa survivors, the healthcare system and society. The
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purpose of this doctoral research, therefore, is to determine the economic impact of
exercise in managing the adverse effects of ADT.
A comprehensive economic analysis of the role of exercise in the management of
PCa would be invaluable in guiding effective policy and investment in health services.
Given the broad application of ADT, across the disease spectrum, the economic
analyses conducted in this thesis will include different stages of PCa. A systematic
literature review will first set the scene for the research objective by evaluating the
evidence on the adverse effects associated with ADT and their risk or incidence.
Two retrospective cost-effective analyses (CEAs) will be conducted alongside
randomised controlled trials (RCTs) of exercise in the management of ADT adverse
effects for two different populations(34, 36). Given the limitations associated with
economic analyses of clinical trials such as lack of data (costs, outcome data
applicable to economic analysis, missing data), small sample size and relatively short
follow up, a modelled analysis will be conducted of the costs and consequences of
exercise for the management of physical function decrements arising from ADT toxicity
in the form of reduced muscle strength and increased bone loss. This modelled
analysis will incorporate evidence from the literature, outcomes from clinical trials and
expert knowledge to determine the cost-effectiveness of exercise in reducing falls and
fractures for men with PCa receiving ADT. Discussion of the findings of this doctoral
research, its implications, limitations and future directions, are provided in the final
chapter.

1.6 Research questions
The research questions addressed in this doctoral research are:
1. What is the risk or incidence of the most common adverse effects of ADT for
PCa patients? (Chapter 2)
2. What is the role of exercise in managing these adverse effects? (Chapter 3)
3. What is the cost-effectiveness of exercise in managing the adverse effects of
PCa?
•

CEA 1: What is the cost-effectiveness of exercise in the management of
advanced PCa or bone metastatic disease? (Chapter 5)

•

CEA 2: What is the cost-effectiveness of exercise in counteracting the
long-term adverse effects associated with ADT for localised/locally
advanced PCa? (Chapter 6)
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•

CEA 3: What is the cost effectiveness of exercise in reducing falls and
fractures for men with PCa receiving ADT: a modelled cost-utility
analysis? (Chapter 7)

4. What are the implications of exercise in the management of adverse effects
of ADT for PCa? (Chapter 8)

1.7 Significance of the study
Australia’s expenditure on health is growing at a faster rate than national income,
therefore policy makers need to know what works, at what cost and how society will
benefit from the investment. This doctoral research is significant in its potential to
inform how exercise can reduce the significant burden of PCa in relation to its expense
and contribution to reducing premature morbidity and mortality. While the effectiveness
of exercise in reversing or even preventing many adverse effects of ADT for PCa is
widely recognised, to date, no economic analyses have been conducted to
demonstrate the impact of exercise on health and economic outcomes. The findings
from this doctoral research will contribute to knowledge and strengthen the evidence
base for the development of effective health policy. The outcomes of this research
could mean changes to clinical practice, improved economic analysis of exercise
interventions, better health and quality of life for PCa patients, survivors and their
families, as well as cost savings or better return on investment for funding bodies.
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Chapter 2 Incidence of the adverse effects of androgen
deprivation therapy for prostate cancer: a systematic literature
review
2.1 Introduction
Since the advent of PSA testing in the 1990s, the rising incidence and burden of
prostate cancer (PCa) has been a cause for concern. Treatment options for men with
PCa are varied and depend on a number of factors such as expected survival, risk of
progression, stage and grade of cancer at diagnosis, age and health of the patient,
family history, personal preferences of the patient and adverse effects of treatment.
Androgen deprivation therapy (ADT) suppresses the production of androgen, which
fuels the growth of PCa. It has broad application in the treatment of PCa and many
types of ADT are currently in use in Australia (Table 6). ADT is predominantly used for
intermediate or higher risk disease as well as advanced and metastatic cancer. It is
also maintained when cancer becomes castration resistant. In addition, it is used as
neo-adjuvant, concurrent and adjuvant therapy with prostatectomy and
radiotherapy(16, 58-60).
Table 6 Androgen deprivation medications currently used in Australia
Type
GnRH/LHRH agonist

Androgen receptor blockers
(anti-androgens)
Steroidal

What it does
Inhibits GnRH release from the testes
with continuous delivery to suppress
testosterone production
Inhibits GnRH release from the testes
by binding to pituitary GnRH
receptors decreasing circulating
levels of testosterone

Format
injection

GnRH/LHRH antagonist

Technical name
goserelin
leuprorelin
triptorelin
degarelix

cyproterone acetate

Inhibits androgen receptor (AR) &
central nervous system effects
Inhibits AR, thereby reducing the
stimulation of PCa cells

tablet

Blocks several steps in the AR
signalling pathway: binding to the AR;
nuclear translocation of activates
receptor; and association of the
translocated receptor with DNA
Inhibits androgen production at all
sources: adrenal glands, testes,
tumour

tablet

Non-steroidal -1st generation
Non-steroidal - 2nd generation

Adrenal androgen inhibitors

bicalutamide
flutamide
nilutamide
enzalutamide
apalutamide

abiraterone acetate +
prednisone/
methylprednisolone

injection

tablet

tablet

Abbreviations: GnRH gonadotropin-releasing hormone; LHRH luteinising hormone-releasing hormone

ADT for PCa is associated with numerous and often debilitating adverse effects.
The National Institute of Cancer defines an adverse effect as: “an unexpected medical
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problem that happens during treatment with a drug or other therapy. Adverse effects
may be mild, moderate, or severe, and may be caused by something other than the
drug or therapy being given. Also called an adverse event.”(61). The increasing use of
ADT for PCa, the longer timeframe for treatment (an outcome of increased uptake of
PSA testing and earlier diagnosis), as well as improved survival and an ageing
population, means patients can live for a considerable period of time on, or after, ADT,
experiencing these adverse effects(62). While much has been published on the
adverse effects of ADT for PCa in recent years, and a number of systematic reviews
exist(63-85), some of these do not include current studies or newer ADTs. No single
systematic review has previously comprehensively examined the evidence for all
adverse effects.
Characterising adverse effects is beneficial for several reasons. Firstly, incidence of
adverse effects will provide valuable information for future burden of disease studies
and better guide clinical management to reduce symptoms for patients. Secondly, in
this era of shared decision making, such information will assist patients to make more
informed decisions about their treatment, thus facilitating compliance with their
treatment plan and potentially improving disease outcomes. For analysts conducting
economic evaluations, inclusion of adverse effect incidence in PCa decision analytic
models can provide more comprehensive and accurate information for decision
makers. The purpose of this paper, therefore, is to systematically review the current
literature on ADT for PCa to identify the highest available level evidence of
risk/incidence of common adverse effects. Given the nature of current evidence, this
review will comprise a review of existing systematic reviews, supplemented where
necessary by evidence drawn from individual studies.

2.2 Methods
Using an a priori defined protocol, this systematic review was conducted as per
Cochrane guidelines (86). In order to locate the most recent high-level evidence and not
duplicate previous research, a systematic search was conducted as outlined below.
2.2.1 Identification - search strategy
A PRISMA compliant systematic search of the literature on the adverse effects of
ADT for PCa was conducted for the years 2010-February 2019)(86, 87). Figure 2
shows the search process (identification, screening, eligibility & inclusion). The study
screening and selection process consisted of three phases. First, a search was
conducted to identify original articles in the following electronic databases: Medline,
17

Embase, PsycInfo, and Cochrane Library. The search strings comprised terms for PCa,
adverse effects and ADT medications (Appendix 1). Where databases allowed,
searches were limited to English language, humans. Language limitations were based
on review time frames and language capacity of team members; pre-clinical trial
research using animals was not relevant to adverse effect incidence, and given the
rapidly changing landscape of PCa treatment, a period of ten years of evidence
generation was deemed adequate by the research team. A Google Scholar search of
adverse effects of ADT for PCa was also conducted.
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Identification

Records identified through
database searching (Medline &
PsycInfo [1161],
Embase[65],Cochrane Library[27])
n=1253

Additional records
identified through
other sources
(Google Scholar
& hand search)
n=6
Records excluded according to eligibility criteria:

Included

Eligibility

Screening

Duplicates removed
n=31

Records screened
(Systematic Review n=67
(Other n=1161)
Total n=1228

Full-text articles assessed
for eligibility
(Systematic Review n=32)
(Other n=86)
Total n=118

Studies included in
qualitative synthesis
(SR n=25)
(Other n=14)
Total n=39

*not ADT for prostate cancer
*not adverse effects of ADT/incidence
*not a peer review journal article (letter, conference abstract,
study protocol, editorial, comment, etc.)
*irrelevant/not prostate cancer
*not English
*not human/preclinical trial
*low level evidence
*AE management only
(Systematic Review n=35)
(Other n=1075)
Total n=1110
3.Full-text adverse effect articles excluded, with reasons
*no AE/specific incidence data
*study quality too weak
*higher level evidence available
*equivalent, more recent evidence available
*not ADT
(Systematic reviews n=7)
(Other n=72)
Total n=79

Figure 2 PRISMA flow diagram ADT adverse effects
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2.2.2 Classification of studies
Identified studies were then classified using a three-step process.
Step 1: Screening

Titles and abstracts of the retrieved articles were screened following the PICOS
criteria in Table 7.
Table 7 PICOS inclusion and exclusion criteria
Parameter
Population
Intervention
Comparator
Outcomes
Study design

Inclusion criteria
Men with PCa receiving ADT
ADT for PCa
No ADT or other PCa treatment
Major adverse effects of ADT;
incidence, rate or risk
Systematic review, RCT,
observational study, populationbased study, cohort study

Exclusion criteria
Men with prostate cancer not receiving ADT
Other forms of PCa treatment
Adverse effects without incidence, rate or risk
evidence
Irrelevant/not PCa; not a peer-reviewed article;
descriptive or review article; not English language;
does not involve human subjects

Abbreviations: PCa prostate cancer; ADT androgen deprivation therapy; RCT randomised controlled trial

Step 2a: Classification of adverse effect groupings

The remaining records were classified into adverse effect groupings using Common
Terminology Criteria for Adverse Events (CTCAE) Version 5.0(17) to enable
comparison of available evidence for specific adverse effects (Table 8).
Step 2b: Identifying highest level of evidence

In order to have incidence data supported by the highest level of evidence
available, classification of articles was guided by the Oxford Centre for Evidence-based
Medicine (OECBM) 2011 Levels of Evidence(88, 89). Studies were classified into: A.
systematic reviews; B. analytic studies, comprising i) experimental studies such as
RCTS and ii) observational studies; and C. descriptive studies. Systematic reviews
were prioritised; where they did not provide the evidence required, RCTs were the next
level of evidence included. Observational studies were maintained until step three, in
the event that higher level studies did not address adverse effect incidence. Descriptive
studies were excluded.
The full text versions of the remaining records were obtained and independently
assessed for eligibility by two reviewers (KE & HT). Disagreements were resolved
through consensus. Where studies of equal quality and evidence level were found, all
results were recorded to strengthen the evidence collected. Remaining lower evidence
articles were then excluded. The following exclusion criteria were applied with the
benefit of full text information: not highest level of evidence available; no incidence
information; more recent but equivalent evidence available. Finally, the reference lists
of included studies were manually reviewed to identify articles not located by the
electronic database search.
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2.2.3 Data extraction
Data was extracted from the included studies by one reviewer (KE) and
independently reviewed by a second reviewer (HT). For each study, information was
recorded on: first author, year and country where study was conducted; sample size
and setting; study type, study outcomes or incidence data; and risk of bias or quality
assessment.
2.2.4 Methodological quality of systematic reviews and single studies
Quality assessment of included systematic reviews was conducted using the
AMSTAR 2, a critical appraisal tool for systematic reviews that include randomised or
non-randomised studies of healthcare interventions, or both(90). Included individual
studies were critically appraised using Cochrane Collaboration recommended tools
ROB 2(91) for RCTs and the Newcastle-Ottawa Scale(NOS)(92) for cohort studies(86,
93). Risk of bias or quality ratings were independently assessed by KE and HT to
address the possibility of rating error. Any discrepancies were addressed via
consensus. Systematic reviews receiving a critically low rating were excluded from the
evidence synthesis.
2.2.5 Analysis
Given that the purpose and characteristics of the included individual studies
(sample populations, treatment types, PCa stages, patient age, control groups, adverse
effect examined and outcomes measured) varied considerably across studies, a metaanalysis was not appropriate for the purposes of this review. Instead, evidence of the
highest level available was collected and compared for each adverse effect and a
range of scores recorded to ensure the most rigorous incidence data was generated by
this systematic review.

2.3 Results
The search of databases located 1,253 records. Google Scholar and a survey of
reference lists generated a further six records (n=1,259). Thirty-one duplicates were
removed electronically. A total of 1,228 records remained for screening. After
preliminary screening of titles and abstracts, 1110 studies that did not match the
inclusion criteria were removed. A total of 118 studies remained. Thirty-two full text
systematic reviews met the inclusion criteria and were evaluated for adverse effect
incidence. Evidence was generated for incidence of body composition changes, bone
loss, osteoporosis, metabolic syndrome, diabetes, hypertension, CVD risk,
thromboembolisms, hepatoxicity, fatigue, body feminisation, vasomotor flushing,
depression, cognitive function and dementia. The remaining single studies (n=86) were
then examined for evidence of adverse effect incidence not generated by the
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systematic reviews (osteoporosis, hepatotoxicity, gait disturbance, fracture, sexual
function) (Table 8). The highest level of evidence generating comprehensive data (e.g.
including sufficient stages of PCa and types of ADT) were included in the evidence
synthesis for these adverse effects. Thirty-nine studies (25 systematic reviews + 14
individual studies) were judged eligible for inclusion in the review. Detailed information
extracted from the 39 studies was recorded in the summary of findings table (Appendix
2).
The following section examines each of the adverse effect sub-groups in turn,
summarising study characteristics and adverse effect incidence.
Table 8 Adverse effect groups and evidence consulted for incidence
Group

Adverse effect (CTCAE)

1

Musculoskeletal changes

2

Metabolic changes

3

Cardiac disorders

4

Nervous system disorders

5

Vascular disorders

6

Hepatobiliary disorders

7

Reproductive system disorders

8

Psychiatric disorders

9

General disorders

Adverse effect sub-group
a) Bone loss
b) Osteoporosis
c) Fracture
a) Body composition changes
b) Metabolic syndrome
c) Diabetes
a) Cardiovascular events
a) Cognitive impairment
b) Stroke
c) Dementia
a) Hypertension
b) Thromboembolic events
c) Hot flashes
a) Hepatic disorders
a) Gynaecomastia and breast pain
b) Sexual dysfunction
a) Depression
a) Fatigue
b) Gait disturbance

Abbreviations: SR systematic review; IS individual study; CTCAE Common Terminology Criteria for Adverse Events
Notes: Some studies have multiple adverse effect outcomes so may count more than once

Studies (n)
1 (SR)
1 (IS)
8 (IS)
1 (SR)
1 (SR)
2 (SR)
11 (SR)
2 (SR)
3 (SR)
1 (SR)
4 (SR)
2 (SR)
5 (SR)
2 (SR); 1 (IS)
3 (SR)
2 (SR); 2 (IS)
2 (SR)
3 (SR)
4 (IS)

2.3.1 Musculoskeletal changes
1a. Bone loss

ADT increases bone turnover and causes significant, progressive decrements in
bone mineral density (BMD) in men with PCa, contributing to an increased risk of
osteoporosis and fractures. The magnitude of bone loss rates tends to be higher early
in treatment, but also decreases steadily during long term treatment(94). The extent of
bone loss differs for measurement site and duration of ADT. One systematic review
included five prospective cohort studies of localised or advanced PCa treated with
orchiectomy, luteinising hormone releasing hormone (LHRH) agonist or anti-androgen
(69). Controls varied across the studies as did treatment duration, with heterogeneity
ranging from 82-99%. Pooled analysis of four studies (n=483) determined mean
percent bone loss for lumbar spine of -3.6% (95% CI -6.72, -0.47, p=0.02). Five studies
(n=515) recorded bone loss for femoral neck of -3.11% (95% CI -4.73, -1.48, p=0.02).
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Mean per cent bone loss for total hip derived from four studies (n=483) was -1.59%
(95% CI -2.99, -0.19, p=0.03)(69).
1b Osteoporosis

ADT induced bone loss is further exacerbated by already high levels of
osteoporosis in the ageing population. Studies in UK(95)and US(96) have reported
levels of around 40% for osteoporosis and between 40% and 50% for osteopenia in
men with PCa initiating ADT. The risk of osteoporosis is heightened by age and
comorbidities common in this population. One recent retrospective cohort study
conducted in Australia using Pharmaceutical Benefits Scheme (PBS) data involved a
10% random sample of the PCa population receiving their first ADT between 2004 and
2010 compared to a matched population not receiving anti-neoplastic agents or having
no comorbidities at baseline(97). There was significant risk of developing osteoporosis
in the ADT PCa population: hazard ratio (HR) 1.65 (95% CI 1.48, 1.85). An adjusted
HR was also calculated for incidence of osteoporosis stratified by duration of ADT
exposure: ≤ 1 year 1.38 (95% CI 1.10,1.72) and > 1 year 1.77 (1.55-2.02)(97).
1c Fracture

Two RCTs and six cohort studies with data on incidence of fractures in men
receiving ADT met the inclusion criteria for this review. Two studies focussed on
localised PCa; one included recipients of ADT alone, curative treatment and ADT, and
orchiectomy(98), the other men received radical prostatectomy or radiotherapy
with/without ADT(99). Four studies focussed on advanced cancer, one included only
men with non-metastatic PCa receiving any type of ADT or orchiectomy(100), another,
men with metastatic PCa comparing gonadotropin releasing hormone (GnRH) agonists
with orchiectomy(101), the third, men with advanced cancer receiving intermittent ADT
(IADT)(102), and the fourth, men receiving GnRH agonists only with non-metastatic or
metastatic PCa(103). Two RCTs examined second generation treatments for nonmetastatic(104) and metastatic castrate resistant PCa (CRPCa)(105). These studies
established a significant association between ADT and incidence of fracture across the
disease spectrum, and identified factors that elevate risk such as age, ADT dose and
duration, time from last dose, osteoporosis, metastases and dementia.
2.3.2 Metabolic changes
2a Body composition changes

Body composition changes increase with duration of treatment and comorbidities;
they tend to be greater in the first three months and continue over time but less rapidly
to six months and longer(67). A meta-analysis by Haseen et al.(67) reported significant
changes in body composition for men receiving ADT. Pooled analysis was conducted
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from 16 studies (14 cohort and 2 RCTs) which varied in type of ADT and stage of PCa.
Analyses included seven studies for increases in body fat mass of 7.7% (95% CI
4.3,11.2, p<0.00001), six for decreases in lean mass of 2.8% (95% CI -3.6, -12.0,
p<0.00001), nine for increases in body weight of 2.1% (95% CI 1.35, 2.94, p<0.00001)
and eight for increases in body mass index (BMI) of 2.2% (95% CI 1.16, 3.14,
p<0.0001). Heterogeneity was quite high across the studies included for each body
composition change, 99%, 73%, 55% and 63%, respectively. Sub analyses for ADT
type showed that luteinising hormone releasing hormone (LHRH) had greater impact
on body composition changes than combination therapy with anti-androgen.
2b Metabolic syndrome

Men receiving ADT tend to experience adverse changes in the following metabolic
features: decreased lean mass, increased fat mass (together known as sarcopenic
obesity), increased waist circumference, alterations in lipids and decreased insulin
sensitivity(106, 107). One systematic review of ADT induced metabolic syndrome
incorporated data for meta-analysis from four cohort studies and five cross sectional
studies(64). The type of ADT varied across studies from any type of ADT in five
studies, GnRH agonist, combined androgen blockade, orchiectomy and anti-androgens
in one study and orchiectomy alone in two. The relative risk (RR) of acquiring metabolic
syndrome was 75% higher for men with PCa receiving ADT compared to those not
receiving ADT (RR 1.75; 95% CI 1.27, 2.41)(64).
2c Diabetes

Two systematic reviews generated data on diabetes incidence. The Bosco et al.
(64) review mentioned above reported a RR of 1.36 (95% CI 1.17, 1.58) for men
receiving ADT. Wang et al.(83), pooled data for meta-analysis from four cohort and four
cross sectional studies. Incidence of diabetes amongst men receiving ADT (GnRH
agonists, combined androgen blockade or orchiectomy) was 10.9% (83). The risk of
diabetes was 39% higher for these men than for men not receiving ADT or men on
watchful waiting or active surveillance (RR 1.39; 95%CI 1.27-1.53, P<0.001)(83). Sub
group analyses for ADT type and duration showed that GnRHa, combined androgen
blockade and orchiectomy are significantly associated with risk of diabetes, and longer
duration of ADT with elevated risk(83).
2.3.3 Cardiac disorders: Cardiovascular (CV) complications and mortality
Since a large observational analysis of Surveillance, Epidemiology and End Results
(SEER) Medicare data demonstrated a significant association between GnRH and
incident coronary heart disease, hospital admission for myocardial infarction (MI) and
sudden cardiac death in men with PCa, the question of whether ADT increases the risk
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of CV events or CV mortality has been raised(108). A systematic review conducted in
2009 showed that ADT is associated with a 17% increased risk of cardiovascular
mortality(109). This analysis, however, was based on only two observational studies
and two RCTs. Since that time, studies of CV risk for ADT recipients have proliferated
and systematic reviews have been conducted of CV risk factors such as hypertension,
as well as CV events including MI and CV mortality. While the included systematic
reviews focus on CV adverse events, the outcomes measured differ, as do type of
ADT, stage of PCa and comparators. Attempts were made to address heterogeneity
via pooled meta-analyses, within trial analyses or analyses by study.
There was an increased risk of CV mortality for all types of ADT and for MI or
stroke from GnRH agonists, anti-androgens and orchiectomy combined. For ADT type,
orchiectomy has the highest risk ratio and anti-androgens(63, 84) or IADT(68, 71) the
lowest risk compared to no ADT. The risk for CV events was similar across types of
ADT and varied dependent largely on the comparator, as the study by Scailteux
shows(80). One systematic review found no significant differences in risk for CV
mortality between ADT and controls across all included studies(77). In other reviews,
degarelix reduced the risk of CV events compared to GnRHa, as did IADT(68, 71, 81).
There was a strong association between grade 3 cardiac adverse events and grade 3/4
vascular events and arbiraterone acetate + prednisone compared to placebo(79). This
impact was lower for all grade events. The relative risk of CV events with enzalutamide
was lower than that for arbiraterone acetate(85, 110).
2.3.4 Nervous system disorders
4a Cognitive impairment

Two systematic reviews examined incidence of cognitive impairment from ADT(72,
111). Sun et al.(82) conducted a meta-analysis of six cohort studies, two of which were
prospective and resulted in an odds ratio (OR) of 1.56 (0.50, 4.91, p=0.441). The
remaining four retrospective sub-groups included men with senile dementia and
Alzheimer’s disease, and while the risk of cognitive impairment was higher, it was not
statistically significant (HR 1.28; 95% CI 0.93, 1.76 p=0.130). They concluded that
results could not reliably confirm the relationship between ADT and cognitive
impairment. A second meta-analysis of 14 studies suggested that for men receiving
ADT for PCa, there was insufficient evidence to support cognitive decline with the
exception of compromised visuomotor skills, where a significant decline was reported.
The weighted average effect was -0.67 (95% CI -1.17, -0.17; P=0.008)(72). The extent
of the deficit was also larger with shorter time to follow-up. However, there was
insufficient evidence to determine whether these deficits were primarily motor related,
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that is arising from ADT related muscle loss, or evidence of low testosterone related
deficits in visuospatial skill. The authors concluded that ADT recipients can expect
cognitive functioning to be similar to that of men with PCa not receiving ADT and men
without PCa, however, clinicians and patients need to be aware of the potential for
visuomotor impairment when deciding on treatment(72).
4b Stroke

Two meta-analyses were conducted to determine incidence of stroke. Meng et
al.(73) found a significant association between stroke and some types of ADT. Pooled
analyses of GnRH alone resulted in a HR of 1.20 (95% CI 1.12, 1.28, P<0.001); GnRH
+ anti-androgen, a HR of 1.23 (95% CI 1.13, 1.34, P<0.001); and orchiectomy a HR.
1.37 (1.33-1.46, P<0.001). The HR for all ADT showed a higher incidence for ADT
recipients compared to control groups, (HR1.12; 95% CI 0.95, 1.32), but no significant
association. Another meta-analysis conducted pooled analyses of a range of different
types of ADT showing a significant association between stroke and ADT(80). For
example, in the only RCT, RR of GnRH agonist compared to GnRH antagonist was
3.44 (95% CI 0.22, 1.32). In observational studies, results varied considerably between
different types of ADT with greater relative risk for GnRH agonists and orchiectomy
compared to anti-androgens and combined androgen blockade (CAB).
4c Dementia

Men receiving ADT have increased circulating β-amyloid protein levels, the
accumulation of which characterizes Alzheimer’s disease(75). Men diagnosed with
dementia tend to have lower testosterone levels and impaired cognitive function, which
for recipients of ADT, has been noted from as early as six months post treatment
initiation(75). One systematic review conducted a meta-analysis of studies reporting
any dementia outcome showed an increased risk associated with ADT (HR 1.47; 95%
CI 1.08, 2.00; p= 0.02). Studies reporting all cause dementia and Alzheimer’s disease
were also analysed separately resulting in hazard ratios of 1.46 (95% CI 1.05–
2.02; p<0.001) and 1.25 (95% CI 0.99, 1.57; p<0.06), respectively. Current evidence
thus suggests that ADT may be associated with an increased risk of dementia(75).
2.3.5 Vascular disorders
5a Hypertension

Hypertension is one of the strongest risk factors for all CV diseases and is strongly
associated with age. ADT, particularly second generation hormonal agents such as
abiraterone acetate and enzalutamide, is associated with significant increases in risk of
hypertension. Four systematic reviews generated data on the incidence of
hypertension for men receiving ADT for PCa (78, 85, 110, 112). One showed a higher
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incidence of long-term hypertension with radiotherapy and GnRH agonists than with
the use of anti-androgens (12% vs 4%)(112). Arbiraterone acetate and enzalutamide
compared to placebo or other forms of ADT was associated with a high risk of
hypertension higher than that for CV events in three systematic reviews (78, 85, 110).
5b Thromboembolic events

Population-based studies of men receiving ADT for PCa have revealed an
association between ADT and increased risk of thromboembolic events such as deep
vein thrombosis (DVT) and pulmonary embolus (PE). Two meta-analyses examined
the evidence for ADT associated thromboembolic events(66, 74). One restricted the
analysis to five cohort studies which compared GnRH agonists alone, GnRH agonists +
anti-androgens, anti-androgens alone and orchiectomy with no ADT(66). In this metaanalysis, DVT was significantly associated with GnRH agonist alone (HR 1.47; 95% CI
1.07, 2.03 p=0.017), GnRH agonist + anti-androgen (HR 2.55; 95% CI 2.1, 2.94,
p<0.001) and anti-androgen alone (HR 1.49; 95% CI 1.13, 1.96, p=0.004), but not with
orchiectomy (HR 1.80 95% CI 0.93, 3.47, p=0.07). Pulmonary embolism was
significantly associated with GnRH agonist alone (HR 2.26; 95% CI 1.78, 2.86,
p<0.001) and orchiectomy (HR 2.12; 95% CI 1.44, 3.11, p<0.001)(66). The other
systematic review included oestrogens in addition to the above-mentioned forms of
ADT and drew evidence from 20 studies comparing ADT with no ADT, short term ADT
and IADT(74). In this meta-analysis, ADT without oestrogen in 10 studies caused a
significant increase in risk of thromboembolic events (RR 1.43; 95% CI 1.15, 1.77,
p<0.001) as did oestrogen alone in 9 nine studies (RR 3.72; 95% CI 1.78, 7.80,
p<0.001). Sub analyses comparing disease stage demonstrated a significantly
increased risk of thromboembolic events from ADT without oestrogen and oestrogen
alone for both localized (RR 1.10; 95% CI 1.05,1.16, p=<0.001) and metastatic disease
(RR 1.58; 95% CI 1.24, 2.03, p <0.001), but not for studies of continuous vs intermittent
ADT. Sub analyses examining impact of ADT duration showed a significantly increased
risk of thromboembolic events for duration >12months. Significant heterogeneity was
resolved in ADT without oestrogen analysis for localized disease (0%) but not for the
metastatic disease analysis (84%) or the oestrogen only analysis (71%)(74).
5c Hot flashes

Five systematic reviews referred to incidence of vasomotor flushing across various
treatments and stages of PCa from locally advanced to metastatic CRPCa(70, 71, 81,
85, 112). Anti-androgens have a significantly lower risk of flashing than orchiectomy
(RR 0.23; 95% CI 0.10, 0.27)(70) and GnRH agonists (<1% vs 45%)(112).
Enzalutamide has a significantly increased risk of flashing compared to bicalutamide or
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placebo (RR 1.94; 95% CI 1.55, 2.42)(85). There was no significant difference in
flashing between CADT and IADT(71) or between degarelix and GnRH agonists(81).
2.3.6 Hepatobiliary disorders
Two systematic reviews examined incidence of hepatotoxicity; one from ADT +
abiraterone acetate + prednisone compared to placebo for metastatic hormone
sensitive PCa (HR 3.09; 95% CI 2.12, 4.50, P<0.001)(79), and one from abiraterone
acetate + prednisone compared to placebo for CRPCa (all grade RR 1.93; 95% CI
1.15, 3.24, p=0.01 & high grade RR 2.94; 95% CI 0.95, 9.08, p=0.06) (78). A large
population-based study (n=82,938) using SEER-Medicare data for 1992-2009 found a
significantly increased risk of any liver disease (HR 1.47, 95% CI 1.35, 1.60), nonalcoholic fatty liver disease (NAFLD) (HR 1.54, 95% CI 1.40, 1.68), liver cirrhosis (HR
1.35, 95% CI 1.12, 1.60), and liver necrosis (HR 1.41. 95% CI 1.15, 1.72) for men with
PCa receiving GnRH agonists and antagonists(113).
2.3.7 Reproductive system disorders
7a Gynaecomastia and breast pain

Gynaecomastia and breast pain are common adverse effects of non-steroidal antiandrogen therapy (bicalutamide, flutamide), and less so, GnRHa therapy, that can
seriously impact men’s masculinity and quality of life(65, 114). Three systematic
reviews analysed the incidence data(70, 71, 112). Two studies reported that, compared
to GnRH agonists, non-steroidal anti-androgen therapy was associated with a
significantly increased risk of gynaecomastia (RR 8.43; 95% CI 3.19-22.28)(70) and
70% vs 11%(112). One of these studies also reported a 23 fold increased risk of breast
pain pooled from eight studies (RR 22.97; 95% CI 14.79, 35.67)(70). There was a
lower risk of gynaecomastia for IADT compared to CADT (RR 0.63; 95% CI 0.36, 1.10)
but the difference was not statistically significant(71).
7b Sexual dysfunction

Sexual dysfunction, which here refers to erectile dysfunction and decreased libido,
is a common and often distressing experience for both men receiving ADT for PCa and
their partners. Two systematic reviews included RCTs with incidence of sexual
dysfunction or decreased libido, one comparing erectile dysfunction between degarelix
and GnRH agonists (RR 0.94 95% CI 0.700, 1.26, p=0.686)(81), the other IADT and
continuous CADT for erectile dysfunction (RR 1.03; 95% CI 0.74, 1.43) and decreased
libido (RR 1.01; 95% CI 0.95, 1.07) (71). No significant differences were found for
erectile dysfunction or decreased libido between types of ADT. There is a paucity of
data on sexual dysfunction, however, two RCTs examined the effect of short-term
neoadjuvant ADT before radiotherapy and compared ADT recipients to those receiving
28

radiation only, reported significant declines in sexual function from two months ADT
administration(115, 116). Daly et al.(115) compared duration of ADT; 54% of men in
the 4-month arm and 39% in the 8-month arm, who had sexual function at baseline,
retained sexual function at one year. There were no statistically significant differences
between arms and smaller decreases in sexual function were recorded after one
year(115). This study found that 26% of men can expect to retain erectile function five
years after receiving three or four months of ADT with age the only significant risk
factor(115). Similar results were obtained in a second RCT comparing men receiving
neoadjuvant ADT and radiotherapy and those receiving radiotherapy alone. There was
a statistically significant difference between arms: number of men who always or
almost always had erectile function at baseline in the ADT arm decreased by over 50%
one year after ADT initiation(116).
2.3.8 Psychiatric disorders: Depression
Depression and anxiety are often unaddressed adverse effects among patients with
PCa and are associated with increased health service use, costs and mortality(117119). Two systematic reviews examined the incidence of depression among men with
PCa receiving ADT(71, 76). One conducted a pooled analysis of 18 studies, both
prospective and retrospective, involving a variety of forms of ADT from primary antiandrogen, radiotherapy or radical prostatectomy plus adjuvant ADT, and orchiectomy.
Comparators included lesser exposed ADT group (e.g. no ADT, short term ADT or
IADT). Relative risk of depression was 1.41 (95% CI 1.18-1.70, p<0.001) (76). The
second systematic review analysed 15 RCTs of which three generated evidence of
depression experienced by recipients of continuous and intermittent ADT and found no
significant difference between IADT and CADT (RR 0.91; 95% CI 0.39, 2.13)(71).
2.3.9 General disorders
9a Fatigue

Two systematic reviews examined the incidence of fatigue for men receiving ADT
for PCa. One conducted a pooled analysis of all stages of PCa and found no significant
difference between IADT and CADT, but an incidence of fatigue that favoured IADT
(HR 0.94; 95% CI 0.60, 1.48)(71). However, for men receiving new hormonal agentbased therapies for metastatic CRPCa, enzalutamide or arbiraterone acetate, fatigue is
one of the most common adverse effects. A significant difference in incidence was
discovered from pooled analyses of both all grade (RR 1.27; 95% CI 1.13, 1.43) and
grade 3 or greater fatigue (RR 1.25; 95% CI 0.92, 1.71, p=0.02)(120).
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9b Gait disturbance, physical function and falls

Clinically meaningful declines in physical functioning occur within 3-6 months after
ADT initiation and stabilise or worsen over time(40, 121, 122). Alibhai et al.(121) report
that for each 5-kg reduction in grip strength over 4 years, there was a 24% increased
mortality risk, and with each 5% loss of relative grip strength, a 6% increased mortality
risk. In a secondary analysis of this same population, the incidence of falls was higher
for men receiving CADT, with a trend towards increased risk (p=0.083)(123). Graff et
al.(124) conducted a sub-group analysis (≥75 years) of participants in the PREVAIL
RCT, where there was a much higher incidence of falls, suggesting enzalutamide may
further increase the risk of falls because all men in the trial were receiving ADT. In a
Phase III, double-blinded RCT examining apalutamide versus placebo, Smith found a
higher incidence of falls for participants receiving apalutamide(104).
2.3.10 Methodological quality of included studies
Systematic reviews

Twenty-five systematic reviews (24 incorporating a meta-analysis) were assessed
using the AMSTAR 2 tool (Appendix 3). Confidence in overall results of the review
rating varied, 10 were rated as low, 11 as moderate, and four as high. Results were
impacted by lack of data or diversity of studies available. ADT is used broadly across
the spectrum of PCa, so patient characteristics differ as do the type and duration of
ADT administration. In addition, studies involved different comparators or control
groups, making comparison across studies difficult. Heterogeneity between studies
within reviews was often quite high. Risk of bias or quality assessments were not
always conducted or just not reported in lower rated studies, despite their critical
importance. Similarly, publication bias was overlooked in a number of reviews. Overall,
systematic reviews brought together a comprehensive collection of the best available
evidence on the adverse effects of ADT for PCa and provide a sound evidence base.
Randomised Controlled Trials

Four RCTs were assessed for risk of bias using the ROB-2 tool generating ratings
such as low, some concerns, or high risk of bias (Appendix 4). Three of the four trials
rated an overall low risk of bias and two of these were studies based on well-known
trials (ICORG 97-01; PREVAIL); all four were published in high ranking journals by
recognised authors/clinicians in the PCa field, however, all four also had varying
degrees of conflict of interest from author association with pharmaceutical companies.
Cohort studies

Ten cohort studies were assessed for quality using the Newcastle Ottawa Scale
(NOS) for a possible rating of good, fair or poor (Appendix 5). All achieved a rating of
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good and only three had weaknesses which were not considered sufficient to require a
downgrading, given their other strengths. One study had missing outcome data that
was not addressed and no measures to prevent confounding from previous falls or
exercise(123); another had a 40% loss to follow up(121) and the third matched their
experimental and control cohorts for age and no prior comorbidity only(97).

2.4 Discussion
This comprehensive systematic review of adverse effects (n=19) of ADT for PCa
confirms that many are commonly experienced by patients and survivors. A broad
spectrum of ADT is represented, comprising GnRH agonists, GnRH antagonists, antiandrogens (steroidal and non-steroidal) and combinations of these drugs or
neoadjuvant and adjuvant therapy with curative treatments like RP or RT. Intermittent
ADT is also represented. Second generation non-steroidal anti-androgens, abiraterone
acetate and enzalutamide, figured strongly in the systematic reviews. Statistically
significant increased risks were evident in all the most common adverse effects from
the CTCAE groupings (musculoskeletal, metabolic, cardiac, nervous system, vascular,
hepatobiliary, reproductive system, psychiatric and general disorders). The dominant
factor across all adverse effect incidence was type of ADT.
For musculoskeletal events duration of ADT was also a factor; for fractures, ADT
dose, age, presence of osteoporosis, metastases and dementia impacted on incidence.
ADT impacted combined CVD morbidity and the risk of specific CV diseases such as
myocardial infarction and ischaemic heart disease. Risk was associated with type(63,
84), adverse event grade(78, 79, 85) and duration of ADT(125). Cardiac mortality was
less common but increased risk was identified for all ADT, ADT monotherapy and
GnRH agonists(84). Increased risk of stroke was associated with orchiectomy, CAB
and GnRH agonist alone(73). There was also a significant association between ADT
and hypertension, particularly for second generation therapies, abiraterone and
enzalutamide. Other vascular disorders like thromboembolic events also showed a
significant association with GnRHa alone, CAB, anti-androgen alone, oestrogen and
orchiectomy(66, 74). For vasomotor flashing, enzalutamide had a significant increased
risk and anti-androgens a significantly lower risk than other types of ADT (70, 71, 81,
85, 112). GnRH agonists and antagonists showed a strong association with
hepatotoxicity(113), as did abiraterone acetate, two to three times higher than placebo
for men with CRPCa(78, 79).
Reproductive disorders were common with significantly increased risk of
gynaecomastia and breast pain for anti-androgens over GnRH agonists(70, 112).
Sexual function was significantly impacted by ADT with only 26% of men expected to
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retain some sexual function five years from initiation of ADT(115). There was no
evidence to suggest a significant difference in relation to type of ADT(71, 81). The
impact of ADT on the risk of depression was confirmed in the systematic review by
Nead et al. which showed a 40% higher risk of depression for men receiving ADT
which, like sexual function, was associated with exposure (76). Fatigue is a complex
adverse effect associated with many cancer treatments but for men receiving
enzalutamide and abiraterone for PCa, there was a 27% greater risk of fatigue and a
50% greater risk for prechemotherapy men initiating ADT(120). Potentially related to
fatigue and other adverse effects, declines in physical function and higher incidence of
falls were also associated with ADT, significantly more-so with enzalutamide(124) and
apalutamide(104).
Cognitive disorders were the exception amongst the adverse effect groupings with
an inconclusive result from two systematic reviews(72, 82). Similarly, the systematic
review of dementia suggested only that there may be an association between ADT and
risk of dementia(75). Interestingly, McGinty et al. found a statistically significant
increased risk associated with visuospatial cognitive skills, suggesting a possible link to
increased incidence of falls and fractures for this population(72). Such a broad range of
adverse effects, some with high levels of incidence, poses problems, not only for the
patient and their family who bear the consequences of increased morbidity or mortality
and reduced quality of life, but also for society. There are significant cost implications of
suffering these adverse effects in the form of their management, supportive care and
increased health services utilisation, without considerations of productivity losses for
those men in this population still actively employed or their carers. Management of
adverse effects can take a number of forms from medications or counselling to
exercise interventions; each involving increased resource utilisation as well as out of
pocket costs for the patient.
In recent years, interest in adverse effects has increased, evidenced by the number
of systematic reviews included in this review. There is growing awareness of the impact
of many of these adverse effects on the part of clinicians, patients, economists and
decision makers, from both a quality of life and a cost perspective. Bourke et al. raised
the need for clearly defined adverse effects, in order that a better understanding of
potential risks and subsequent treatment costs is developed to accurately inform the
costs and effects associated with these drugs(126). Pearce et al. make a similar point,
advising that economic evaluations should include all adverse effects regardless of
severity(127). While the adverse effects associated with ADT are many, varied and
complex, it is important that economic evaluations include consideration of them to
32

ensure models are developed that accurately reflect the impact of adverse effects on
drug cost-effectiveness, particularly given the current emphasis on personalised care.
No single systematic review has previously provided such a comprehensive review
of this topic. This review, conducted and reported following Cochrane guidelines,
updates the current knowledge across all common adverse effects of ADT for PCa(86).
We employed an a priori designed protocol and carried out an extensive literature
search using multiple databases, Google Scholar and bibliographic hand search.
Methodological quality of included studies was assessed using three Cochrane
approved instruments and, with few exceptions, provided moderate to strong evidence
of ADT adverse effects. This systematic review also includes new ADT medications like
apalutamide, enzalutamide and abiraterone acetate, and through the weight of recent
evidence, confirms effects previously considered contentious, such as cardiovascular
toxicity, or rare, such as hepatotoxicity.
This review was limited by available data; while the full range of PCa stages from
localized to metastatic CRPCa were represented, not all types of ADT or all stages of
PCa were captured for all adverse effects, particularly for newer therapies. Studies
were characterised by considerable heterogeneity in study design, aims, outcomes,
sample size, exclusion criteria, geographical location, number of sites involved and
length of follow up. While all study participants were men with PCa receiving ADT,
there was considerable variation between and across studies in relation to age, PCa
stage, treatment, comorbidities, and demographics. Heterogeneity was not always
addressed in meta-analysis. While a rigorous search of the literature was conducted, it
is possible that not all studies reporting the adverse effects of ADT for PCa were
identified.

2.5 Conclusion
This review provides the first comprehensive incidence of the most common
adverse effects of ADT for PCa based on currently available evidence. These findings
are significant for clinicians, researchers, health providers, health economists, PCa
patients, their carers and society. It is evident that more research is needed in adverse
effects of ADT for PCa; questions also remain in terms of potential recovery and
management. It is hoped this review will assist in stimulating further questions and
research around adverse effects, as well as the development of suitable interventions
to decrease their risk. These findings also highlight the importance of supportive care
for PCa patients receiving ADT and their carers. Consideration of adverse effects and
their management in economic evaluations of PCa treatment is also important,
particularly given their potential to add further costs to what is already costly treatment.
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Chapter 3 The role of exercise in the management of adverse
effects of androgen deprivation therapy for prostate cancer: a
rapid review
3.1 Introduction
Prostate cancer (PCa) is the most commonly diagnosed cancer in Australian men,
accounting for one quarter of all new cancer diagnoses for males (128). With a
predicted 5-year global prevalence of 3.7 million in 2018 and an incidence of 18,274 in
Australia alone, PCa represents a considerable public health burden (129). The cost of
PCa in Australia has been estimated at US$270.9 million in 2016, rising to US$384.3
million by 2025 (130). Androgen deprivation therapy (ADT) is the standard first-line
therapy for metastatic PCa but also improves survival in men with high-risk localised,
locally advanced and castrate resistant PCa. Thus, ADT is used across much of the
spectrum of disease, often for considerable periods of time (16). Debilitating adverse
effects are a significant and largely unavoidable feature of ADT for men with PCa. A
recent systematic review (131) identified 19 adverse effect sub-groups classified
according to the Common Terminology Criteria for Adverse Events (CTCAE) Version
5.0 (17). Statistically significant increased risks were evident for all nine ADT adverse
effect groups (musculoskeletal, metabolic, cardiac, nervous system, vascular,
hepatobiliary, reproductive, psychiatric and general disorders), with evidence of
increased risks for 17 out of the 19 sub-groups (131). Cognitive disorder and dementia
were the exceptions, with inconclusive results or suggested associations with ADT
only, based on currently available evidence(131). Given the incidence of these adverse
effects, there is a need for management strategies that minimise the burden of PCa
treatment with ADT. The potential for multiple simultaneous adverse effects, the impact
these have on cancer outcomes and quality of life, as well as their associated
management, are important considerations in the treatment and supportive care of men
with PCa. While the value of exercise as medicine has long been acknowledged for the
general population (132) as well as cancer (47, 48) and PCa populations (32, 37), it is
increasingly being recognized as an efficacious strategy in managing the adverse
effects associated with cancer treatment.
In 2019, the Exercise and Sports Science Australia (ESSA) position statement and
the American College of Sports Medicine (ACSM) guidelines were updated with current
scientific evidence, clinical experience and exercise science principles. They
emphasise the importance of an appropriate exercise prescription for cancer patients,
which is individualised and targeted for the specific health issues most impacting the
patient (50, 51). The ACSM guidelines for cancer survivors recommend moderate
intensity aerobic training at least three times per week, for at least 30 minutes. The
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addition of resistance exercise to aerobic training, at least twice a week, using at least
two sets of eight to 15 repetitions, results in similar benefits, though evidence suggests
resistance training alone may not be enough (51). The ESSA guidelines recommend a
more tailored approach with exercise mode and dosage prescribed specifically to
ameliorate, in priority order, the health issues and mortality risks of greatest concern for
the patient. Both these documents were based on extensive evidence reviews to
ascertain the strength of evidence supporting the use of exercise for cancer patients
and survivors. Strong evidence was available for a number of cancer-related outcomes:
anxiety and depression, fatigue, health related quality of life (HRQoL) and physical
function. Moderate evidence was also available for bone health and sleep. While
organisations such as the American Society of Clinical Oncology (ASCO)(133), the
National Comprehensive Cancer Network (53) and the National Institute for Care and
Excellence(54) have PCa survivorship guidelines that support exercise for adverse
effect management, there is no comprehensive review of the benefits of exercise in
managing the adverse effects of ADT for PCa. Therefore, the aim of this review is to
identify existing evidence of the benefits of exercise in managing the adverse effects of
ADT for PCa.

3.2 Methods
A rapid review of the literature was undertaken by the authors to examine the role
of exercise in the management of ADT adverse effects outlined above (131). A search
was conducted in Medline, PsycINFO, Google Scholar and Google for the years 2010
to September 2019. A period of ten years of evidence generation was chosen by the
research team in order to focus on more current treatment regimes and approaches to
management. Search terms comprised: androgen deprivation; prostate cancer;
adverse effects; adverse events; toxicity; complications; management; guidelines; and
exercise; or physical activity. The Population, Intervention, Comparator and Outcome
(PICO) inclusion and exclusion criteria are outlined in Table 9. Evidence was prioritised
according to the Oxford Centre for Evidence-based Medicine (OECBM) 2011 Levels of
Evidence (88) and included: A. systematic reviews; and B. analytic studies, such as
randomised controlled trials (RCTs). Where little or no evidence of the effect of
exercise was available for men with PCa receiving ADT for a particular adverse effect,
a subsequent search was conducted to identify evidence of exercise impact for other
cancer patients, disease specific evidence (e.g. diabetes or cardiovascular disorders)
or evidence from the general population. This required removing prostate and
androgen deprivation from the search terms and including other terms relevant to ADT
adverse effects like hormone therapy, cardiovascular, diabetes, metabolic, depression,
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falls, fractures, cognitive, dementia, hot flushes, deep vein thrombosis and liver
disease. PICO inclusion criteria were also broadened. The population parameter
included the general population and other disease risks; the intervention parameter
other adverse effects or disease risks; and the outcomes parameter adverse effect or
disease risk management. The comparator parameter was maintained. PICO exclusion
criteria remained the same with the exception of the population parameter which was
changed to younger people (<50 years). Qualitative judgments of currently existing
evidence were based on agreement between authors due to the heterogeneity of
sources and paucity of evidence in some areas.
Table 9 PICO inclusion and exclusion criteria
Parameter
Population
Intervention
Comparator
Outcomes

Inclusion criteria
Men with PCa receiving androgen
deprivation therapy ADT
Supervised or prescribed exercise to
manage ADT adverse effects for PCa
No management, pharmaceuticals or
medical treatment only
ADT adverse effect management (higher
levels of evidence: Systematic Review,
Meta-analysis, RCT, cohort study,
population-based observational study)

Exclusion criteria
PCa population not receiving ADT
Unsupervised or purely recreational
exercise (i.e. without prescription or
professional oversight)
Lower ranked evidence (e.g. review,
cross sectional study)

Abbreviations: ADT androgen deprivation therapy; PCa prostate cancer; RCT randomised controlled trial

The adverse effects of ADT were classified according to the CTCAE (17) subgroups to facilitate comparison of available evidence for specific adverse effects (131).
Evidence of the role of exercise in addressing each of these adverse effect sub-groups
is described below.

3.3 Results: Effectiveness of exercise in managing adverse effects of ADT
Results will be presented in two sections. Section 1 will present the evidence for the
role of exercise in managing the adverse effects of ADT. Section 2 will provide
evidence from other populations for the role of exercise in managing other adverse
effects or disease risks, where there is little or no evidence for the PCa population.
3.3.1 Musculoskeletal changes
1a Bone loss, 1b osteoporosis and 1c fracture risk

Management of bone loss, osteoporosis and fracture risk consists of baseline
assessment of bone mineral density (BMD) using dual-energy X-ray absorptiometry
(DXA) of the spine, hips and forearm, which should then be followed by lifestyle
interventions comprising exercise and diet, and pharmacological treatment with
bisphosphonates only if required (23). Resistance exercise training and high impact
loading exercises help to mitigate ADT related bone loss, thus improving bone health
and reducing fracture risk. While one systematic review and meta-analysis of the most
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effective methods for preventing osteoporosis in men taking ADT for PCa concluded
exercise alone was insufficient to address bone loss(134), improvements in or
preservation of BMD for men with PCa receiving ADT who participated in an exercise
intervention have been reported in three recent RCTs (135-137). These studies
reported improvements in hip and/or spine BMD (where the most problematic fractures
occur). Endurance and resistance exercise improved bone mineral density in the right
and left total hip and right and left femur in one study (136), combined resistance,
aerobic and impact loading exercise improved lumbar spine BMD in another study
(135), and combined impact loading and resistance exercise attenuated the decline in
both spine and hip BMD in another (137). These findings highlight the impact of
targeted exercise and are critical for a population at high risk of falls and fractures
(131).
3.3.2 Metabolic changes
2a Body composition

Androgen deprivation therapy causes increased fat mass and decreased lean mass
possibly progressing to sarcopenic obesity in many men with PCa. Increased
abdominal fat promotes insulin resistance and reduced lean mass contributes by
reducing glucose uptake in muscles. Visceral obesity has also been associated with
increased fatigue (138), reductions in BMD and bone strength and the potential, if not
managed, to impact adversely on other disease risks, morbidity and mortality. An
intensive lifestyle intervention should be instituted to prevent weight gain and
worsening insulin resistance (23). Exercise has been shown to be effective in
improving body composition in seven systematic reviews (49, 139-144). Outside these
systematic reviews, evidence of exercise induced reductions in fat mass were reported
in one RCT (145), and evidence for increased lean mass and/or muscle strength in four
RCTs (135, 137, 146, 147).
2b Metabolic syndrome

Metabolic syndrome requires similar management strategies to its individual
features such as obesity/weight gain (increased waist circumference), hyperglycemia
(increased fasting glucose), hypertriglyceridemia (increased triglycerides), decreased
serum high density lipoprotein (HDL), increased insulin and hypertension. Importantly,
close monitoring and intervention is recommended, particularly in the first year of ADT,
because adverse effects can occur from three months post treatment (22, 148) and
there are subsequent risks associated with diabetes and cardiovascular health.
Exercise and lifestyle change are important considerations in addressing these risks.
Results from one systematic review on the effect of exercise for men receiving ADT
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reported inconclusive results for cardiometabolic risk markers (49).
2c Diabetes

Diabetes risk is a serious concern for PCa survivors receiving ADT due to the effect
of ADT on insulin sensitivity and other CVD risk factors. Exercise is recognised as a
critical tool in the prevention and treatment of diabetes (149-151), however, no PCa
specific evidence exists in relation to the effect of exercise in mitigating diabetes.
3.3.3 Cardiac disorders
3a Cardiovascular events

Androgen deprivation therapy is associated with elevated cardiovascular (CV)
morbidity or mortality, and given the aforementioned metabolic effects of ADT and
associated CV complications, it is advisable that patients receiving ADT undergo
metabolic evaluation at baseline and periodically during follow-up visits (152). There is,
however, a paucity of consistent data on the impact of exercise on these outcomes for
men receiving ADT for PCa. Only one systematic review included evidence in relation
to PCa survivors, which showed exercise training is associated with significant
improvements in vascular endothelial function and peak oxygen volume (VO2) (153).
Improvements in flow-mediated dilation (FMD) are associated with improved CVD risk
independently of more traditional risk factors such as body mass index (BMI),
cholesterol or blood pressure (153). The effect of exercise on change in FMD (1.3%)
was similar to that reported for other healthy and diseased populations (153).
3.3.4 Nervous system disorders
4a Cognitive impairment

While the suppression or blocking of testosterone by ADT is likely to increase
cognitive decline, there is a lack of conclusive evidence in relation to the deleterious
effect of ADT on cognition, especially verbal, spatial and executive functioning; thus,
there is no definitive recommendation for preventing or treating cognitive impairment in
men with PCa (131). Age, stage of disease and co-morbidities may contribute to
cognitive changes in patients on long-term ADT (154). While evidence exists to show
that exercise improves cognitive function in the general population, this has not been
demonstrated in PCa patients receiving ADT.
4b Stroke

Little evidence exists in relation to the impact of exercise in reducing risk of stroke
or its management specifically for men with PCa receiving ADT outside improved
endothelial function as for cardiovascular disorders above (153).
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3.3.5 Vascular disorders
5a Hypertension

Androgen deprivation therapy, particularly second generation hormonal agents
such as abiraterone acetate and enzalutamide, is associated with significant increases
in risk of hypertension (131). While there is currently no evidence of the impact of
exercise on hypertension for men with PCa receiving ADT, regular screening and
lifestyle modification (including exercise and diet) are recommended (23).
5b Thromboembolic events

While there is evidence of an association between ADT and increased risk of
thromboembolic events such as deep vein thrombosis (DVT) and pulmonary embolus
(PE) (131), no PCa specific evidence currently exists for the role of exercise in
mitigating this effect.
5c Hot flashes

There is an established association between ADT and vasomotor flushing across
various treatments and stages of PCa from locally advanced to metastatic castration
resistant prostate cancer (mCRPCa) (131). Exercise could potentially benefit men with
PCa receiving ADT and experiencing hot flashes, however, no evidence currently
exists, and more research is needed.
3.3.6 Hepatobiliary disorders
Arbiraterone acetate and gonadotropin-releasing hormone (GnRH) agonists are
both associated with an increased risk of hepatotoxicity (131). Currently, there is no
evidence for exercise as a mitigating strategy specifically for men receiving ADT for
PCa.
3.3.7 Reproductive system disorders
7a Gynaecomastia and breast pain

Gynaecomastia and breast pain or mastalgia, often referred to in the literature as
breast events, are a common adverse effect of non-steroidal antiandrogen therapy
(bicalutamide, flutamide) and, while less common for GnRH agonist therapy, can
seriously impact men’s masculinity and quality of life (65). There is no evidence to
support the use of exercise as a strategy to manage gynaecomastia in men with PCa
receiving ADT.
7b Sexual dysfunction

The adverse effects of ADT that relate to sexual dysfunction can result in a
perceived loss of masculinity and difficulties in the relationship dyad. Qualitative
research conducted alongside a RCT which involved interviews with PCa patients
39

found that exercise reinforces masculinity and thus enhances sexual wellbeing (155).
Evidence from one systematic review (143) and one RCT indicates exercise can
enhance sexual health following PCa treatment and exercise initiated with treatment
can help to maintain sexual function in men who were sexually active prior to
commencing ADT (156).
3.3.8 Psychiatric disorders
8a Depression and anxiety

A PCa diagnosis is a major source of life stress for most men and treatment can
exacerbate this effect, contributing to significant decrements in quality of life. Age,
cancer stage, comorbidities, psychological disposition, self-efficacy, even marital
status, can impact on the nature and severity of this effect(157). From a physiological
perspective, exercise causes alterations to hormones (e.g. endorphin and monoamine
levels), corticosteroids, pro-inflammatory cytokines, growth factors and neurogenesis,
impacting mood and cognitive function and in this way may contribute to improvements
in mental wellbeing(157). Systematic review evidence shows exercise improves quality
of life (including mental health domains) in the PCa population (141, 158, 159).
3.3.9 General disorders
9a Fatigue

In recent years, there has been recognition of the need to address the debilitating
effects of cancer related fatigue. Strong evidence from eight systematic reviews (49,
140, 141, 160-164) and one RCT (165) support the effectiveness of exercise in
addressing fatigue during and after treatment with ADT for PCa. Moderate intensity
aerobic exercise and combined aerobic and resistance programs had significant
effects, with moderate to vigorous exercise most effective.
9b Gait disturbance
Functional decline is one outcome of the ageing process and ADT for men with
PCa can exacerbate this decline and result in frailty that impacts significantly on
activities of daily living (ADLs) and quality of life (166). Strong evidence from eight
systematic reviews (49, 139-142, 144, 160, 163) and two RCTs (145, 147) not
elsewhere included, supports the efficacy of exercise in addressing the functional
decline associated with ADT. Men with PCa undergoing ADT benefit from exercise
training, demonstrating consistent, positive results in physical and muscular
performance.

3.4 Results: Effectiveness of exercise in managing adverse effects or
disease risks in other populations
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3.4.1 Musculoskeletal changes
Strong evidence for the effectiveness of exercise in addressing the adverse effects
of ADT for PCa is currently limited, however evidence often exists in other populations.
This is the case for the musculoskeletal adverse effect, fractures. Sherrington et al.
(167) conducted a comprehensive systematic review of the effectiveness of exercise
interventions in preventing falls in older people (i.e., older than 60 years) living in the
community and found reductions in falls and fall-related fractures.
3.4.2 Metabolic changes
While results for ADT induced metabolic changes are inconclusive in the PCa
population, a large meta-analysis of RCTs conducted in the general population
demonstrated that exercise training significantly improved CVD biomarkers of lipid and
lipoprotein metabolism, glucose intolerance and insulin resistance, systemic
inflammation, and hemostasis. The effects of exercise on cardiorespiratory fitness
measures also showed that people with type 2 diabetes, hypertension, hyperlipidemia
or metabolic syndrome appeared to benefit more from exercise. Significant modification
of effects on total cholesterol and low density lipoprotein cholesterol (LDL-C) were also
observed for people with these conditions (168).
A number of systematic reviews report the importance of exercise for people with
diabetes(168-171). Resistance exercise improves insulin sensitivity and glucose
tolerance, while improving lean body mass and strength parameters. Both resistance
and aerobic exercise can assist with management of blood glucose levels, lipids, blood
pressure, cardiovascular risk, mortality and quality of life (168-171).
3.4.3 Cardiac disorders
The effect of exercise on cardiovascular toxicity resulting from cancer treatment is
an emerging discipline (51, 172). Poor cardiorespiratory fitness is associated with a
higher risk of treatment toxicity, higher symptom burden and increased risk of all-cause
and cancer specific mortality in cancer patients, but is not recognized as a traditional
CVD risk (172). The importance of vascular adaptation to exercise and the impact on
cardiovascular risk in the general and CVD populations is increasingly being
recognized (173, 174). A systematic review and meta-analysis of lifestyle modification
programs for patients with coronary heart disease showed that comprehensive
programs reduced mortality by 34% and re-incidence and re-admission rates by 35%
over follow-up of between 1-5 years (174). Following treatment, there were significant
reductions in blood pressure, total cholesterol, and smoking, as well as significant
improvements in exercise behaviour and dietary habits. Treatment benefits were
41

maintained at later follow up, with the exception of smoking, and improvements in BMI
had become evident(174).
3.4.4 Nervous system disorders
An increasing number of studies suggest exercise has a positive effect on
cognition. For example, a systematic review and meta-analysis of RCTs in community
dwelling adults older than 50 years found a 29% improvement in cognitive function for
at least moderate intensity exercise. Results were independent of cognitive domain or
cognitive status of participants (175). Another meta-analysis of longitudinal cohort
studies of physical activity in adults ≥40 years, with prevention of cognitive decline and
dementia as the focus, concluded there was a case for causality (176).
Management of stroke involves consideration of a number of major modifiable risk
factors such as physical inactivity (177), high cholesterol, hypertension, metabolic
syndrome, diabetes, diet and nutrition, obesity and body fat distribution (177, 178),
cigarette smoking, and alcohol (177). Exercise has been shown to have a lowering
effect on hypertension in several meta-analyses (179-181). Significant modification of
effects on total cholesterol and LDL-C have also been observed for people with
hypertension, hyperlipidemia and metabolic syndrome in another systematic review
(168). Exercise also increases blood flow and improves the release of blood clot
dissolving tissue plasminogen activator (t-PA). Stroke, a cardiovascular disease, has
similar risk factors and requires prevention measures like those of other cardiac
disorders (149, 182, 183).
3.4.5 Vascular disorders
In four systematic reviews and meta-analyses, exercise was shown to have a
lowering effect on hypertension (179-181). While included studies were heterogeneous,
there was a post exercise reduction in blood pressure, regardless of participant
characteristics or type of exercise (aerobic and/or resistance or isometric), findings
supported by the American Heart Association(184). One meta-analysis focused on
isometric exercise training (179). In the other two, the lowering effect was greater when
exercise was a preventive strategy in physically active participants, not taking
antihypertensive medication (180, 181).
Deep vein thrombosis is particularly prevalent amongst cancer patients and an
important cause of morbidity and mortality in this population (185). One systematic
review reported positive effects after exercise for patients in the general population with
prior or current DVT(186).
While there is no evidence for exercise in mitigating hot flashes for men receiving
ADT, several studies have noted that physically active women in the general population
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report fewer somatic and climacteric symptoms during menopause compared to
sedentary women, suggesting that physical activity is beneficial in improving quality of
life for this population (187, 188).
3.4.6 Hepatobiliary disorders
Both aerobic and resistance exercise have been shown to reduce hepatic fat
content (111). Exercise impacts on fatty liver disease in a number of ways. Improved
insulin resistance reduces excess delivery of free fatty acids and glucose for synthesis
to the liver. In the liver, exercise increases fatty acid oxidation, decreases fatty acid
synthesis, and prevents mitochondrial and hepatocellular damage (111). Two
systematic reviews (189, 190) support exercise as a therapeutic strategy to improve
fatty liver disease in the general population.
3.4.8 Psychiatric disorders
Depression and anxiety

A number of systematic reviews and meta-analyses have found similar effects for
exercise in the general population (191) and other cancer populations (192-196). One
meta-analysis of high quality exercise trials showed large and significant effects,
providing robust evidence for exercise in the management of depression (191). Aerobic
and mixed mode exercise were found to have large antidepressant effects across all
studies when compared to no exercise controls. Supervised interventions of moderate
to vigorous intensity had the largest effects and exercise supervised by professionals
with relevant training such as exercise physiologists, physical educators, and
physiotherapists was associated with the greatest improvements (191).
For cancer populations, several meta-analyses confirm reductions in depressive
symptomology in cancer survivors following exercise interventions, mostly in those not
depressed at baseline (192-196). Cancer populations included in these meta-analyses
were comprised mostly of breast cancer survivors.

3.5 Exercise as medicine for men with PCa receiving ADT
Evidence for each of the CTCAE ADT adverse effect sub-groups is summarised in
Table 10. The source of evidence for exercise as medicine in managing the adverse
effects of ADT for PCa and brief, qualitative comments on the overall quality of
currently available evidence are presented.
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Table 10 Summary of evidence for exercise as medicine in managing adverse effects of ADT for PCa
Group

Adverse effect
(CTCAE)

Adverse effect sub-group
a) Bone loss

1

2
3
4

Musculoskeletal
changes

Metabolic
changes
Cardiac
disorders
Nervous
system
disorders

5

Vascular
disorders

6

Hepatobiliary
disorders

7

Reproductive
system
disorders

8

Psychiatric
disorders

9

General
disorders

Exercise as medicine evidence

Overall quality of currently available exercise as medicine evidence

3 RCTs (135-137, 197)

** moderate evidence of significant improvements in bone loss; more exercise RCTs and
more evidence of sustained improvements needed
* exercise recommended but not alone; latest exercise RCT evidence not included in this
medication focussed SR
* no evidence for falls or fractures; improved bone health & physical function may reduce risk
of falls & fractures
***strong evidence for muscle strength and lean mass across 7 SRs & 4 RCTs; less
consistent results for fat mass & waist circumference (49, 139)
*inconclusive evidence for cardiometabolic risk markers from 1 SR
*no evidence to support exercise as a management strategy
*little consistent evidence; emerging field suggesting improvements in cardiac and vascular
function

b) Osteoporosis

1 SR (134)

c) Fracture

0

b) Metabolic syndrome
c) Diabetes

7 SRs (49, 139-144);
4 RCTs (135, 137, 146, 147)
1 SR (49)
0

a) Cardiovascular events

1 SR (153)

a) Body composition

a) Cognitive impairment and
dementia
b) Stroke
a) Hypertension
b) Thromboembolic events
c) Hot flashes

0

*no conclusive evidence to support exercise as a management strategy

1 SR (153)
0
0
0

*little evidence, but emerging field suggesting improvements in cardiac and vascular function
*no evidence, but emerging field suggesting improvements in cardiac and vascular function
*no evidence to support exercise as a management strategy
*no evidence to support exercise as a management strategy

a) Hepatic disorders

0

*no evidence to support exercise as a management strategy

a) Gynaecomastia and
breast pain

0

*no evidence to support exercise as a management strategy

b) Sexual dysfunction

1 SR (143);
1 RCT (156)

**some inconsistency in evidence, but improved sexual function (143) & maintenance of
sexual activity (156) reported for ADT PCa; more research needed

a) Depression, anxiety

5 SRs (141, 158, 159, 161, 164)

** moderate evidence for HRQoL

a) Fatigue

8 SRs (49, 140, 141, 160-164);
1 RCT (165)

***strong evidence

8 SRs (49, 139-142, 144, 160,
163); 2 RCTs (145, 147)

***strong evidence

b) Gait disturbance

Abbreviations: CTCAE Common Terminology Criteria for Adverse Events; PCa prostate cancer; ADT androgen deprivation therapy; RCT randomised controlled trial; SR systematic review; DVT deep vein thrombosis; HRQoL
health related quality of life
Notes: *low level evidence; **moderate level evidence; ***high level evidence
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3.6 Discussion
This rapid review has highlighted the evidence for the role of exercise in managing
the adverse effects of ADT for PCa and identified where there is a lack of evidence
(Table 10). There is strong evidence for exercise as medicine in addressing a number
of the adverse effects of ADT such as reduced muscle mass and strength, fatigue and
declining physical function. Moderate level evidence of the benefits of exercise was
found for psychosocial effects of ADT (e.g. depression, anxiety, quality of life),
particularly for supervised interventions; however, the evidence is not consistent across
all of these effects (144). Moderate level evidence also exists for bone loss and sexual
dysfunction. For the remainder of the adverse effects of ADT sub groups (osteoporosis,
fracture, metabolic syndrome, diabetes, cardiovascular events, cognitive impairment
and dementia, stroke, hypertension, thromboembolic events, hot flashes, hepatic
disorders, gynaecomastia and breast pain), evidence is non-existent or the data to
support it is limited and more research is needed to address these deficiencies.
While the exercise as medicine evidence is lacking for many ADT for PCa adverse
effect sub-groups, evidence in the PCa, cancer or other clinical populations is strong
and many clinical guidelines recommend exercise as a fundamental part of their clinical
management (50, 51, 53, 54, 133). With the exception of gynaecomastia and breast
pain, there is increasing evidence to suggest that exercise has the potential to reduce
and even prevent many of the adverse effects of ADT, thus improving survivorship
outcomes for men with PCa. Exercise has the potential to provide an effective
approach to adverse effect management, with few associated risks. It can be combined
with pharmacotherapy and/or psychotherapy where required(157), however, larger,
well designed studies with longer follow-up that address more adverse effects are
needed to strengthen the evidence base.
Not only is exercise effective in addressing many of the adverse effects of ADT, but
epidemiological evidence for PCa drawn from prospective cohort studies, also shows a
moderate inverse association between physical activity and risk of advanced and fatal
disease(198). For example, outcomes from one study showed that men in the highest
quintile of vigorous activity had a 77% lower risk of advanced PC(198). Men with high
levels of occupational activity in another study also had lower risk of advanced
PCa(198). Men with high levels of recreational physical activity in another study had a
31% lower risk of aggressive PCa than men who did not participate in recreational
physical activity(198). For men already diagnosed with PCa, physical activity is
associated with improved survival and decreased PCa progression(37). Vigorous
activity is associated with lower risk of PCa specific mortality, both vigorous and non-
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vigorous activity are associated with lower risk of all-cause mortality in this
population(37). Thus, exercise is critical to health and quality of life, as well as survival,
for PCa survivors.
Ideally, GPs, oncologists or urologists treating men receiving ADT for PCa would
recommend exercise to manage potential adverse effects from the time of diagnosis.
The ACSM advises oncologists to “Assess, Advise and Refer” so that cancer patients
are connected with appropriate exercise professionals who will provide an
individualised prescription(51). The prescription could take several forms but would
initially incorporate assessment and a progressive program devised and supervised by
an accredited exercise physiologist or physiotherapist to assist each individual to
achieve improved muscle mass and strength, cardio-respiratory fitness, fat loss and
body function. Depending on the capacity of the individual PCa patient or survivor, this
could be accompanied or followed by a home-based program of exercise such as
cycling, walking or jogging(50, 51).
While considerable evidence exists to support the use of exercise as an essential
part of a cancer treatment and care plan, there has been limited uptake of this
approach. Research in the UK has examined the national guidelines (NICE guidelines
CG175) on exercise training for men with advanced PCa to determine whether
healthcare professionals were supportive of the guidelines(57) and whether they were
being implemented as part of PCa care(199). Healthcare professionals were aware of
the guidelines and confused as to why no action had been taken to implement
them(57). Despite the support of healthcare professionals and men on ADT, evidencebased guidelines were not being delivered. Traditional values in oncology and the need
for financial support from the government to assist translation from a hospital/clinic
environment were identified as the major barriers(57). A recent systematic review of
interventions for PCa survivorship cautioned that more research is needed to examine
the effectiveness and acceptability of exercise and psychosocial interventions outside
clinical trials and to support translation into practice(144). These concerns are widely
recognised. The transition to widespread application clinically and post-clinically
present a challenge, particularly in design and implementation, when a targeted or
personalised medical approach is viewed as critical to the efficacy and safety of
exercise for cancer patients (172, 200). There is a recognised need for prescription of
exercise medicine to address variation in treatment effects, treatment intensity, patient
comorbidities or fitness levels(50, 172).
This rapid review is not without its limitations. While a systematic and comprehensive
search was conducted, this is not a systematic review and there may be studies that
were missed in the conduct of the search. In addition, qualitative judgments of currently
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existing evidence were based on agreement between authors due to the heterogeneity
of sources and paucity of evidence in some areas. The purpose of this review was to
identify the available evidence in relation to the role of exercise in managing the adverse
effects of ADT for PCa. In doing so, evidence gaps were also identified. Supplementing
the evidence for the ADT PCa population with evidence from other populations supports
the potential for exercise as medicine to address these evidence gaps. Future research
needs to focus on the evidence gaps in relation to PCa to strengthen the current
evidence base.
The use of exercise in PCa management has the potential to translate into health
and economic benefits in improved quality of life and fewer complications, resulting in
savings to the health care system, enhanced productivity and reduced patient and
carer burden. Exercise thus has the potential to improve quality of life for this
population as well as generate significant cost savings. To date, there has been no
attempt to quantify the economic impact of exercise programs for men with PCa.
Future research should determine the economic impact of exercise in managing the
adverse effects of ADT via cost-effectiveness analysis of exercise interventions for
PCa patients and survivors. Such evidence is needed to inform decision makers of the
health and economic impact of exercise to support effective implementation of exercise
training for PCa patients and survivors in real world settings and thus achieve research
translation.
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Chapter 4 Methods
4.1 Introduction
This chapter provides a general summary of the methods used to achieve the aim
of this thesis which is to determine the cost-effectiveness of exercise medicine for
prostate cancer (PCa). While the methods will be described in detail in each chapter,
this chapter will provide a general methodological overview of the economic
evaluations employed in the thesis. Although Chapter 2 established the incidence of
the adverse effects of androgen deprivation therapy (ADT) and the potential impact on
patients, the health system and society in terms of cost and health-related quality of life
(HRQoL), the question of how best to manage these adverse effects was raised.
Chapter 3 established the important role of exercise in managing many of these
adverse effects. However, the cost effectiveness of exercise in managing the adverse
effects of ADT for PCa is currently unknown. To date, no other studies have assessed
the value for money of exercise programs to manage adverse effects of ADT for PC.
Chapters 5, 6 and 7 comprise economic evaluations to determine the cost
effectiveness of exercise for PCa patients and survivors treated with ADT.
The first section of this chapter (4.2) will provide a brief background to economic
evaluation in health and the types of economic evaluation. The second section (4.3)
will outline the approaches used in economic evaluation. The third section (4.4)
situates and provides an overview of the included healthcare interventions. The final
section (4.5) describes the methods employed in each economic evaluation included in
this thesis (Chapters 5, 6 and 7).

4.2 Economic evaluation in health
In the 2017-2108 financial year, an estimated $185.4 billion was spent on health
goods and services in Australia, accounting for over 10% of overall economic activity,
with an average per capita health expenditure of $7,485(201). With increasing health
care expenditure and limited resources, it is important to critically evaluate the delivery
of both current and future interventions in order to ensure cost effective resource
allocation. This involves comparison of opportunity cost with programme benefits, that
is, the value of the benefits achievable in the original program that has been forgone in
committing resources to an alternative programme(202). The aim of economic
evaluation in health is to inform clinical and health system decision making and policy.
Economic evaluation can be defined as “the comparative analysis of alternative
courses of action in terms of both their costs and consequences”(202). All economic
evaluations require the identification, measurement, valuation and comparison of the
costs and consequences of the alternatives under consideration(202). The decision
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question and the interventions will determine the outcomes being evaluated and the
type of economic evaluation conducted(202). There are three types of commonly used
full economic evaluation (those which compare alternative costs and consequences):
cost-effectiveness analysis (CEA), cost-utility analysis (CUA) and cost-benefit analysis
(CBA)(Table 11)(202). While cost minimisation analysis (CMA) is often included in this
group of economic analyses, CMAs do not strictly conform to the definition provided of
full economic evaluation. Cost minimisation analysis tends to refer to a situation where
the consequences of one or more programmes or treatments are largely equivalent,
such that the difference is reduced to a comparison of costs(202, 203).
Table 11 Full economic analyses
Type of economic
evaluation
Cost-effectiveness
analysis
Cost-utility analysis

Measurement of consequence

Question that can be answered

Natural units such as life-years
saved, or strokes avoided
Health state preference values
(QALYs)

What is the cost per outcome?

Cost-benefit analysis

Monetary units

Abbreviations: QALYs quality adjusted life years

What is the cost of gaining the improvement in
health state? How does it compare with
competing interventions?
Is this health care goal worth achieving?
What is the return on investment?

A CEA is undertaken to evaluate the costs and consequences of two or more
interventions where there is a single, unambiguous objective of therapy or outcome of
interest(202). The incremental costs are compared with the incremental outcomes and
measured in natural units. For example, diagnostic tests might be compared in terms of
cost per case detected or vaccinations by cost per case prevented. The aim of CEA is
to maximise health benefits while operating within a limited budget(2). While there are
many advantages of using CEA such as its ease of interpretation, one disadvantage is
that it cannot be used to compare interventions treating different diseases or conditions
because it does not address ‘opportunity cost’. In addition, a single measure of
outcome may not address the full range of patient outcomes generated by an
intervention(2).
In CUA, outcomes are measured as health-related preferences (e.g. utility values),
which are usually expressed as quality-adjusted life-years (QALYs) gained. The QALY
attempts to capture the two most important features of a health intervention: its effect
on survival in life years and its effect on quality of life. A QALY places weight on time in
different health states via a utility score recorded between 1 (perfect health) and 0
(death). This is reported as the cost per QALY(204). In this way, outcomes can be
compared across different disease states and used to measure opportunity cost(205).
Cost-utility analysis thus addresses the comparative limitation of CEA by measuring
the patient’s preference for being in a particular health state or quality of life outcome.
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Because decision-makers are often required to make decisions about resource
allocation across several different areas of health, the quality adjusted life year (QALY)
is used as a generic measurement of outcome in CUA(2).
Both CEAs and CUAs express the incremental costs and benefits as the
incremental cost-effectiveness ratio (ICER), which is the difference in cost divided by
the difference in effect between mutually exclusive interventions. The term dominance
is often used when interpreting ICERs. For example, one program or intervention can
be said to dominate another if it is more effective and less costly. The ICER is
compared with the decision maker’s willingness-to-pay threshold. An intervention is
said to be cost-effective when the ICER is less than the willingness-to-pay threshold.
This threshold, in a budget-based healthcare system, is the opportunity cost of health
benefits foregone from the investment in the new intervention(206). In Australia, a
commonly used willingness-to-pay threshold is AU$50,000(207). Recently, an
empirically derived reference ICER was estimated for the Australian health system
suggesting opportunity costs of 1 QALY for every additional AU$28,033 of government
health expenditure(208).
Another way of expressing the result of a CEA or CUA is to use the summary
statistic, net monetary benefit (NMB) which represents the value of an intervention in
monetary terms when a willingness-to-pay threshold for a unit of benefit is known. The
NMB scales both health outcomes and use of resources to cost, permitting comparison
without the use of ratios (e.g. ICERs)(209). It is calculated by multiplying the
incremental benefit (∆Ε) by the willingness-to-pay threshold (𝜆𝜆), less the incremental
cost (∆∁). An intervention is cost effective when the NMB is positive (∆Ε ∗ λ − ∆∁ >
0)(210).

Cost-benefit analysis is the third type of full economic evaluation. It places

monetary valuation on healthcare resources and on health outcomes, and thus
provides a broader measure of value than other economic analyses(202). A CBA of a
health intervention measures the monetary value of any health benefits gained by the
patient, as well as the value to society of any consequences or outcomes. Welfare
theory underpins the methods used in CBA. It is based on the assumption that social
welfare comprises the welfare of each individual member of society and that individuals
are the best judges of their own welfare. The underlying principle of welfare economics
is collective willingness-to-pay or what those who gain from an intervention are willing
to sacrifice to have the intervention, recognising that not all individuals will benefit and
some may therefore require compensation. The focus on compensation for reduced
health and willingness-to-pay for improved health led to the use of stated preference
surveys to elicit willingness-to-pay for hypothetical scenarios as a way of determining
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value, referred to as contingent valuation. A CBA uses these methods to assess
whether the monetary value of the benefits is greater than the costs of obtaining these
benefits, which is expressed as a cost-benefit ratio (total benefits divided by total costs)
or return on investment (total program benefits minus total program costs)(202).

4.3 Approaches to economic evaluation
Full economic analyses, like those described above, can be conducted using
patient level data from a clinical trial or using a decision-analytic model.
4.3.1 Economic evaluation of a clinical trial
Economic evaluation using trial data is conducted by measuring and averaging all
relevant cost and outcome data across all patients in each trial arm to determine a
mean cost and mean outcome for each patient group. The perspective of the economic
evaluation will determine which resource use data from the trial follow-up is identified,
measured and valued(202). This might include healthcare utilisation such as
emergency department visits, hospital admissions, GP visits, and allied health
appointments, as well as medications, diagnostic tests and out-of-pocket costs like
travel. When conducting a CUA where the outcome measure is QALYs gained,
patients complete a pre-scored HRQoL questionnaire or multi-attribute utility
instrument (MAUI) (e.g. EQ-5D(211), HUI2(212), AQoL(213), or SF-6D(214), reporting
their functional/health status across a variety of domains, to which the pre-existing
preference weights (utility values) are attached. This health state preference data is
then integrated with time to generate QALYs(215).
Costs and outcomes from the trial and the differences across the trial arms are
generally presented as means (average cost and average effect), that is, when the
sample size is large enough to ensure approximate normality based on the central limit
theorem (CLT)(202, 216). Nonparametric bootstrapping, a technique that re-samples
from a population by sampling a dataset with replacement, is also used to compare
means and calculate confidence intervals. Nixon et al.(217) showed that, even with
small samples from skewed data, both methods (CLT and bootstrapping) provide
estimates of the mean and that bootstrapping generated at least as acceptable
estimates of the uncertainty in mean values(202).
While economic evaluations based on RCTs are not guaranteed to be unbiased,
prospective, trial-based analyses providing access to primary, patient level data on
costs and outcomes and the opportunity to perform sub-analyses, can be beneficial
both for the analysis and internal validity(202, 215). However, economic analyses are
not always planned alongside RCTs and must often be conducted retrospectively,
impacting on data availability and the accuracy of both costs and outcomes. For
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example, the comparison therapy chosen for the trial may not be appropriate for the
economic analysis if it does not provide a measure of the incremental impact of the
new intervention(202). Costs incurred in a clinical trial may also need to be adjusted to
reflect a real-world implementation of the intervention(202, 218).
Thus, there are disadvantages associated with relying on the results of a single
clinical trial to inform decision making. It is unlikely that a single trial will compare all the
interventions relevant to the disease or condition or, provide evidence on all relevant
inputs and have a large enough sample to be representative of the larger population.
As the purpose of a clinical trial may be to determine intermediate outcomes like
improvements in cardiovascular fitness, not long term outcomes like morbidity or
mortality, data is usually collected for a short period of time, with no indication of the
longer term implications for health outcomes and costs(202, 219). Data for the trial
population may not be representative of other populations within or outside the country
and thus may not be relevant to the decision context. Relying on a single trial may also
mean evidence from other trials or sources, such as observational studies or metaanalyses, is excluded and does not support an economic evaluation of the rigour
required to inform regulatory or policy decisions. It is not uncommon, therefore, for
retrospective economic analyses to utilise multiple trials or sources of information in the
construction of a model(219). Decision-analytic models based on trial data and
evidence synthesis is thus the preferred approach to economic evaluation for the
purpose of informing decision making.
4.3.2 Economic evaluation using decision analytic models
Frameworks such as decision-analytical modelling provides a feasible alternative to
clinical trials. Modelling uses secondary or derived data on efficacy, health state
transitions and utilities for the development of the model from a single clinical trial,
multiple trials or a combination of sources (clinical data, meta-analysis, the literature).
Modelling thus provides a way of bringing evidence from a diverse range of sources
together to address uncertainty(219).
The first stage in developing a decision model is to specify the decision problem or
clearly identify the question to be addressed in the analysis, based on the requirements
of the decision maker(219). Then the scope or boundaries of the evaluation need to be
established by identifying the perspective, the populations expected to benefit, the
location and the setting, the treatment or intervention options, the time frame and the
outcome measures(219, 220).
The second stage is to develop the model structure. Commonly used models
include decision trees, Markov models, micro-simulation, discrete event simulation and
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dynamic models(221). A general rule of thumb is to use the simplest model that fits the
purpose(222). The decision tree is the simplest form of a decision model and is
typically adequate for simple problems with short time frames. However, when the
decision problem involves a number of health states, a Markov model is more
equipped to handle the complexity of modelling options with numerous possible
consequences(219). Rather than modelling possible consequences over time using a
large number of possible pathways as in a decision tree, Markov models are structured
around mutually exclusive disease (health) states reflected as a set of possible
transitions between the disease (health) states, over a series of discrete time periods
or cycles(219). Where individual considerations, such as patient history are important,
patient level simulation is a more appropriate modelling framework or when the
treatment process involves interactions between individuals, discrete event simulation
would better capture the effects of these interactions. A combination of different model
types may also be appropriate for some decision problems. Regardless of the model
framework chosen, all structural assumptions such as cycle length and time horizon
should be adequately described and justified(219, 221).
The third stage is to identify and synthesize the evidence for the input parameters
of the model(219). Data inputs used to populate the model should be derived from the
best available sources of evidence. When the evidence required for all variables has
been collected, the model can be run for each intervention to estimate the costs and
outcomes. Results are typically presented as ICERs and NMBs(219).
The model provides a framework for synthesising the available evidence from a
range of sources together to estimate costs and outcomes for the intervention and
determine the cost-effective option, rather than relying on a single RCT. Decision rules
can be applied to determine the optimal alternative based on the evidence. Models can
thus provide flexibility to incorporate heterogeneity and identify uncertainty and future
research priorities. The results are, however, dependent on the availability of data and
the assumptions that underlie or form the structure of the model(219, 223). Modelling,
therefore, is important, particularly when there are resource allocation decisions to be
made, providing that the methods employed are sound and critically reviewed. When
faced with conducting an economic analysis, the economist must decide to use the
clinical data as collected, supplement it, adjust it to reflect a more naturalistic setting or
incorporate modelling.
Uncertainty is inherent in every economic evaluation to some degree and can arise
from methodological assumptions, the data used in the analysis, the need to
extrapolate data over time or generalize results to other settings. Methods for handling
uncertainty vary according to the source of the uncertainty and the type of economic
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evaluation(202). For example, if the economic evaluation involves a patient level
analysis with stochastic data, uncertainty in the form of sampling variation can be
addressed using statistical analysis, extrapolation using modelling methods and
generalisability using sensitivity analysis. In decision-analytic modelling studies, the
preferred method for parameter uncertainty is probabilistic sensitivity analysis and for
modelling uncertainty and generalisability, sensitivity analysis. For both types of
economic evaluation, patient level analysis or decision analytic modelling,
methodological uncertainty is best addressed via sensitivity analysis or methodological
standards, such as a ‘reference case’(202).

4.4 The healthcare interventions
The Exercise Medicine Research Institute (EMRI) was established in 2003 and
houses a productive, multidisciplinary exercise science research team, dedicated to
investigating the extent to which exercise can be employed in chronic disease
management, principally cancer, to improve patient outcomes. Central to the Institute’s
achievements in cancer research is the unique combination of clinical patient care,
exercise medicine, and innovation in health interventions. Their seminal work in PCa
has enabled translation of their research findings into practical outcomes for patient
benefit and led to the design and implementation of clinical and community-based
cancer survivorship programs(224). Researchers from EMRI are part of the research
team at the Centre for Research Excellence in Prostate Cancer Survivorship, which
received funding from the National Health and Medical Research Council (NHMRC) in
2016(225).
Exercise interventions for men receiving ADT for PCa have been shown to be
effective at managing many of the associated adverse effects (Chapter 3), yet no
economic evaluations have been conducted to determine the cost-effectiveness of
these interventions. As PCa involves a number of stages, and the needs of men at
various stages are different, it is important to include exercise interventions that
address these differences. For this reason, economic evaluations were conducted of
two clinical trials. These clinical trials provide a platform from which to begin
exploration of the cost-effectiveness of supervised exercise for men receiving ADT for
PCa. The first trial was a small RCT of supervised exercise for men receiving ADT for
advanced disease, metastatic to bone(34). This population are often excluded from
exercise RCTs due to fear of fragility fracture and thus, also difficult to recruit. Given
the high risk of falls and fractures and elevated mortality risks after a fall in this
population, it is particularly important to establish the safety and efficacy of supervised
exercise. The results of this RCT showed that supervised exercise was safe for PCa
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patients with bone metastases. At 3-month follow-up, there were significant differences
favouring the exercise group in physical function (greater strength in leg extension, and
faster speeds over the 400m and 6m timed walks), improved physical activity and body
composition (increases in whole body and appendicular lean mass)(34).
The second RCT involved men with a longer life expectancy, who were from the
Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen
Deprivation and Radiotherapy (RADAR) trial(36). Long-term PCa survivors are at
increased risk for comorbidities and physical deconditioning, so the aim of this trial was
to determine the effectiveness of a year-long randomised controlled trial of exercise
training on physical functioning in PCa survivors more than five years after diagnosis.
The sample size in this trial was larger (n=100) and the follow-up longer (6-months
supervised + 6-months home-based exercise). For those in the intervention group,
results showed significant improvements in cardiorespiratory fitness, lower body
physical function and muscle strength, as well as increases in appendicular lean
mass(36).
Given the limitations associated with economic evaluations of single clinical trials
described above, a decision-analytic framework using Markov modelling was employed
for the third economic evaluation, a cost-utility analysis of exercise for men with high
risk localised or locally advanced PCa receiving curative therapy and ADT. The
methods employed in these three economic evaluations are briefly described below.

4.5 Economic evaluation of the healthcare interventions
4.5.1 Cost-effectiveness analysis of a pilot RCT of supervised exercise for
PCa patients with bone metastases (Chapter 5)
A trial-based economic evaluation of the above RCT, a pilot, 3-month supervised
exercise intervention versus a recommendation to exercise is conducted. An Australian
healthcare payer perspective is presented as a reference case analysis with a societal
perspective presented as a sensitivity analysis. The primary outcome measure for the
economic analysis is QALYs, estimated by the area-under-the curve method from
patient-reported health status at baseline and three months using the SF-36
questionnaire(226). QALYs are calculated from participant responses using the SF-6D
standard gamble health state valuation to estimate utility, a preference based single
index score(227). UK weights based on Brazier et al. were used to value the SF-6D
because the original analysis was conducted in 2014 before the release of the
Australian utility weights(214). QALYs were generated by multiplying three months of
life by the utility score for each participant.
Costs and monetary benefits are expressed in Australian dollars (AUD) at 2018
prices. Costs and effects are not discounted because the duration of the trial is one
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year. Random sampling of the intervention and control group (n=20) is conducted to
generate values for the non-parametric bootstrapping used to derive uncertainty
intervals around point estimates of the ICERs. Bootstrapping with replacement is used
to generate 1000 cost and outcome pairs to determine the probability distribution of
costs and outcomes, which are plotted on a cost-effectiveness plane. Costeffectiveness acceptability curves are derived to depict the probability that the
intervention is cost effective across a range of willingness-to-pay thresholds.
Given the high levels of uncertainty associated with a pilot study with a small
sample size, a value of Information (VOI) analysis is conducted. VOI is a systematic
approach to measure decision uncertainty and determine whether there is sufficient
evidence to support the adoption of new interventions(228). It provides a framework for
quantitatively estimating the value of additional evidence in informing a decision. By
estimating the probability of error and the opportunity costs of error, the expected cost
of uncertainty or expected opportunity loss associated with a decision can be
calculated(219). This involves the difference between the expected net benefit of a
decision made without perfect information (current information) and one made with
perfect information. This is referred to as the expected value of perfect information
(EVPI) and, because decisions are taken at the population level, population EVPI is
also calculated(219, 229).
4.5.2 Cost-effectiveness analysis of a supervised exercise intervention for
men with PCa previously treated with radiation therapy and androgen
deprivation therapy (Chapter 6)
A trial-based economic evaluation of the above RCT, a six-month supervised
exercise intervention versus a recommendation to exercise and a physical activity
booklet is conducted. An Australian healthcare payer perspective is presented as a
reference case analysis with a societal perspective presented as a sensitivity analysis.
The primary outcome measure is QALYs gained which are calculated from participant
responses to the SF-36 questionnaire using the SF-6D standard gamble health state
valuation to estimate utility, a preference based single index measure for health(226,
227). QALYs are generated by multiplying six months of life (the follow-up period for
the supervised intervention) by the utility score for each participant. Costs and
monetary benefits are expressed in Australian dollars (AUD) at 2018 prices. Costs and
effects are not discounted because the duration of the trial is one year. Random
sampling of the intervention and control group (n=100) is conducted to generate values
for the non-parametric bootstrapping used to derive uncertainty intervals around point
estimates of the ICERs. To determine the probability distribution of costs and
outcomes, 1000 cost and outcome pairs are generated by bootstrapping with
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replacement and plotted on a cost-effectiveness plane. Cost-effectiveness acceptability
curves are derived to depict the probability that the intervention is cost effective across
a range of willingness-to-pay thresholds.
4.5.3 Cost-utility of a supervised exercise intervention to prevent falls and
fractures in men with PCa: a Markov model (Chapter 7)
Limitations of within trial analysis and advantages of a modelled analysis are
described above (4.3.2). A decision-analytic framework using Markov modelling is
conducted for the third economic evaluation, a cost-utility analysis of exercise for men
with high risk localised or locally advanced PCa receiving curative therapy and ADT.
The analysis is conducted from an Australian healthcare payer perspective. The time
horizon is three years so as to capture the longer-term impact of ADT on physical
function and bone mineral density, which can impact on risk of falls and fractures.
Costs and monetary benefits are discounted at 5% over the time horizon and
expressed in Australian dollars at 2019 prices. The primary outcome measure is NMB.
This model incorporates evidence from the literature, outcomes from clinical trials and
expert knowledge. All economic evaluations included in this thesis conformed to the
Consolidated Health Economic Evaluation Reporting Standards (CHEERS)
Statement(230), and the ISPOR Good Research Practice Guidelines for Costeffectiveness Analysis Alongside Clinical Trials(231).
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Chapter 5 Demonstrating the value of early economic
evaluation alongside clinical trials: exercise medicine for men
with metastatic prostate cancer
5.1 Introduction
Prostate cancer (PCa) patients with bone metastases tend to have significant
functional impairment from long-term androgen deprivation therapy (ADT), exacerbated
by subsequent treatments such as second-line hormone therapies (abiraterone and
enzalutamide), first and second line chemotherapy or immunotherapies(56). They are
at significant risk of falls, fractures and consequent hospitalisation. There is a growing
body of evidence to support the effectiveness of exercise in addressing the adverse
effects of advanced PCa treatment(50). Despite recommendations for men with bone
metastases to participate in supervised exercise, there is often a reticence on the part
of clinicians and/or patients due to concerns of fragility fracture or other adverse
effects(56). These men with significant treatment toxicity and a high disease burden
are an important patient group for whom exercise has been demonstrated to improve
quality of life (QoL)(147). To inform policy and improve accessibility of exercise for
advanced PCa patients, it is important to determine whether such interventions
represent value for money.
Economic evaluations of effective programs, especially those based on the
outcomes of randomised controlled trials (RCTs), are important sources of information
to support decision-making about allocation of scarce resources. To date, no costeffective analyses (CEAs) of exercise interventions for PCa patients with bone
metastases have been conducted. Therefore, in this article, we demonstrate how an
exploratory CEA of a pilot RCT of supervised exercise training for men with metastatic
PCa can determine whether this exercise intervention is potentially cost-effective
compared to usual care and, using value of information (VOI) analysis, whether a
larger RCT is worthwhile.

5.2 Cost-effectiveness analysis methods
A trial-based CEA was conducted of a pilot RCT involving 20 patients with
metastatic PCa at university affiliated exercise clinics in Perth, Western Australia, from
July 2011 to July 2012(34). Ten patients were randomised into each arm: resistance
exercise or usual care. There were no significant differences between groups at
baseline. The exercise intervention involved twice-weekly 60-minute resistance
exercise sessions conducted in small groups over 12 weeks. Usual care involved
maintaining customary activities throughout the intervention period. Outcome
assessments were conducted at baseline and after the 12-week intervention and
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included objectively measured and patient-reported outcomes. Details of the study
methods and outcomes are reported elsewhere(34).
The CEA was conducted from a healthcare payer perspective. The primary
outcome measure was quality adjusted life years (QALYs), calculated by multiplying
the utility weight by the duration spent in each health state from patient-reported health
status at baseline and after the 3-month intervention using the SF-36 questionnaire.
Participant responses were scored using the SF-6D standard gamble health state
valuation to estimate utility weights, a preference based single index score measured
on a cardinal scale which typically ranges from 0 (death) to 1 (best health). The
duration in each health state was then multiplied by the utility weight to calculate
QALYs(227).
Costs associated with the intervention were calculated as those costs additional to
usual care of PCa patients. The total cost of implementing the exercise intervention
included labour costs for participant registration, a pre-intervention consultation with an
accredited exercise physiologist (AEP), administration and conduct of exercise
sessions by the AEP, and the GP visit to determine eligibility to participate in exercise
training.
We compared mean costs and mean effects between the intervention and control
groups to determine incremental cost and incremental effect. Incremental costeffectiveness ratios (ICERS) were calculated, which represent the additional
expenditure required to deliver each additional unit of benefit. We set WTP at
$AU50,000 per QALY, a commonly used threshold for cost-effectiveness in
Australia(207).
To derive uncertainty intervals around point estimates of the ICERs, non-parametric
bootstrapping was used by random sampling of values from the intervention and
control groups (n=20). The economic analysis was carried out using Excel for Office
365 (MSO 2016, Version 1902, Microsoft, Seattle). All costs were reported in
Australian dollars (AU$) and adjusted to real prices in the 2018 reference year(232)
(AU$1 ≈ £0.56; US$ 0.68). Discounting future costs and benefits was not used due to
the 12-month trial duration.

5.3 Value of information analysis methods
To estimate the potential value for money of future research (e.g. larger RCT), VOI
analysis was conducted. VOI provides a framework for quantitatively estimating the
value of additional evidence to reduce uncertainty and better inform funding decisions.
It considers the probability of a funding decision error, the opportunity costs of error,
and the size of the population expected to benefit from research results over a given
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time horizon(228). Based on the bootstrap simulation, we calculated the expected
value of perfect information (EVPI), which is the difference between the expected
monetary benefit of a decision made without perfect information (current information)
and one made with perfect information. The estimated EVPI was scaled up to the
population expected to benefit from the intervention (i.e., men with metastatic PCa)
over the coming 10 years with a 5% discount rate(228). To calculate population EVPI,
the 2017 PCa prevalence was converted to absolute incidence and projected to 2028
(233, 234). Men with metastatic cancer in Australia represent approximately 3% of this
population (n=13,122)(233).

5.4 Results
Cost-effectiveness results for the three months of the pilot study are shown in
Table 12. The intervention group cost $461 more than the control group per patient.
The QALY gain for the intervention group versus the usual care group was 0.0035, with
an incremental cost per QALY gained of $133,509. A cost-effectiveness acceptability
curve of gains in QALYs shows that, at a WTP of $50,000, the base case intervention
would have a 30% probability of being cost-effective (Figure 3a); the probability
distribution of costs and outcomes, generated by bootstrap sampling, are depicted on
the cost-effectiveness plane (Figure 3b).
Table 12 Cost-effectiveness results for supervised exercise intervention
Variable
Mean cost
Mean QALYs

Control
group
$0
0.1741

Intervention
group
$461
0.1776

Difference
(95% CI)
$461
0.0035
(-0.0162 - 0.0225)

Abbreviations: ICER incremental cost effectiveness ratio; QALY quality adjusted life years
Notes: 1Fewer QALYs gained at an additional cost

ICER
(95% CI)
$133,509
($20,494 - Dominated1)
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Figure 3 Cost-effectiveness results: QALYs (3a & 3b)
Figure 3a Cost-effectiveness acceptability curve showing probability supervised exercise intervention was cost-effective compared to usual care
Willingness-to-pay threshold AU$50,000
Figure 3b Bootstrap results on the cost-effectiveness plane: incremental costs and incremental QALYs
Q1: quadrant 1 more effective and more costly than comparator
Q4: quadrant 4 less effective and more costly than comparator
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The per person EVPI for the intervention group was $85. The population EVPI for
the intervention was $971,520 which represents the upper-bound (i.e., maximum)
expected benefit of future research. While there are opportunity costs to funding any
research, if the population EVPI exceeds the expected costs of additional research
(direct research costs and indirect (i.e. opportunity cost), then additional research is
potentially worthwhile (i.e., it is likely to be cost-effective to conduct further research).

5.5 Discussion
This study investigated approaches to economic analysis of exercise interventions
for PCa patients with bone metastases to examine the potential value of a larger trial.
The intervention achieved a small QoL gain and was effective in increasing physical
activity, improving physical function and increasing lean body mass, thus addressing a
number of the risks confronted by PCa patients with bone metastases. However, the
costs to gain these QoL and clinical benefits were relatively expensive.
The main limitation of the analysis was the small sample size of the pilot study, the
consequence of an older population with high disease load, typically difficult to enrol in
exercise trials(34). In addition, no data were collected beyond three months, which
meant that it was not possible to determine post intervention outcomes such as falls,
fractures, adverse events, metabolic and lifestyle diseases or further improvement in
trial outcomes for participants. The absence of such data means that related
healthcare treatment costs or cost-savings for the post intervention phase could not be
captured, which would have an impact on the CEA.
Due to the uncertainty associated with a small sample, short follow-up and lack of
evidence required to construct a modelled analysis of the impact of exercise on the
adverse effects of ADT for PCa patients with bone metastases, the feasibility of more
research to enhance decision making is an important consideration. VOI analysis
generated a population EVPI of $971,520 over ten years, suggesting a further study,
undertaken for a lower cost than the EVPI, is likely to be worthwhile.
To improve the quality of economic evaluations conducted alongside clinical trials,
there is a need for these evaluations to be part of early pilot studies to demonstrate
feasibility and inform economic data collection in future studies. Under constrained
research resources (e.g. funding and participants) quantitative approaches such as
VOI analyses can be applied to inform the value for money of larger RCTs. Early
economic evaluations are important in identifying research gaps in order to more
rapidly advance an important field of study such as exercise for PCa patients with bone
metastases. Future research should address the methodology to better capture health
benefits and involve a larger sample with longer follow up to improve CEA in this
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population. Improved CEA means better informed decision makers, and potentially,
more accessible exercise and improved QoL for PCa patients with bone metastases.
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Chapter 6 Cost-effectiveness analysis of supervised exercise
training in men with prostate cancer previously treated with
radiation therapy and androgen deprivation therapy
6.1 Introduction
Prostate cancer (PCa) is a significant public health issue. It has a high incidence
and is the cause of significant morbidity and mortality. In Australian men, it is the most
commonly diagnosed cancer and the second most common cause of cancer death
after lung cancer(234). PCa needs testosterone, an androgen (male sex hormone), to
grow. Androgen deprivation therapy (ADT), which reduces or blocks androgen
production, is thus widely used across the spectrum of PCa from high-risk localised
disease to metastatic disease. However, it is associated with potentially debilitating
adverse effects such as changes in body composition (e.g., increased fat mass,
reduced muscle mass [sarcopenia]), metabolic complications and decline in physical
function. The risk of adverse effects is an important consideration for men with long life
expectancies, such as those men receiving neoadjuvant or adjuvant therapy with
curative radiation(36). In older PCa survivors (>70 years), testosterone does not
always recover, so adverse effects for this population may not be temporary(36).
Exercise has been shown to be effective in addressing metabolic function and
associated comorbidities (e.g. diabetes, CVD, etc.), as well as sarcopenia and
significant functional impairment resulting from long term androgen deprivation(36, 48,
49, 139, 141, 142, 161, 199, 235-237). A recent meta-analysis of exercise for cancer
randomised controlled trials (RCTs) using individual patient-level data found that
supervised exercise effectively improves quality of life and physical function across sub
groups of cancer patients with different demographic and clinical characteristics, both
during and after treatment(235). In addition, an umbrella systematic review of metaanalyses of exercise clinical trials concluded that exercise was beneficial for cancer
survivors, and seventy-five per cent of these beneficial effects were statistically
significant(236). The largest effect sizes were for cardiovascular fitness and muscle
strength. If increased physical activity significantly improves cardiorespiratory fitness,
muscle mass and physical functioning, which can potentially reduce the risk of
metabolic diseases and comorbidities, as well as falls and subsequent fractures, and
improve quality of life, then it is important to determine whether such interventions are
cost effective to implement.
Economic evaluations of effective programs, particularly those based on the
outcomes of RCTs, play an important role in the allocation of scarce resources. Costeffectiveness analysis evaluates the effectiveness of interventions relative to their cost
with the purpose of informing health care policy decision making(202). While there has
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been an increase in the number of studies evaluating the cost- effectiveness of
exercise interventions in recent years, only a small number of studies have
investigated the impact of exercise interventions on adults with cancer(238-245). Eight
studies were identified in the literature, six related to breast cancer(239, 241-245), one
to lung cancer(238) and another to a number of different cancers (breast, colon,
ovarian, cervical, testicular and lymphoma)(240). Mode of delivery of exercise
interventions differed across studies, from the use of a DVD in the home with no
supervision(239); delivery by physiotherapists(240-243, 245); or face-to-face or
telephone delivery by qualified exercise physiologists (AEPs) (244, 245). Intensive
exercise interventions for cancer patients were most often not cost effective. Results of
the economic analyses tended to generate high incremental costs per QALY and/or
low probability of cost-effectiveness, and none included participants with PCa. Given
that over 80% of Australian men diagnosed with PCa have Stage I or II disease, they
will potentially need to manage the impacts of ADT for a long period of time(234).
Therefore, identifying those most likely to benefit from increased physical activity, and
the cost and cost-effectiveness of providing exercise interventions is important, and
especially important for those with PCa receiving ADT.
We conducted an economic evaluation of a multi-centre RCT of supervised
exercise training (resistance and aerobic) in long-term PCa survivors (>5 years post
diagnosis) from the Trans-Tasman Radiation Oncology Group (TROG) 03.04
Randomised Androgen Deprivation and Radiotherapy (RADAR) trial designed to
determine the effectiveness of supervised exercise training on cardiovascular fitness
and physical functioning(36).

6.2 Methods
6.2.1 RCT targeted population, setting and location
A multicentre, RCT of exercise training (resistance and aerobic) was conducted
with long-term PCa survivors previously treated with ADT and radiotherapy from the
TROG 03.04 RADAR trial. One hundred PCa survivors diagnosed approximately five
years previously were randomised into one of two arms: 1. a 6-month supervised
exercise intervention followed by a 6-month home-based maintenance programme or
2. a general recommendation to perform 150 minutes of moderate physical activity
based on a printed booklet. Supervised exercise comprised twice weekly 1-hour
sessions in small groups for six months and consisted of moderate- to high-intensity
resistance training using exercise machines and aerobic exercise such as walking,
cycling or jogging. The exercise intervention was supervised by accredited exercise
physiologists in 13 university-affiliated exercise clinics across Western Australia, New
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South Wales and Wellington, New Zealand(36). The comparator arm represents usual
care; healthcare providers should recommend their patients perform 150 minutes of
moderate physical exercise per week(50, 51).
There were no significant differences in characteristics between the two
groups(36). For the total sample, baseline means were as follows: age - 72 years; time
since radiation cessation - 51 months; time since ADT cessation - 38 months; and
duration of previous ADT - 12 months. Outcome assessments were conducted at
baseline, after the initial 6-month supervised exercise portion of the intervention and at
12 months after the 6-month home-based maintenance program. Details of the study
methods are reported elsewhere, as well as intervention effects at six months(36). The
RCT was registered with the Australian New Zealand Clinical Trials Registry
(ACTRN12609000729224) and approved by the Edith Cowan University Human
Research Ethics Committee (HREC No. 3636).
6.2.2 RCT outcomes
The primary trial outcome (400 metre walk test) at 6-month follow-up significantly
favoured the intervention group. The adjusted mean group difference in
cardiorespiratory performance between groups for the 400 metre walk test was 19
seconds (95% CI 3.95 - 42.0; p=0.029)(36).
6.2.3 Economic evaluation
A trial-based economic evaluation of the 6-month supervised exercise portion of the
RCT versus a recommendation to exercise and provision of a physical activity booklet
was conducted. The 6-month intervention included 100 men aged 62-85 years, 50 in
each arm(36). The 12-month SF-36 outcome data collected after the home-based
maintenance exercise program was not incorporated in the main analysis because the
initial intention was to capture the benefits of supervised exercise. Exercise
intervention adherence and sustainability is a recognized problem in exercise
interventions for older community dwelling adults(246). At-risk and frail older adult
populations tend not to maintain behavioural change or functional improvement at 12
months post intervention(247), however, for this trial, there is evidence of benefit
maintenance post intervention. In addition, older adults who are physically active have
been shown to maintain behavioural and functional improvement from 6-24 months
post intervention(247-250). With consideration of this evidence and the fact that the
intervention involves men with PCa, for whom little evidence currently exists outside
this trial, maintenance of HRQoL outcomes at 12 months are presented as a sensitivity
analysis.
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An Australian healthcare payer perspective was presented as a reference case
analysis with a societal perspective presented as a sensitivity analysis. This paper
conformed to the Consolidated Health Economic Evaluation Reporting Standards
(CHEERS) Statement(230), and the ISPOR Good Research Practice Guidelines for
Cost-effectiveness Analysis Alongside Clinical Trials(231).
6.2.3.1 Primary outcome: Quality adjusted life years (QALYs)

The primary outcome measure for the economic analysis was QALYs, estimated by
the area-under-the curve method from patient-reported health status at baseline and 6
months using the SF-36 questionnaire, a measure of general health widely used in
clinical studies internationally(226). QALYs were calculated from participant responses
using the SF-6D standard gamble health state valuation, a preference based single
index measure for health, to estimate utility(227). UK weights based on Brazier et al.
were used(214). QALYs were generated by multiplying six months of life (the follow-up
period for the supervised portion of the study) by the utility score for each participant.
6.2.3.2 Secondary outcome: Cardiorespiratory fitness and functional mobility

Cardiorespiratory fitness is important in addressing metabolic and CVD risk, as well
as risk of falls and fractures, particularly for men who have received curative treatment
and ADT for PCa, who typically have a relatively long life expectancy. The 400-metre
walk, measured in seconds, was the secondary outcome for the economic analysis.
Performance on this test is associated with mortality, CVD and functional mobility(251,
252).
6.2.3.3 Measuring resource use and costs

The total cost of implementing the physical activity intervention was estimated from
a healthcare payer perspective. Costs arising from research (e.g. cost of heart monitor
for exercise arm and pedometers for both arms of the trial) and development
(engagement with oncologists and general practitioners (GPs) to refer patients; time
spent on development of exercise booklet for control arm) were excluded so that only
the costs of replicating the intervention were captured. Project records relating to
intervention delivery, including costs, were kept for the period of the trial.
Implementation costs included labour for participant registration, a pre-intervention
consultation with an accredited exercise physiologist (AEP), administration and
conduct of the exercise sessions by the AEP, and the GP visit to determine eligibility
for inclusion in the trial. Resource use costs included those costs specific to the
intervention such as communication (telephone calls) with participants, material and
printing costs.
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A societal perspective was estimated as a sensitivity analysis (see SA2
below)(253). Participant out-of-pocket costs for the sensitivity analysis (SA2) included
gym membership as a proxy for attendance at the university exercise clinic (imputed as
an average concession rate across a number of gyms) and travel costs for the six
months participation. It was assumed that participants would choose a gym that was
relatively close and convenient to their home or workplace, hence minimising travel
time and cost.
6.2.3.4 Valuing resource costs

To provide monetary values for resource use, prices or unit costs were applied.
Resources were valued using local or national costs where appropriate. All costs were
reported in Australian dollars (AU$) (AU$1 ≈ US$ 0.68) and adjusted to real prices in
the 2018 reference year(232). Discounting was not applied due to the evaluated
portion of the trial being less than 12 months. Usual care involved an information
booklet on exercise and a recommendation to exercise for 150 minutes per week, so
the cost assigned to usual care was that of the information booklet. The incremental
costs associated with the intervention were calculated as those costs additional to
usual care of PCa survivors. Edith Cowan University (ECU) higher education worker
(HEW) pay scales were used to impute labour costs for graduate AEPs(254). On-costs
(labour costs in addition to salaries and wages such as superannuation, payroll tax,
workers compensation and long service leave) of 30% were included. This figure was
used to account for variation arising from casual, short-term or ongoing contractual
arrangements (16%-40%)(255). Attendance was collected for twice weekly exercise
sessions and this cost was based on attendance of four people per session across 13
gyms for the period of the trial. The cost of the Level B GP visit was determined using
the Australian Medicare Benefits Schedule (MBS)(256). All other resource use
categories were valued using market rates.
For the societal perspective, patient out of pocket exercise session costs were
imputed as concession rate gym membership averaged across a number of exercise
facilities. Travel costs were estimated based on a cents per kilometre rate (AU$0.64)
for a car with a 1600cc engine, as per the Australian Taxation Office(257). Distances
travelled were estimated from participant data collected by exercise physiologists. In
calculating a representative travel cost, consideration was given to participants using
public transport(258).
6.2.3.5 Cost-effectiveness analysis

Cost-effectiveness analysis was carried out using Microsoft® Excel version 16.0.1
(Microsoft, Seattle). We compared the mean costs and mean effects between the
68

intervention and control groups to determine incremental cost and incremental effect.
Missing data for the primary outcome measure (QALYs) was addressed using
maximum likelihood imputation (expectation maximisation). SF-36 generates multiple
values within eight domains. From these values a composite utility score using the SF6D algorithm is calculated. However, missing values in any of the eight domains results
in the utility values not being generated. For the purposes of calculating accurate utility
values and QALYs gained for the economic analysis, multiple imputation was
conducted separately for the SF-36 baseline and six-and 12-month outcomes in R
(version 3.4.1 (2017-06-30) – "Single Candle"). In order to check for convergence, five
imputations (with 30 iterations each) using multiple imputation by chained equations
(MICE) was computed. Predictive mean matching (imputations are restricted to the
observed values) was used to impute the variables of interest(259). In addition, the
iNMB was calculated as the difference in mean QALYs multiplied by the maximum
willingness-to-pay for a QALY minus the difference in mean cost.
Incremental cost-effectiveness ratios (ICERs) were calculated for the secondary
outcome (cardiorespiratory fitness and functional mobility) and represent the additional
expenditure required to deliver each additional unit of benefit. The ICER calculated was
the cost per mean reduction in walking time (seconds) over 400 metres. The difference
in mean costs was divided by the difference in mean effects between the intervention
and control groups over the six months of the intervention.
6.2.3.6 Uncertainty analyses

Random sampling of the intervention and control group (n=100) was conducted to
generate values for the non-parametric bootstrapping used to derive uncertainty
intervals around point estimates of the ICERs. To determine the probability distribution
of costs and outcomes, 1000 cost and outcome pairs were generated by bootstrapping
with replacement and these were plotted on a cost-effectiveness plane. Costeffectiveness acceptability curves were derived to depict the probability that the
intervention is cost effective given a decision maker’s willingness-to-pay per QALY.
6.2.3.7 Sensitivity and scenario analyses

Univariate sensitivity analyses were undertaken to explore the impact on the ICER
of variations in the evaluation components from the trial (Appendix 4). These included:
Sensitivity analysis 1 (SA1). variation in the magnitude of effect size using the upper
and lower confidence interval limits; Sensitivity analysis 2 (SA2). societal perspective
based on addition of patient out-of-pocket costs; Sensitivity analysis 3 (SA3). variation
in cost based on number of participants attending the exercise session and reduced
pre-consult time with AEP; and Sensitivity analysis 4 (SA4). maintenance of quality of
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life outcomes after the 6-month home-based exercise program. Two scenario analyses
were also undertaken to explore their potential cost-effectiveness. Scenario 1 (S1)
involved scaling up the intervention to a community-based group based on a minimum
of 10 participants, MBS costs for the AEP, and administrative staff wages to reduce
implementation costs. Scenario 2 (S2) involved a private cancer clinic in-house
exercise gym. The provision of the gym is part of the business model as a way of
creating competitive advantage. Patient requires a Chronic Disease Management Plan
and cost of exercise equipment and maintenance is included as an opportunity cost in
patient fees.

6.3 Results
6.3.1 Costs and outcomes
Intervention costs calculated are shown in Table 13 From a healthcare payer
perspective, the cost of the intervention over six months was calculated as AU$550
(2018). The cost of the control arm, usual care, was AU$4 (2018) for the provided
exercise booklet, because usual care for PCa survivors is typically a recommendation
to do light to moderate exercise or no advice, creating no additional cost. The
incremental cost of the intervention was thus AU$546 (2018).
Table 13 Breakdown of costs of exercise intervention over 6 months of RCT
Intervention cost
component

Cost description

Unit of measure

GP consent

MBS Item 23: Level B GP
consultation less than 20 minutes
ECU HEW level 5 Step 2 + 30%
on-costs $78,335 (2012)
Calls to participants during
intervention
1 hour consult @ HEW level 5
Step 2 + 30% on-costs

1 consultation ($37.05)

Registration of
RCT participants
Program
administration
AEP pre-program
consultation
Subtotal
26-week exercise
intervention

Cost per
participant
AU$
$37

1.3% of workload allocated across 2
concurrent programs
Three calls per participant at 0.26

$1

Hourly rate ($30.38) + 30% on- costs

$40

1 hour consult @ HEW level 5
4 participants (mean no.) per session
step 2 + 30% on-costs
over 6 months follow up of trial across
mean no. of sessions attended 40 13 gyms Hourly rate $40.17
Total healthcare perspective (rounded to nearest 2011$)
Adjusted to 2018$
Societal perspective: Participant out of pocket costs
Exercise program 6-month concession exercise
6 months while participating in
membership
membership averaged across
intervention; approx. $25/fortnight
several exercise clinics
Travel
Car costs/return bus travel
$0.64 per km 1600cc engine. Approx.
mean no. of sessions (n=40)
$5/week or $2.50/ session attended
(includes consideration of those who
take free public transport)
Total societal perspective (rounded to nearest 2011$)
Adjusted to 2018$

$20

$98
$402
$500
$550
$325
$100

$925
$1017

Abbreviations: GP general practitioner; MBS Medicare benefits schedule; RCT randomised controlled trial; ECU Edith Cowan University; HEW
higher education worker; AEP accredited exercise physiologist.
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6.3.2 Outcomes
The results for the primary and secondary outcomes are reported in Table 14.
Table 14 Cost-effectiveness results for supervised exercise intervention
Variable
Mean cost
Mean QALYs
Mean seconds change
in walking time
(400m walk test)

Control
group
$4
0.3681

Intervention
group
$550
0.3766

2.9

-18.6

Difference
(95% CI)
$546
0.0085
(-0.0093 - 0.0256)
192
(3.95 - 42.0)

ICER
(95% CI)
$64,235
($21,307 - Dominated1)
$29
($13 - $110)

Abbreviations: ICER incremental cost-effectiveness ratio QALYs quality adjusted life years
Notes: 1Fewer QALYs gained at an additional cost; 2adjusted for baseline

Quality adjusted life years gained for the intervention versus the usual care group
was 0.0085, with the incremental cost per QALY gain at six months being AU$64,235.
At a willingness-to-pay of AU$50,000, the lower bounds of the iNMB statistic were less
than zero (-AU$1000), which suggests the intervention may not be cost effective. A
cost-effectiveness acceptability curve of gains in QALYs shows that, at a willingness to
pay of AU$50,000, the reference case intervention would have a 41% probability of
being cost effective (Figure 4). A cost-effectiveness plane shows the probability
distribution of costs and outcomes generated by bootstrap sampling (Figure 5). The
results are distributed across quadrants one and four, showing the intervention was
more costly and more effective, but also more costly and less effective, respectively.
The cardiovascular fitness outcome for the intervention versus control group was a 19
second reduction in walking time over 400 metres (95% CI 3.95-42.0). The incremental
cost per second was AU$29 (95% CI $13-$110).

71

Incremental difference in cost (AUD)

Figure 4 Cost-effectiveness acceptability curve
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Incremental difference in effect: QALYs

Figure 5 Cost-effectiveness plane
6.3.3 Univariate sensitivity analysis
For the primary outcome, QALYs, SA1 increased the mean magnitude of effect
(0.0085) to the upper confidence interval limit (0.0256), resulting in a cost per QALY
gain of AU$21,307. SA2 presents the societal perspective which, at an incremental
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cost of AU$1012 results in a cost per QALY gain of AU$119,059. SA3 reduced the cost
of implementing the intervention which resulted in a cost per QALY gain of AU$41,882.
SA4 extended the impact of the intervention to 12 months (6-month supervised
intervention + 6-month home-based intervention with exercise booklet) and resulted in
a cost per QALY gain over 12 months of $32,051.
6.3.4 Scenario analyses
Scenario 1 varied costs of implementing the intervention in a real world setting such
as a community-based program with increased numbers of participants per session,
MBS item numbers to calculate AEP time and clerical awards to cost administrative
duties, resulting in reduced implementation costs and a cost per QALY gain of
AU$31,175. In Scenario 2, which incorporated the use of an in-house exercise gym at
a private cancer clinic, the cost per QALY gain of the intervention was AU$19,752.
6.4 Discussion
In this study, patient-level data were used to explore the cost-effectiveness of
supervised exercise for long-term PCa survivors who had previously received radiation
therapy and ADT as part of the TROG 03.04 RADAR trial. This is the first costeffectiveness study of a RCT of a supervised exercise intervention for long-term PCa
survivors. The intervention demonstrated significant improvements at six months in
terms of improved cardiorespiratory fitness, lower-body physical function and increased
muscle strength, suggesting it is effective in addressing many of the health risks
confronted by long-term PCa survivors receiving ADT, which could potentially lead to
hospitalization, reduced quality of life and increasing health costs into the future for this
population.
The cost-effectiveness analysis assessed the value of the exercise intervention
using QALYs gained and outcomes from the 400-metre timed walk. From a healthcare
payer perspective, the incremental cost of the intervention was $546. The value of the
ICER was AU$64,235 per QALY gained. For cardiorespiratory fitness and functional
mobility, the ICER per second reduction in walking time in the 400-metre walk was
AU$29. While this seems inexpensive and there is evidence that better performance in
this test impacts on mortality, risk of CVD, functional mobility and functional disability, it
is an intermediate and abstract outcome(252). There is no way to evaluate what this
means for the patient and it therefore provides little useful information for a decision
maker.
Very few cost-effectiveness analyses have been conducted of exercise for any type
of cancer(238-245), of which, only one was cost effective(245) and one had a high
probability of cost-effectiveness(240). Many of these studies had short term follow-up,
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small sample sizes, adherence or persistence issues, effected little change in quality of
life measures and involved costly interventions, all of which impacted on costeffectiveness outcomes. Systematic reviews of economic evaluations of physical
activity interventions have also noted that intensive exercise programs tend to be more
expensive and thus less cost effective(260-262). The challenge with cost-effectiveness
analysis of exercise interventions relates to consistently measuring the impacts of
physical activity and the diseases or effects associated with not doing physical activity.
Outcomes used to measure the impact of exercise tend to be intermediate such as
increased walking speed, reduced body fat and increased muscle mass or muscle
strength. The lack of long-term data is a contributing factor. It is likely that were such
evidence collected, cost-savings based on reduced incidence of falls or fractures,
metabolic and lifestyle diseases such as diabetes or CVD and cancer recurrence or
progression, would contribute to the cost-effectiveness of exercise programs.
QALYs are the recommended method for measuring benefit in a cost-effectiveness
analysis because they provide a common metric which enables comparison of
effectiveness across a wide range of health conditions. However, there are challenges
in using QALYs and the instruments used to derive the utilities from which QALYs are
calculated(263, 264). As this study and others have shown, quality of life measures are
not always sensitive to change, despite the beneficial outcomes of the trials(265-268).
The incremental utility when converted to QALYs can thus be relatively small, which
may impact on cost-effectiveness, particularly of an intensive intervention. However, it
is often such interventions that are more effective(262, 269). Recipients of curative
treatment for PCa are typically younger than those with more advanced disease and
the RADAR cohort were well-functioning(36), which means there may also be a ceiling
effect in terms of perceived benefit. Given that QALYs may not adequately capture all
the benefits associated with cancer-related interventions, cancer MAUIs have recently
been developed from which utilities can be derived that are more sensitive to the
experience of cancer populations(270). In addition, broader measures of quality of life
such as the e-QALY, that capture benefits other than health, are also being
developed(271). These alternatives to currently existing MAUIs and broader measures
of benefit may provide more sensitive measurements of quality of life for cancer
patients and survivors in the future.
While the supervised exercise intervention for PCa survivors from the RADAR trial
at 6-month follow-up was not cost effective at a willingness-to-pay threshold of
AU$50,000, sensitivity analysis 4 (SA4), which showed maintenance of HRQoL
outcomes at 12 months (after the 6-month home-based exercise program), reduced
the cost of the program by almost half and brought the cost per QALY gained well
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below the willingness-to-pay threshold of AU$50,000. If achievable in a real-world
implementation, a similar intervention would potentially provide an attractive policy
option. Similarly, interventions with reduced costs (SA3, S1 & S2) or improved HRQoL
outcomes (SA1), also brought the cost per QALY below this threshold.
The cost-effectiveness of any intervention inevitably depends on decision makers
and how they value the intended outcome for the relevant population. In this case, it is
what policy makers are willing to pay for the improved cardiovascular fitness and
functional mobility of PCa survivors given the potential impact this will have on their risk
of chronic disease, falls and fractures and their consequent health resource use and
productivity. There was no within trial evidence to determine the benefits associated
with the significant trial outcomes, and while modelling might be an option, sufficient
evidence to populate such a model is not currently available. Research has
demonstrated the association between performance in the 400-metre walk test and
mobility limitation, as well as CVD(252) and the cardiovascular toxicity associated with
ADT(63, 78-81, 84, 85, 272). Numerous studies in the literature report on the health
benefits of exercise(49, 141, 235, 236, 273, 274), particularly in relation to muscle
strength and falls prevention and metabolic diseases like diabetes or CVD(173, 275282). There is therefore potential for supervised physical activity to impact on the risk
of falls, fractures, diabetes and CVD for PCa survivors resulting in cost savings
associated with reduced health utilisation and medication use, improved productivity
and quality of life.
This study is unique in that it is the first cost-effectiveness analysis of a supervised
exercise intervention for PCa survivors previously treated with curative radiation
therapy and ADT. Strengths of the analysis include a sound trial design, and conduct,
analysis and reporting, which follow best-practice methods(230, 253). The economic
analysis was conducted from a healthcare payer perspective, supplemented by a
sensitivity analysis which adopted a societal perspective. The use of primary data
permitted the measurement of variance around mean costs and outcomes without
having to employ assumptions related to their distribution. The fact that the data were
drawn from a RCT controls for possible confounding of the results. The costing
included the costs of implementation of the intervention, as well as patient out of
pocket costs. As there was no evidence to support cost savings from downstream
resource use such as reduced medications, health service utilisation or productivity
losses (only seven of the 100 participants were still working and only three full time),
these were not included in the analysis. The retrospective nature of the evaluation and
a six-month follow-up meant that it was impossible to determine post intervention
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outcomes like cardiovascular events, falls, fractures, metabolic and lifestyle diseases
or further improvement in outcomes for the intervention group.

6.5 Conclusion
The results of this supervised exercise intervention for long-term PCa survivors
after curative radiotherapy and adjuvant ADT show the intervention is effective, but
unlikely to be cost effective after six months at a willingness-to-pay of AU$50,000 per
QALY. It is likely that evidence to support downstream cost-savings such as reduced
medication and health service use, carer costs and productivity losses, would
contribute to a more comprehensive cost-effectiveness analysis. A further six months
of exercise via a home-based program maintained HRQoL benefits and represents a
potentially cost-effective option for future implementation outside a clinical trial. Future
RCTs should incorporate longer follow-up durations and collection of data to support
modelling to capture future health benefits. Measures of quality of life or utility more
sensitive to the impact of physical activity would also improve future economic
evaluations.
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Chapter 7 Exercise in preventing falls and fractures for men
with prostate cancer receiving androgen deprivation therapy: a
modelled cost-utility analysis
7.1 Introduction
In Australia, over 80% of men with prostate cancer (PCa) are diagnosed with Stage
I (localised) or II (locally advanced) disease(234) and have a 5-year survival rate of
almost 100%, whereas men with distant metastatic disease have a 5-year survival rate
of 28%(128). For men with local and regional disease, this can mean dealing with the
adverse effects of treatments such as androgen deprivation therapy (ADT) for many
years, highlighting the importance of finding a cost-effective way of managing them.
A number of ADT adverse effects are components of frailty such as muscle loss,
reduced muscle strength, walking speed or cardiorespiratory fitness (40, 283) that,
through impaired physical function and associated fatigue(138), place patients and
survivors of PCa at high risk of falls(284). Another adverse effect of ADT is bone loss,
which contributes to a high risk of fractures in this population. Studies of men receiving
ADT report significant bone mineral density (BMD) declines at all sites in the first year,
(ranging from 1.8%-6.5% at the femoral neck and 2%-8% at the lumbar spine)(22),
which progress, but at a slower rate, in subsequent years.
Prevalence of osteoporosis in men receiving ADT for PCa is high. Over 50% of
patient will suffer from osteoporosis if treated with ADT for three years and over 40%
will have osteopenia(285). A recent Swedish cohort study confirmed that patients with
PCa receiving ADT have increased risk of incident osteoporotic fractures(286). Risk of
fracture was most pronounced in younger patients (70 years) where ADT contributed to
an almost three-fold risk of any fracture (HR 2.63 95%CI 1.99, 3.48; p<0.001) and an
almost four-fold risk of hip fracture (HR 3.89 95%CI 2.51, 6.02; p<0.001) compared to
patients with PCa not receiving ADT(286). Men with PCa receiving ADT thus represent
a particularly vulnerable population at significant risk of falls and fractures.
For Australians over the age of 50, falls and fractures result in significant morbidity
or even mortality, and are a considerable burden to the healthcare system and
society(287). Falls can have serious consequences such as major fracture (defined as
major osteoporotic fracture [MOF] of hip, spine, lower and upper arm)(288) or head
injury. Minor injuries such as bruising, lacerations, sprains and strains can still cause
considerable pain, reduced function and fear of falling, and generate significant
healthcare costs(289). By 2022, the community costs of managing osteopenia and
osteoporosis are predicted to increase by 33%, adding weight to the argument for
funding to be directed towards lifestyle changes such as exercise to decrease the
prevalence of osteoporosis in the ageing population.
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Exercise has been shown to have an important role in managing many of the
adverse effects of ADT for PCa(290), particularly in relation to key fall risk factors such
as ADT induced musculoskeletal changes(49, 137), the potential to prevent fall related
fractures and injuries(167), as well as reduce fear of falling, a strong predictor of
falls(291). Recently revised exercise for cancer guidelines reported strong evidence to
support improvements in physical function and moderate evidence to support
improvements in bone health(51). However, without any CEAs of exercise in this
population, there is no economic evidence to support the implementation of such
guidelines.
Given the burden of falls and fractures and the increased incidence for men with
PCa on ADT, the purpose of this paper is to determine the cost-effectiveness of
exercise in preventing falls and fractures in this high-risk population. A modelled costutility analysis was conducted to address the absence of available RCT evidence for
men receiving ADT for PC. Economic modelling is a timely and cost-effective method
for providing decision makers with the information required to determine allocation of
scarce resources. This study conforms to Consolidated Health Economic Evaluation
Reporting Standards (CHEERS)(292) and economic modelling guidelines(221, 293).

7.2 Methods
7.2.1 Population, perspective, time horizon and cycle length
The target population was individuals 65 years or older living in the community with
a diagnosis of non-metastatic PCa (Stages I & II) receiving curative radiation therapy
(RT) and adjuvant ADT, a population representative of the men expected to receive the
exercise intervention. The population was assumed to be similar to that of the men with
PCa participating in the RADAR trial (Chapter 6), a well-functioning group of men
(n=100) motivated to participate in the exercise training program, who are more likely
to be comparable to the general population than other PCa populations (e.g. older or
more advanced PCa)(36). The mean BMI (24.9 kg/m2) was identical across both arms
and adherence for the exercise arm was approximately 80% over the 12 months of the
trial intervention. Based on this population, the mean age at commencement of the
model was 68(36).
The rationale behind the model is that exercise, comprising twice weekly group
sessions of resistance, balance and functional training, supervised by an accredited
exercise physiologist (AEP), will reduce the risk of falls as well as the number of
fractures and injuries sustained. These outcomes will translate into reduced treatment
costs from health service use and hospitalisation, and improved quality of life. Given
that Australia has a publicly funded healthcare system, a health system perspective
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was adopted to measure the cost per quality adjusted life year (QALY) for the exercise
intervention compared to no intervention or usual activity.
The model consisted of two arms. The intervention arm was 12-month AEP
supervised exercise training conducted for 1-hour twice weekly in small groups of up to
10 participants. Training comprised a combination of moderate- to high-intensity
resistance exercise using machines and aerobic exercise such as walking, cycling or
jogging. The comparator arm or usual care was based on guidelines that healthcare
providers advise their patients to perform 150 minutes of moderate physical exercise
per week(50, 51). A three-year time horizon for the economic model was deemed
appropriate to capture the effect of one year of exercise training and an additional twoyear sustained effect of exercise in preventing falls(36, 294). The cycle length was
three months, the period of time generally required to recover from a fall injury or
regain close to pre-fracture health-related utility(295).
7.2.2 Model structure
The Markov model was designed to capture the natural transition between various
health states. Individuals move between five Markov states in the model: 1) at risk of
falling; 2) at recurrent risk of falling; 3) fracture; 4) non-fracture injury; and 5) death.
The state transition diagram is depicted in Figure 6. All patients begin in the ‘at risk of
falling’ state and remain there until they fall when they progress to fracture, nonfracture injury or death. Survivors then move to ‘at risk of recurrent fall’ state until they
fall again, when they progress to fracture, non-fracture injury or death. Survivors then
return to ‘at risk of recurrent fall’ each time after they fall.

Figure 6 State transition diagram
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7.2.3 Model input parameters
Model input parameters comprise transition probabilities, utilities and costs.
Transition probabilities represent the probability of moving between the five states in
the model and were based on published evidence of the highest level available. It was
assumed that minor injuries or fractures do not cause death; major injuries or fractures
may.
Health state utilities represent a preference value placed on a health state ranging
from 1 for perfect health to 0 for death. Utility decrements reflect how an event such as
a fall or fracture can impact negatively on a person’s health state. The resulting utility
can then be used to calculate quality adjusted life years (QALYs), where the utility
represents the quality adjustment which is calculated over “life years” or the amount of
time spent in that health state.
Costs were calculated for falls and consequent injury treatment. Assumptions
made when calculating costs of treatment were as follows: a major injury or fracture
refers to events requiring ED presentation and hospitalisation, followed by clinical and
supportive care; minor fracture refers to a fracture requiring ED presentation and
outpatient treatment in a hospital; minor injury refers to bruises, strains, cuts and
sprains.
Exercise intervention cost was calculated with the assumption that cancer patients
have access to 50 group sessions per year medical services funded by the Australian
Medicare Benefits Schedule (MBS). Resource use costs included those costs specific
to the intervention such as communication (telephone calls) with participants, material
and printing costs (Appendix 5 - Supplementary file 1). Resources were valued using
local or national costs where appropriate. All costs were reported in 2019 Australian
dollars(232). All other resource use categories were valued using market rates.
Model input parameters were derived from numerous sources.
7.2.3.1 Transition probabilities

Evidence for number of men who experienced a fall (health state 1) and men who
experienced a recurrent fall in the same year (health state 2) was based on a crosssectional, survey-based study that examined falls and frailty in PC survivors with data
on current and past users of ADT(284). This source most accurately represents our
high fall risk population. Evidence from a recent systematic review of exercise for
preventing falls in older people in the community was used to represent number of
people experiencing fall related fractures (health state 3)(167). While this systematic
review and meta-analysis(167) refers to the general population of community dwelling
people 60 years and over, it provides high level evidence where there was an absence
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of such evidence with regard to fall related fractures for PC patients receiving ADT.
Probabilities of non-fracture injury (health state 4), type of non-fracture injury (major
and minor) and type of fracture (major and minor) were derived from evidence for
patients with PC receiving ADT in a large population-based cohort study(286).
Evidence for death (health state 5) in the population age groups of interest were based
on Scuffham, Chaplin and Legood(296) for fall related death and on Australian Bureau
of Statistics Life Tables for age related mortality(297). Evidence for exercise in
reducing the risk of falls, fall related fractures and non-fracture injuries, was drawn from
two meta-analyses(167, 298).
7.2.3.2 Utilities

A baseline utility score representing the “well” state for men with PC (pre-fall) was
based on a population of men who had been receiving radiation therapy with adjuvant
ADT for two months(299). The health states in this study were measured using the
Patient Oriented Prostate Utility Scale (PORPUS-U), a PC-specific indirect utility
instrument which was used to elicit standard gamble utilities (PORPUS-USG)(299).
Fracture utilities were based on evidence from the Australian arm of the
International Cost and Utility Related to Osteoporotic Fractures Study
(AusICUROS)(295). Health related quality of life was estimated in this study using the
EuroQoL EQ-5D-3 L questionnaire, a time trade-off (TTO) questionnaire. The values
attached to each of the EQ-5D health states were based on the Australian TTO utility
weights from general Australian population samples(295). The utility value applied in
the model for fracture was the mean of the utility score at time of fracture and the utility
score at three months or one cycle in the Markov model. Utility for major fracture was
based on major osteoporotic fracture (MOF) as defined in the Fracture Risk
Assessment Tool (FRAX) (hip, vertebral, wrist or humerus fracture)(288). Hip (40%)
and vertebral fractures (30%) were the most common major fractures experienced by
men with PC receiving ADT(300) and constituted a fracture group in the AusICUROS
study(295). Utility for minor fractures was based on non-MOF fractures.
Utility for major non-fracture injury was based on a utility decrement for moderate
traumatic brain injury (TBI), the second most common fall-related injury after hip
fracture(301). Those aged between 65 and 75 tend to be at highest risk due to a more
active lifestyle. Utilities for minor non-fracture injury, recurrent falls and fear of falling
(FOF) were based on evidence from a study of falls and EQ-5D related quality of life of
community dwelling seniors with chronic diseases(302). Exercise and the reduction in
FOF was based on a Cochrane systematic review and meta-analysis of exercise for
reducing FOF in older people living in the community(303).
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7.2.3.3 Costs

Cost of treatment for fractures, both minor and major, were based on Watts et
al.(304) and converted from 2012 to 2019 AUD. Costs for major injury (moderate
traumatic brain injury as proxy) were based on the approach used by Pavlov et al.(305)
with Australian costs calculated from the Independent Hospital Pricing Authority NEP
2019-20 for hospital care and costs of primary and community healthcare based on
those calculated by Hall and Hendrie(306) converted to 2019 AUD. Cost for treatment
of minor injury was calculated over 3-months using the IHPA for hospital costs and Hall
and Hendrie(306) for primary and community healthcare costs. Given the vast
difference in minor injuries and variation in the treatment required, it was assumed that
at time of fall, 50 per cent of fallers attend ED and are discharged after treatment; 25
per cent see a GP and 25 per cent do not seek medical treatment(307).
The cost of the exercise intervention was based on AEP led supervised training
comprising two 1-hour sessions per week over one year for men with localized or
locally advanced PC, estimated from a healthcare payer perspective(308).
Implementation costs included labour for participant registration (Clerks private sector
award), a pre-intervention consultation with an AEP (MBS no. 81110), conduct of
exercise sessions of up to 10 people by an AEP (MBS no. 10953), and a GP visit (MBS
no. 23) to determine eligibility for participation in exercise training. Services provided by
the AEP and GP were valued using the MBS(256).
7.2.4 Cost-utility analysis
Costs and outcomes are represented in the model as the mean value per state per
cycle. All one year input parameters will be converted to three monthly values for the
four cycles of the Markov model with the exception of cost of treatment which was
attributed in the first 3-month cycle after the fall event only, when the majority of costs
are incurred. Costs and QALYs will be aggregated for the time horizon and compared
between the intervention and control to calculate incremental net monetary benefit
(iNMB) or the difference in quality-adjusted life years (QALYs) times the willingness-topay threshold (AU$50,000), minus the difference in costs. All costs and outcomes were
discounted at a rate of 5% per year, a commonly applied rate in Australia(309).
Uncertainty in the model was explored via deterministic univariate and probabilistic
sensitivity analysis. The analysis was conducted in TreeAge Pro Healthcare 2019 R1.1
and half-cycle corrections were used to adjust for overestimation of rewards in a
traditional Markov model.
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Table 15 Model parameters
Transition probabilities (12 months)
Fall in first year – control
Recurrent fall in same year
RR of fall in one year - exercise group
One or more fall related fractures - control
RR of one or more fall related fractures exercise
Major fracture (MOF)
Minor fracture
Non-fracture injury
RR of non-fracture injury-exercise
Major non-fracture injury
Minor non-fracture injury
Death from fall

Distribution
Beta
Beta
logNormal
Beta
logNormal

Mean value
0.36
0.65
0.76
0.12
0.44

(95% CI)
(0.29, 0.43)
(0.53, 0.77)
(0.70, 0.81)
(0.09, 0.15)
(0.25, 0.76)

Source
(284)
(284)
(167)
(167)
(167)

Beta
Beta
Beta
logNormal
Beta
Beta
Beta

0.62
0.38
0.88
0.70
0.06
0.94
0.023
0.043
0.065
Table

(0.58, 0.66)
(0.34, 0.42)
(0.87, 0.89)
(0.54, 0.92)
(0.055, 0.065)
(0.93, 0.95)
(0.015, 0.031)
(0.033, 0.053)
(0.062, 0.068)

(286)
(286, 300)
(167)
(298)
(286)
(286)
(296)

(305, 306, 310)

60-64yrs
65-69yrs
70-74yrs
60-75 yrs

Age-related mortality
Cost (12 months)
Treatment major injury

(297)

Gamma

$10,040

Treatment major fracture

Gamma

$20724

Treatment for minor fracture
Treatment for minor injury (ED, nonadmitted care, post discharge care)
AEP supervised exercise intervention
Utility
Baseline pre-fracture/injury
Major fracture (MOF)
Minor fracture (‘non-hip, non-wrist, nonvertebral’)
Major fall injury (not fracture)
Minor fall injury/no injury (not fracture)
Recurrent fall (FOF)
Recurrent fall exercise (FOF)

Gamma
Gamma

$8797
$1115

(9729,
10,351)
(20,082,
21,366)
(8524, 9070)
(1080, 1150)

Gamma

$767

(743, 791)

(311)

Beta
Beta
Beta

0.79
0.475
0.565

(0.78, 0.80)
(0.47, 0.49)
(0.55, 0.59)

(299)
(295)
(295)

Beta
Beta
Beta
Beta

0.47
0.765
0.72
0.74

(0.46, 0.48)
(0.76, 0.80)
(0.70, 0.74)
(0.72, 0.76)

(301)
(302)
(302)
(303)

(304)
(304)
(306, 310, 311)

Abbreviations: RR relative risk;MOF major osteoporotic fracture – hip, vertebrae, upper or lower arm; ED emergency department; AEP accredited
exercise physiologist; FOF fear of falling

7.2.5 Univariate sensitivity analysis
Assumptions were tested over a range of values using univariate deterministic
sensitivity analyses to assess the robustness of the uncertainty in the parameter
estimates including variation in intervention and health service costs, probability of
occurrence of events and utility values (Appendix 5 – Supplementary file 2).
7.2.6 Probabilistic sensitivity analysis
Probabilistic sensitivity analysis (PSA) involves random resampling of the model
parameters followed by a recalculation of the NMB. The uncertainty around input
parameters was modelled by fitting appropriate distributions to estimates obtained from
the literature (Table 15). These were then used in a Monte Carlo simulation with
10,000 iterations to model joint parameter uncertainty. The results of the PSA are
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presented as a cost-effectiveness acceptability curve (CEAC) which plots the likelihood
an intervention is cost-effective against a range of willingness to pay thresholds.

7.3 Results
7.3.1 Base-case analysis
At a willingness-to-pay of AU$50,000 per QALY gained, the exercise intervention
dominated, as it was less costly and more effective than usual care. The exercise
intervention was cost saving at $1183 less than usual care and the incremental effect
was 0.04 QALYs gained. The iNMB of the exercise intervention was $3,010 per
patient, suggesting that the intervention is cost-effective (Table 16).
Table 16 Results modelled CUA of supervised exercise intervention (12 months)
Variable

Control
group

Intervention
group

Difference
(95% CI)

Mean cost

$4,135

$2,952

$1,183

Mean QALYs
at 12 months

2.06

2.10

0.04
(0.039 - 0.041)

NMB
(95% CI)

iNMB
(95% CI)

$102,112
($98,948 - $105,276)

$3010
($2918 - $3104)

Abbreviations: NMB net monetary benefit; iNMB incremental net monetary benefit; QALYs quality adjusted life years

7.3.2 Univariate sensitivity analyses
The results of the univariate sensitivity analyses are shown in Figure 7. The most
sensitive parameters with the greatest influence on the incremental net monetary
benefit were cost of exercise, exercise induced fall risk reduction and probability of first
fall. Only when the cost of exercise increases to amounts such as those in SA2a
($2338), SA4 ($2154) and SA4a ($3304) does the exercise intervention cease to be
cost saving and become cost effective at a willingness-to-pay threshold of $50,000 per
QALY gained (e.g. SA4a ICER $37050 per QALY gained) (Appendix 5).
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Lower value of parameter

Higher value of parameter

Figure 7 Univariate sensitivity analyses
7.3.3 Probabilistic sensitivity analysis
Probabilistic sensitivity analysis with 10,000 iterations of the parameter distributions
resulted in a NMB of $102,085 (95%CI $101,808 - $102,362). The probability that the
intervention was cost effective at a willingness-to-pay threshold of $50,000 per QALY
gained was 58 per cent. The cost-effectiveness acceptability curve (Figure 8) shows
that exercise compared to usual care will be cost saving over a range of willingness-topay values per QALY gained.

Figure 8 Cost-effectiveness acceptability curve
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7.4 Discussion
This is the first economic evaluation conducted of exercise in preventing falls and
fractures for men with PCa. The main finding indicates that exercise is cost saving at a
willingness-to-pay of $50,000 per QALY gained. The model suggests that even if
exercise interventions are provided by the health system twice weekly for a year and
patient OOP costs (gym membership and travel costs) are included, the intervention
would be cost effective at $37,050 per QALY gained. This is important information for
policy makers when deciding which public health programmes to support. Univariate
sensitivity analyses showed the results were sensitive to the effectiveness of exercise
in reducing risk falls, the cost of the exercise intervention, and probability of first fall.
Probabilistic sensitivity analysis showed a 58 per cent probability that the exercise
intervention would be cost effective at a willingness-to-pay of $50,000.
A number of cost-effectiveness analyses of falls prevention exercise interventions
for community dwelling older adults have been conducted, including both trial
based(312, 313) and modelled or combined trial and model evaluations(314-317).
However, none included men with PCa and they varied considerably in terms of
population age (stratified and not), fall risk, the interventions included (group or homebased exercise, nurse or AEP led, multi-factorial or multiple intervention), the
comparators, outcomes measured and model structures. The two trial-based CEAs did
not incorporate a MAUI, so results were expressed as ICER per fall averted rather than
QALYs gained, making comparison to our model impossible. The New Zealand trial
which used nurses to conduct group resistance and balance exercise training people
aged 80 years and older was more cost-effective, with an ICER of $AU1219 (2019) per
fall averted(313), than the more costly UK multidisciplinary falls prevention program for
people aged 70 years and older (including physiotherapy, occupational therapy, nurse,
medical review and referral to other specialists) at AU$7679 (2019) per fall
averted(312).
The results of this study are consistent with some of the modelled studies. Two of
the four modelled CEAs of fall prevention programs were cost-effective in some form.
One Markov model resulted in an ICER of AU$28,931 per QALY gained at a
willingness-to-pay of AU$50,000, suggesting a public health intervention should be
implemented. This result was based on a cost of $700 (2011 AUD) and a risk ratio for
falls prevention of 0.75 for the general population aged 65 and over. The costs avoided
of residential care admission, one arm of the model, would have contributed to the
cost-effectiveness of this intervention(315). The second model incorporated a care
pathway (GP screening for falls risk) with two interventions, a home-based exercise
program (Otago) and a group exercise program (FaME)(316). The comparator was no
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care pathway. Results were stratified for age. FaME was dominant for ages 65-89,
whereas Otago was dominant in the 75-89 age group, but cost-effective for the 70-89
age group. In the other two models, group-based exercise was only cost-effective in
the women only program in one study(317) and neither home-based nor group-based
exercise was cost-effective in the other(314). Differences tend to derive from model
structure. Only the FaME program achieved similar results to our study, but in a slightly
older age group (70-89 vs 65-75). This is possibly because men with PCa receiving
ADT are at higher risk than the general population of a similar age. The fact that our
model included costs for all injuries treated, regardless of severity, may also have
contributed to exercise being dominant in most scenarios analysed.
The results of this modelled study indicate that a public health program of AEP
supervised exercise for fall prevention should be implemented for men with PCa who
are receiving or have received ADT. A systematic review of exercise to prevent falls
and fractures in older community dwelling people found that functional and balance
exercise supervised by health professionals (e.g. accredited exercise physiologists and
physiotherapists) is more effective in reducing rate of falls(167). Having access to this
expertise is particularly important for men with PCa who may have been impacted by
the adverse effects of ADT and at a higher risk of falls and fractures than the general
population.
The strengths of this modelled evaluation are the use of QALYs as an outcome
measure enabling policy makers to make comparisons across different health
programs. The model structure reflects a realistic fall scenario by incorporating
transition probabilities for falls, recurrent falls, utility decrements for fear of falling and a
range of fall consequences such as fall related fractures and non-fracture injuries, both
major and minor. The time horizon is relatively short and based on only one year of
supervised exercise. However, sensitivity analyses doubling the time horizon to a 6year time frame almost doubled the NMB and the exercise intervention maintained its
dominance. Incorporation of longer follow-up to collect data on the impact of ADT
induced metabolic changes such as diabetes, cardiac and vascular disorders, for
example, and their associated treatment costs is likely to contribute to more costeffective outcomes. Men similar to the population in this study can maintain the
benefits of six months supervised exercise with home-based exercise(36). Many men
find the health and wellbeing benefits, camaraderie and masculinity enhancing aspects
of group exercise rewarding and continue to exercise beyond intervention timelines.
For these men, the time horizon for exercise and the associated benefits would be
extended, potentially enhancing cost effectiveness (34, 318). This would also suggest
the results of our model are conservative.
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Where there is an absence of individual level patient data, models must utilise
numerous sources to derive evidence. As with any model, not all model inputs were
drawn from the PCa population. In the absence of evidence for men with PCa,
evidence from comparable populations and from the highest level sources available,
such as systematic reviews and meta-analyses(167, 298, 303) were used.

7.5 Conclusion
This is the first cost-utility analysis of exercise in preventing falls and fractures for
men with PCa treated with ADT. Supervised exercise is likely to improve quality of life
and be cost saving in this vulnerable population. These findings strongly suggest that a
public health program of AEP led exercise for falls prevention should be implemented
for men with PCa who are receiving or have received ADT. This model is likely to be
applicable to other cancer populations, other disease populations and older adults in
the general population.
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Chapter 8 Thesis results and discussion
This chapter is a summary of the thesis results and the work carried out in this
doctoral research. The first section is a reiteration of the overall aims and objectives
of the thesis. The key questions and summary of the results is presented in the
second section. This chapter concludes with discussion of the research findings,
implications, limitations and future directions.

8.1 Study aims and objectives
The aim of this research was to examine the cost-effectiveness of supervised
exercise training in addressing the adverse effects of androgen deprivation therapy
(ADT) for prostate cancer (PCa). The first objective was to identify the incidence of
the most common adverse effects of ADT. Given the economic basis of the thesis,
and the additional cost to treatment of managing ADT toxicity, the next objective was
to examine the role of exercise in managing these adverse effects as a potentially
cost-effective approach.
The approach taken was to conduct economic evaluations of two randomised
controlled trials (RCTs) of exercise interventions for men with different stages of PCa
(1. metastatic; and 2. localised and locally advanced). Due to the time limitations
inherent in a PhD and the availability of data for this population, economic analyses
were conducted on published RCTs. Given the limitations of conducting economic
analyses of clinical trials, such as the lack of data (costs, outcome data applicable
to economic analysis), short term follow up and small sample size, and armed with
evidence of the important role of exercise in improving physical function for men
receiving ADT for PCa, a modelled economic analysis was also conducted to
determine the longer term impact of exercise in reducing falls and fractures for this
population.
The four questions being addressed by the research were:
1. What is the risk or incidence of the most common adverse effects of ADT for PCa
patients? (Chapter 2)
2. What is the role of exercise in managing these adverse effects? (Chapter 3)
3. What is the cost-effectiveness of exercise in managing the adverse effects of PCa?
•

CEA 1: What is the cost-effectiveness of exercise in the management of
advanced PCa or bone metastatic disease? (Chapter 5)

•

CEA 2: What is the cost-effectiveness of exercise in counteracting the long-term
adverse effects associated with ADT for localised/locally advanced PCa?
(Chapter 6)
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•

CEA 3: What is the cost-effectiveness of exercise in reducing falls and fractures
for men with PCa receiving ADT? A modelled cost-utility analysis. (Chapter 7)

4. What are the implications of exercise in the management of adverse effects of ADT
for PCa? (Chapter 8)

8.2 Results: Responding to the study questions
8.2.1 What is the incidence of the most common adverse effects of ADT for
PCa patients?
A systematic review of existing systematic reviews (n=25) is presented in
Chapter 2, supplemented by evidence drawn from individual adverse effect studies
where no systematic review existed (n=14), generated incidence evidence for nine
adverse effect groups and 19 sub-groups, classified according to the common
terminology criteria for adverse events (CTCAE)(17). Statistically significant
increased risks were evident for 17 out of 19 adverse effect sub-groups as
experienced by PCa patients and survivors (Appendix 2).
8.2.2 What is the role of exercise in managing these adverse effects?
A rapid review was undertaken and presented as Chapter 3, using the same
CTCAE classifications applied in Chapter 2, revealed strong evidence for exercise in
improving body composition (particularly, muscle strength and lean mass), physical
function and fatigue. Moderate level evidence was also found for exercise in mitigating
the bone loss, sexual dysfunction and psychosocial effects (anxiety, depression,
HRQoL) associated with ADT. The second part of the rapid review, designed to
address the current lack of PCa data, showed strong exercise as medicine evidence in
other populations to support the role of exercise in managing the adverse effects of
ADT for PCa.
8.2.3 What is the cost-effectiveness of exercise in managing the adverse
effects of ADT for PCa?
Androgen deprivation therapy (LHRH agonist or orchiectomy) is used broadly in the
treatment of PCa. Given the different stages and associated treatments and the varied
capacity for exercise amongst patients, particularly for those receiving ADT for
metastatic disease versus men receiving neo adjuvant or adjuvant ADT alongside
curative treatment, we conducted economic evaluations of both these patient types.
8.2.3.1 Cost-effectiveness of exercise for men with bone metastases secondary to
PCa

Prostate cancer patients with bone metastases are an important population as they
tend to suffer considerable adverse effects associated with long-term ADT such as
muscle atrophy and functional impairment, often exacerbated by subsequent
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treatments like chemotherapy. These patients are at significant risk of falls and
fractures. A considerable number of men with metastatic PCa (40-50%) will experience
a skeletal-related-event (SRE), and per patient average lifetime cost for these men who
experience one or more SREs is 50% higher than the cost of matched controls who
remained SRE free(319). However, exercise intervention studies tend to exclude men
with bone metastases due to the risk of fragility fractures; medical practitioners are
often reticent for their patients to participate and patients are similarly disinclined. It is
therefore difficult to recruit trial participants in this population and sample sizes tend to
be small.
Two such RCTs have been conducted to date; the first, a preliminary study
designed to test safety and efficacy of exercise in this population with a sample size of
20 (10 men in each arm; exercise and usual care or a recommendation to
exercise)(34). SF-36 HRQoL data was collected which can be converted to utilities for
use in cost-utility analysis (CUA). The second and more recent RCT extended the
preliminary RCT, recruiting 57 participants between 2012 and 2015. This trial was an
evaluation of the efficacy and safety of a multimodal exercise program comprising
resistance, aerobic and flexibility training three times per week(147). However, the
primary outcome measure was the SF-36 physical function subscale; other SF-36
subscales were not collected, so without the complete set of data, it wasn’t possible to
calculate a utility score or derive a QALY measure. In the absence of this data, the
preliminary RCT was used to determine whether the exercise intervention was costeffective compared to usual care. Given the small sample size and associated
uncertainty, a value of information (VOI) analysis was conducted to examine the need
for and value of a larger trial to collect the required evidence for a more comprehensive
CEA.
This first within-trial CEA of supervised exercise training for men with metastatic
PCa resulted in an incremental cost-effectiveness ratio (ICER) of $133,509 per QALY
gained and a 30% probability of being cost-effective after three months at a
willingness-to-pay of AU$50,000 per QALY (Chapter 5). VOI analysis resulted in a
population EVPI of $971,520 which represents the upper-bound expected benefit of
future research, suggesting further research is likely to be cost-effective to conduct.
8.2.3.2 Cost-effectiveness of exercise for long-term PCa survivors (>5years post
diagnosis) from the Randomised Androgen Deprivation and Radiotherapy trial

Men with early stage PCa (Stages 1 and 2 - localised) represent a significant
proportion of PCa population (82%) and, due to longer survival rates, can receive ADT
and suffer the adverse effects over many years(320). The second within trial CEA
involved a multi-centre RCT of exercise in long-term PCa survivors (>5 years post
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diagnosis) who had received curative radiation therapy and adjuvant ADT (Chapter 6).
This RCT was designed to determine the effectiveness of six months of supervised
exercise training followed by six months of home-based exercise (with an instruction
booklet)(36). The incremental cost per QALY gain at six months (supervised exercise
training only) was AU$64,235 (dominated - $715,454). At a willingness to pay of
AU$50,000, the supervised exercise intervention had a 41% probability of being costeffective. At 12-month follow up (6-month supervised intervention + 6-month homebased intervention with exercise booklet), the resulting cost per QALY gain is $32,051
(dominated - $399,153) because the six-month QALY gain is maintained at no further
cost, making the combined (supervised + home-based) intervention cost-effective at a
WTP of AU$50,000.
8.2.3.3 A modelled cost-utility analysis of exercise in preventing falls and fractures
for men with localised and locally advanced PCa.

In order to address some of the challenges encountered in within trial analyses and
the lack of available RCT evidence for men in this high-risk population, a modelled
CUA was conducted. We chose to focus specifically on falls and fractures as an
outcome of the ADT adverse effect physical function for several reasons. The link
between exercise and body composition and physical function is clearer than with other
adverse effects such as metabolic syndrome, CV disease, and depression which can
be confounded by other variables such as diet, pre-existing disease and comorbidities.
This decision was supported by advice received from exercise physiologists and
clinicians. A rapid review of the role of exercise in managing ADT adverse effects is
presented as Chapter 3, also revealing strong evidence of the effect of exercise on
lean mass, muscle strength, physical function and fatigue, attributes that have the
potential to prevent falls as well as mitigate the resulting injury.
A decision analytic Markov model was developed in TreeAge (2019 R1.1) to
evaluate the cost effectiveness of an exercise intervention in preventing falls and
fractures for men with PCa receiving ADT. The target population was individuals 65
years or older living in the community with a diagnosis of localised and locally
advanced disease, normally treated with curative radiation therapy and adjuvant ADT
(a population representative of the men expected to receive the intervention), who
have a high probability of survival(36, 234). The cost-effectiveness model has two arms
to compare the health benefits in quality-adjusted life years (QALYs) and costs of
treatment associated with the exercise intervention and those receiving a
recommendation to exercise. A combination of sources (e.g. clinical data, systematic
reviews and meta-analyses, population-based studies) were used in the development
of the model. Costs, transition probabilities and utilities were based on published
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evidence of the highest level available. Costs and outcomes were represented in the
model as the mean value per state per cycle. The cycle length was three months and
the model terminated after three years, one year for the duration of the exercise
intervention and the following two years to capture the sustained effect of exercise in
preventing falls(36, 247-250, 294).
At a willingness-to-pay of AU$50,000 per QALY gained, the exercise intervention
dominated, as it was less costly and more effective than usual care (a recommendation
to exercise). The incremental cost of the exercise intervention was $1183 less than
usual care and the incremental effect was 0.04 QALYs gained. The NMB of the
exercise intervention was $102,112 ($98,948 - $105,276) and the iNMB was $3,011
($2918 – $3104) per patient, suggesting the intervention is cost-effective.
8.2.4 What are the implications of exercise in the management of adverse
effects of ADT for PCa?
Exercise in the management of adverse effects of ADT for PCa has the potential to
impact on exercise medicine research and practice; nursing and allied health practice;
medical practice; economic analysis and policy decision making; as well as on the
health and wellbeing of PCa patients and survivors and their families. These will be
explicated and discussed in section 8.3.2.1 below.

8.2 Discussion
8.2.1 Thesis findings
No comprehensive review of the incidence of adverse effects of ADT for PCa
has previously been carried out. The systematic review of existing systematic
reviews (n=25), supplemented by evidence drawn from individual adverse effect
studies where no systematic review existed (n=14), generated comprehensive
incidence evidence for nine adverse effect groups and 19 sub-groups, classified
according to the CTCAE. Statistically significant increased risks were evident for
17 out of 19 adverse effect sub-groups as experienced by PCa patients and
survivors. These adverse effects impact negatively on quality of life, contributing to
risk of falls and fractures and chronic diseases like diabetes and cardiovascular
disorders, increasing healthcare utilisation and downstream costs. The need for
more clearly defined ADT adverse effects, greater understanding of their
incidence, the potential for subsequent treatment costs and the need for cost
effective management given the potential for adverse effects to add further costs to
what is already expensive treatment were highlighted.
In 2019, the Exercise and Sports Science (ESSA) position statement and the
American College of Sports Medicine (ACSM) guidelines were updated, emphasising
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the importance of appropriate exercise prescription for cancer patients. These updates
were well supported by extensive scientific evidence(50, 51). While Australian and
International PCa survivorship guidelines support exercise for adverse effect
management(52-54), no comprehensive review of the benefits of exercise in managing
the adverse effects of ADT for PCa has been conducted. The rapid review revealed
strong evidence for the role of exercise in improving body composition (particularly,
muscle strength and lean mass), physical function and fatigue adverse effects.
Moderate level evidence was also found for exercise in mitigating ADT associated
bone loss, sexual dysfunction and psychosocial effects (anxiety, depression, HRQoL).
More research is needed for other adverse effect sub-groups because data for the ADT
for PCa population is currently either limited or non-existent. However, exercise as
medicine evidence in other populations is strong and, with the exception of
gynaecomastia and breast pain, there is increasing evidence to suggest that exercise
has the potential to reduce and even prevent the adverse effects of ADT for PCa,
improving survivorship outcomes.
Exercise as medicine is not only effective in addressing the adverse effects of ADT
for PCa, research also shows an association between exercise and risk of advanced
and fatal disease(198). Men who participate in vigorous exercise, or had high levels of
occupational and/or recreational physical activity, had reduced risk of advanced PCa
and aggressive PCa(198). For men already diagnosed with PCa, exercise is
associated with improved survival, reduced risk of progression and all-cause mortality.
Such survivorship evidence extrapolated over the long term has the potential to reduce
healthcare utilisation and PCa treatment costs contributing to more cost-effective
outcomes for exercise interventions. Vigorous activity is also associated with lower risk
of PCa mortality for this population(37). While more evidence of the effectiveness of
exercise is needed for some adverse effects to strengthen the evidence-base, exercise
medicine has the potential to provide a cost-effective alternative to other treatments
(Chapter 3).
Despite the growing evidence of the important role of exercise as an essential
part of any cancer treatment and care plan, uptake, adherence and implementation
still needs to be addressed beyond the clinical trial period, when there is limited
Medicare or private health insurance coverage for exercise medicine. While many
healthcare professionals and men with PCa support exercise medicine, one study
identified two major barriers to translation outside a hospital/clinic environment:
traditional values in oncology and financial support from government(57). It is not
uncommon for clinicians to be skeptical about the effectiveness of exercise,
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disregarding it or considering it a fad. This is also reflected in the conservative values
of government which tend to favour pharmaceuticals over lifestyle interventions.
Economic evaluation plays an important role in informing healthcare decisions.
Cost-effectiveness analysis of effective programs, especially those based on the
outcomes of randomised controlled trials (RCTs), are important sources of information
for policy makers and essential tools to support the translation of research into
practice. A rapid review of the literature from 2000 to June 2019 identified only eight
cost-effectiveness analyses (CEAs) of exercise interventions for older community
dwelling adults, none of which included interventions for PCa (238-245), yet PCa is the
most common non-skin cancer in Australian men(234). Patients and survivors
represent a particularly vulnerable population, especially those treated with ADT due to
the number of associated and often long-lasting adverse effects. These can add
considerable costs to treatment and reduce quality of life, highlighting a need to
evaluate the cost- effectiveness of exercise in the ADT for PCa population. This gap is
addressed in Chapters 5-7.
The two within trial CEAs (Chapters 5 and 6) included in this thesis provided an
opportunity to examine the available data and investigate approaches to economic
evaluation of exercise interventions for patients and survivors of PCa treated with ADT.
There are advantages to conducting economic analyses alongside RCTs; the internal
validity provided by the trial design such as blinding and randomisation reduces the
potential for bias and makes it easier to attribute an effect to the intervention being
compared. There is also the opportunity to collect patient level data on costs and
outcomes and the likelihood that conducting an evaluation alongside a trial will be less
costly than funding a stand-alone economic evaluation(321).
Both within trial cost-effectiveness analyses conducted as part of this thesis
demonstrated that supervised exercise in the short term (3-6 months) is unlikely to be
cost-effective. In the first CEA (Chapter 5), there was a 30% probability that an
exercise intervention for men with bone metastases would be cost-effective at a
willingness-to-pay per QALY of AU$50,000. This preliminary RCT with a small sample
size provided the opportunity to conduct an early economic evaluation and value of
information (VOI) analysis. The results showed that further research involving a larger
trial would be cost-effective. Early economic evaluation and the use of VOI analysis is
important because there is always uncertainty in economic analyses and in the
decisions they inform. VOI is a systematic approach to measure this uncertainty and
quantify the value of further research in reducing uncertainty. The second CEA
(Chapter 6) was based on a 6-month supervised exercise intervention which, at a
willingness-to-pay of AU$50,000, resulted in a cost per QALY gain of $64,235 and a
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41% probability of cost-effectiveness. However, a 6-month home-based intervention
immediately following the supervised intervention maintained QALY outcomes over 12
months and lowered the cost per QALY gained to $32,051, making the combination
intervention cost-effective at a 57% probability of cost-effectiveness.
Typically, exercise medicine RCT sample sizes for these populations are small
and there are associated levels of uncertainty. There are two main reasons for the
small numbers. The first relates to the purpose of exercise RCTs, which is usually
to determine the effect of exercise on a physical or biological outcome, like
cardiorespiratory fitness, physical function, fat mass, lean mass, bone mineral
density and so on. In most cases, changes in such outcomes can be determined in
three to six months, so longer follow-up is unnecessary. Related to the purpose of
RCTs is short funding time frames. Thus, it can be difficult to recruit eligible
participants with cancer within the required time frame. This is particularly true for
patients with advanced cancer and/or bone metastases due to comorbidities and
the perceived risk of fragility fractures.
Cost and outcome data, such as downstream costs like health utilisation,
medicines, allied health services and benefits like QoL, which are often not
collected as part of an RCT, also impact on cost-effectiveness results.
Interventions are generally conducted for three to six months, which is insufficient
time to capture many of the benefits of exercise measurable in an economic
analysis. The economic impact of exercise in reduced health utilisation, fewer
medicines or greater benefits from improved QoL and reduced incidence of chronic
disease that may become apparent over a longer time frame are not captured, so
exercise appears to be less cost-effective without the inclusion of such data in the
analysis. This situation is exacerbated for a cancer population grappling with a
diagnosis, at the beginning of treatment and possibly suffering from the ill effects
of the disease, cancer related anxiety and/or treatment.
The challenges associated with RCTs, small sample sizes, short follow up and a
lack of data most suited to economic analysis, led to a modelled economic evaluation.
Modelling provides a framework for synthesising the available evidence from a range of
sources rather than relying on a single RCT to address uncertainty. Decision rules can
be applied to determine the optimal alternative based on the evidence. The results are,
however, dependent on the availability of data and the assumptions that underlie or
form the structure of the model. Modelling is important, particularly when there are
resource allocation decisions to be made, providing that the methods employed are
sound. Based on findings from the systematic review (Chapter 2) and the rapid review
(Chapter 3), which showed strong evidence to support the use of exercise in mitigating
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ADT induced decline in body composition and physical function, the third economic
evaluation was a modelled CUA of supervised exercise to address the risk of falls and
fractures in the ADT for PCa population (Chapter 7). Model inputs (costs, transition
probabilities and utilities) were derived from a combination of sources. Little real-world
data around transition probabilities and utilities exists in the ADT for PCa population, so
proxy data from like populations such as men with osteoporosis and older (65+ years)
community-based populations were used. Results of the CUA of a 12-month exercise
intervention to prevent falls and fractures for men with PCa modelled over three years
showed that the intervention was cost saving compared to usual care (a suggestion to
exercise). The drivers of the model were the effectiveness of exercise in reducing the
risk of falls, the cost of exercise and the probability of first fall. Probability sensitivity
analysis showed the probability that the exercise intervention was cost effective at a
willingness-to-pay threshold of AU$50,000 per QALY gained was 58 per cent. This
result provides strong evidence to support exercise prescription, particularly for
vulnerable populations such as men with PCa receiving ADT who are at high risk of
falls and consequent fractures or injuries.
In cost-effectiveness analysis, QALYs are the recommended approach to
estimating the benefits of an intervention because they address heterogeneity by
providing a common metric that enables comparison of effectiveness across a wide
range of health conditions. However, there are challenges in using QALYs and the
instruments used to derive utilities, particularly for older or chronically ill
populations(263, 264). Questions regarding willingness-to-pay thresholds for cancer
survivors and the possibility of giving greater weight to QALYs achieved in the later
stages of terminal disease have been raised(269, 322). However, this highlights equity
considerations, as to whether health can be distributed in a fairer way and how, a topic
long debated in the literature(323, 324).
As the economic analyses in this thesis and others have shown, HRQoL
measures are not always sensitive to change and the estimated QALY gain
derived using a MAUI may not accurately reflect the experience of the patient,
despite the beneficial outcomes of the trial(241, 242, 244, 265-268, 325). Given
the characteristics of the study population, it may be unreasonable to expect a
direct QALY benefit, particularly within the time constraints of the trial. Patients
may not perceive a great change in wellbeing due to the short time frame or other
factors like the impact of illness or concerns associated with a cancer diagnosis.
The increase in utility when converted to QALYs can thus be relatively small,
impacting on cost-effectiveness, particularly of a more intensive and costly
intervention. In addition, MAUIs used to derive utility scores from which QALYs are
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calculated for CEAs may not be sensitive to the benefits of exercise and may not
capture the impact of exercise. For example, the scores for exercise relevant
subscales can be diluted in a composite HRQoL tool by responses to other
subscales.
Given that QALYs may not adequately capture all the benefits associated with
cancer related interventions, there has been increased interest in alternatives or
changes to QALYs(271, 325) or the development of condition-specific preferencebased MAUIs(270, 326). An alternative for future studies, once such instruments have
been validated, may be to use a new preference-based MAUI like the Australian
specific European Organisation for Research and Treatment of Cancer EORTC quality
of life utility measure-Core 10 dimensions (QLU-C10D) derived from the EORTC
quality of life questionnaire for cancer patients (QLQ-C30)(270). While this instrument
is more sensitive to utility decrements associated with cancer than more generic
measures, it is focused on decrements associated with chemotherapy, not ADT. A new
version of SF-6D, SF-6Dv2 for SF-36v2 has recently been developed which improves
the classification of physical function and may contribute to more sensitive results in
relation to utility for exercise interventions in the future(327). Another alternative may
be the e-QALY, a broader measure of quality of life, which is being developed by
researchers at the University of Sheffield(271). The e-QALY has the potential to
improve the sensitivity of the QALY to capture the broader benefits of treatments for
PCa patients receiving ADT.
In summary, the current research has comprehensively identified the incidence
of the adverse effects of ADT and the important role of exercise in managing them.
Economic evaluation of exercise medicine for PCa patients and survivors is in its
infancy and this series of investigations represent the first economic analyses
conducted, internationally. Results of two CEAs of exercise medicine RCTs
demonstrated the need for more data and longer follow up and raised questions
about QALYs as an outcome measure for exercise in the PCa population. Results
of the modelled CUA showed supervised exercise was cost saving in preventing
falls and fractures for men with PCa, an important finding for public health policy
and research translation. The implications of this thesis have broad application and
future research in PCa, exercise medicine and health economics can build on
these findings.
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8.3.2 Implications, limitations and future directions
8.3.2.1 Implications

The findings of this thesis have the potential to impact on exercise medicine
research and practice, nursing and allied health practice, medical practice, economic
analysis and policy decision making, as well as on the health and wellbeing of PCa
patients and survivors and their families. The comprehensive identification of adverse
effects of ADT and the role of exercise in managing them will contribute to the
knowledge of exercise physiologists and physiotherapists treating PCa patients and
survivors. For those conducting research, where there is an absence of strong data,
there is an opportunity to conduct research on those adverse effects and strengthen
the existing evidence base for the role of exercise in mitigation or management.
Oncology nurses and allied health practitioners (exercise physiologists,
physiotherapists, nurses, psychologists, counsellors, social workers) play an important
role in the treatment and supportive care of men with PCa suffering the adverse effects
of different treatments. Men with PCa have identified support from peers, specialist
oncology nurses and trusted partners as their preferred means of support(328). Nurses
and partners can be instrumental in encouraging men to participate in exercise and
nurses often actively refer men to allied health professionals as well as local support
groups and organisations such as the Prostate Cancer Foundation of Australia (PCFA)
to better address their unmet needs(157, 329). Aside from its physical and
psychological benefits, exercise has also been shown to be an effective hook for men
to participate in psychosocial support, where they otherwise may not get together and
talk about their PCa or the difficulties they may be facing. The relationships men
develop during exercise as a PCa patient can often persist after the transition to PCa
survivor, when regular visits to their health professional team end and when many
cancer patients may feel vulnerable and abandoned(330-334). This psychosocial
support can also have a positive effect on the relationship dyad(318, 335). Short
courses conducted by AEPs to disseminate information on how exercise is effective in
managing adverse effects could be offered for nurses and allied health staff in
hospitals and cancer clinics. Similar information sessions could also be offered to
partners of patients.
For medical practitioners (e.g. GPs, oncologists, urologists), awareness raising of
the full complement of adverse effects of ADT for PCa means that patients can be
provided accurate information on the extent of the potential adverse effects they may
experience and the impact on QoL. Exercise is particularly important for men receiving
ADT, but findings with regard to the role of exercise emphasise the importance of
providing exercise prescriptions to patients at PCa diagnosis, regardless of stage,
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because exercise not only addresses adverse effects but slows progression and
reduces morbidity and risk of mortality(37). Clinicians thus have an important role to
play, particularly given the lack of any real understanding of the benefits of exercise in
the community, aside from the fact that it is good for your health(336). Barriers to
exercise in older people are numerous and common and when a suggestion to
exercise is often all a health professional offers a PCa patient, there is little chance he
will take the initiative(337, 338). Even an exercise prescription may not be enough; a
referral to an AEP or contact with a PCa exercise group could perhaps be organized in
the surgery and flexible arrangements that include a spouse or friend may help to
inspire better uptake(328).
For health economists, the CEAs of RCTs (Chapters 5 and 6) have highlighted the
importance of working with AEPs and clinicians when designing clinical trials, so data
collection for economic analysis can be embedded in the trial data collection and
prospective analysis carried out. Longer trial timeframes would assist in recruiting
larger cohorts. Longer follow up would capture the physiological, physical and
psychosocial benefits of exercise, which tend to take longer than three months to
manifest and longer to impact on risk of falls and fractures, risk of metabolic and CVD,
reductions in healthcare utilization, medicines, and so on. Value of information analysis
was effectively used in an early economic evaluation of a preliminary RCT (Chapter 5)
to determine that more research would likely be cost-effective, demonstrating the
usefulness of this approach in measuring uncertainty and quantifying the value of
further research.
In the two trial-based CEAs (Chapters 5 and 6), questions were raised with regard
to the sensitivity and suitability in this population of currently available MAUIs used by
health economists to calculate utility values and derive QALYs (e.g. SF-6D, AQoL, EQ5D, HUI). Both RCTs used the SF-36 instrument to collect HRQoL data. There was
little difference in QALY scores between baseline and follow-up or between control and
intervention, suggesting there was insufficient time, or the instrument was not sensitive
enough, to capture any change in exercise induced HRQoL. It is possible the SF-6D
and other MAUIs may not be suited to measure the change in exercise-related QoL
outcomes or the benefits of exercise may be diluted in a composite measure. These
concerns deserve further investigation.
For policy makers, the findings of this research are an evidence base to better
inform decision making with regard to the needs of men with PCa receiving ADT
and their families. Raising awareness of the incidence of the numerous adverse
effects and the effectiveness of exercise in addressing these should encourage
policy makers to support funding of exercise interventions and their
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implementation. With sound evidence supporting the cost-effectiveness of exercise
in managing falls and fractures and benefits in relation to other adverse effects of
ADT, there is a strong argument for adoption of a public health exercise program
and the inclusion of regular supervised group exercise training for PCa patients
and survivors as a Medicare Benefits Schedule subsidised service. Those who are
receiving/have received ADT would provide a good test case given their
vulnerability to falls and fractures. This type of program could then be extended to
other cancer patients/survivors or the older (≥60 years) general population.
Implementation strategies have shown to be effective in increasing uptake of
exercise programs(339) and implementation science is important in ensuring
implementation is not only effective, but cost effective. While there is currently a
paucity of implementation evidence and deficiencies in the application of economic
evaluation methods, this is a burgeoning field with a recently published guideline
for the conduct and reporting of economic evaluations of implementation
interventions in public health(340). Economic evaluation makes a critical
contribution to exercise medicine research translation via its determination of the
cost-effectiveness of exercise interventions and their implementation for policy
makers.
Importantly, it has been shown that more research is needed to examine the
effectiveness and cost-effectiveness of exercise as medicine to support translation
into practice. Design and implementation presents challenges for exercise
physiology practice, given the recognised need for prescription of exercise
medicine to address variation in treatment effects, treatment intensity, patient
comorbidities and fitness levels(50, 144). The transition to widespread application,
clinically and post-clinically, presents a challenge, requiring collaboration between
numerous stakeholders (patients, AEPs, nurses, psychologists, oncology
specialists, GPs and policy makers) to achieve sustainable implementation
strategies that promote access to and uptake of exercise for men with PCa(172,
200, 341). Co-location of exercise and cancer treatment has been suggested as a
way of potentially addressing cost and adherence concerns(341). Economic
evaluation also needs to include consideration of all aspects of intervention
implementation.
Finally, the implications of this thesis for patients, survivors and families is that
they receive more accurate information about all the current adverse effects of
ADT for PCa and the important role of exercise in addressing them. The findings
should encourage greater support for exercise medicine from medical practitioners
which will mean men receive and act on exercise prescriptions, which has the
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potential to minimize adverse effects, slow progression and improve quality of life
and survival outcomes. Given the cost saving outcomes of exercise in relation to
preventing falls and fractures, there is also the potential for exercise, via a
Medicare subsidized public health program, to be more accessible for men with
PCa. These benefits for PCa patients and survivors will have a flow-on effect for
their partners and families.
8.3.2.2 Limitations

With systematic reviews and rapid reviews there is always the potential that a
paper may have been missed or overlooked and excluded. In the specific case of ADT
for PCa, the field is rapidly changing as new medicines are developed by
pharmaceutical companies and approved for use by authorities like the Pharmaceutical
Benefits Scheme (PBS) in Australia. New medicines can mean novel adverse effects
depending on the nature of the drug, how it acts and the individual response a patient
may have to it. Thus, there is a need to continually update the evidence on adverse
effects. Similarly, the evidence base for the role of exercise in managing the adverse
effects of ADT for PCa is currently incomplete and requires more research input.
Economic evaluation of exercise training in men with PCa receiving ADT is a
nascent area of research and, as borne out in this program of research, only eight
economic evaluations of exercise interventions for older populations had been carried
out when the CEAs in this thesis were undertaken, none of which involved men with
PCa, and few incorporating supervised exercise. Given the time constraints associated
with a PhD, retrospective CEAs on published clinical trials were conducted. While
results confirmed the effectiveness of exercise in managing ADT for PCa, the RCTs
had not been designed with an economic evaluation in mind, so the costs were limited
to those collected within-trial or estimated as accurately as possible where no data
were collected and the benefits limited to those experienced within the trial follow up.
When the follow up is 3-months to 6-months or even 12 months, it is difficult to capture
cost savings and benefits. Benefits from exercise tend to accrue later than the time
frame of a RCT, when a man who exercises doesn’t develop metabolic adverse effects
(which can lead to diabetes and CVD), bone loss (which can lead to osteoporosis and
a greater risk of fractures) or declines in lean mass and physical function (which can
lead to higher risk of falls and consequent fractures) to the same extent as a patient
who doesn’t exercise. When the outcomes of this treatment toxicity manifest, costs
related to greater health service utilisation and associated medications are
considerably higher and QoL considerably lower. It is likely to be the long-term cost
savings from reduced health service utilization, reduced medication use and HRQoL
102

benefits of exercise that contribute most to the cost-effectiveness of exercise
interventions.
There were also limitations associated with the SF-36 instrument used to measure
HRQoL in both within-trial CEAs as it was not sensitive enough to capture the benefits
of exercise or discriminate between the exercise and control groups. A number of
reasons may have contributed to this result. The sample population may have been
unusually fit and already at a ceiling they couldn’t improve on or too unwell to effect a
change within the time frame; the composite nature of the tool may have meant the
results of other sub scales (not exercise related) may have diluted the exercise benefit;
or the length of follow up may simply not have been long enough to capture any
perceived improvement. It is also possible MAUIs like the SF-6D may not be suited to
measure exercise related changes in HRQoL outcomes. Questions raised in the
economic analyses could be addressed in further research and methods improved.
Economic modelling is a feasible alternative to economic analysis based on a
single RCT, which is unlikely to contain all the relevant inputs, have long enough
follow-up to capture exercise benefits or a large enough sample to be representative of
the population. However, there is always a level of conjecture around any model input.
Not all data used in the modelled CUA were derived from ADT for PCa patients. Data
derived from osteoporotic or healthy older adult populations were used as proxies for
transition probabilities and utility scores, where there was an absence of PCa data. The
model time horizon was short and captured only falls and fractures and consequent
treatment, not long-term effects like diabetes or CVD.
8.3.2.3 Future directions

Adverse effect findings need to be continually updated, particularly when new
medicines are added to the treatment regimen. Similarly, as more research is
conducted on the impact of exercise on different ADT adverse effects, existing
evidence needs to be updated and new evidence added.
Future exercise medicine research should involve collaboration with economists
at research design phase in order to ensure the required data is collected and the
research design, including longer follow-up, will support a rigorous economic
evaluation. Another potential solution to longer follow-up times, which can be
expensive to achieve, is the consideration of epidemiological evidence, where
evidence exists, that links intermediate and long-term outcomes. VOI analysis can
be conducted to quantify the value of further research and optimise trial design.
Based on the outcomes of the within-trial CEAs, there is potential that a MAUI
could be developed that is more sensitive to the benefits of exercise or better
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discriminates between the quality of life of those participating in exercise and controls.
Both RCTs measured HRQoL using the SF-36 and the SF-6D to derive utilities, and
were found to be insensitive to change, so further exercise medicine economic
analyses need to be conducted over longer time frames and possibly with different
MAUIs, particularly new preference-based MAUIs such as the Australian specific
EORTC QLU-C10D, derived from the cancer specific QoL questionnaire, EORTC QLQC30. A potential alternative may be the SF-6Dv2 or the eQALY, a broader measure of
quality of life being developed at the University of Sheffield. With the increasing
recognition of the importance of exercise medicine and its application in prevention,
and across numerous health conditions and diseases, it is also possible that an
exercise sensitive MAUI could be developed in the future.
The modelled CUA revealed a lack of real-world data for men with PCa and the
need to develop an evidence base for this population to use in economic models. The
falls and fractures model could also be modified for application in other cancer or
disease populations or equally in healthy populations. Genuine ADT for PCa data from
real world sources such as hospital databases could be used to strengthen the rigor of
the model. Extrapolating the model over a longer time horizon to capture the impact of
exercise on the reduced burden of metabolic diseases such as diabetes and CVD
would also improve the model and contribute to more cost-effective outcomes.

8.4 Conclusion
This doctoral research is the first investigation of the cost-effectiveness of exercise
medicine in managing the adverse effects of ADT for PCa. The incidence of a
comprehensive list of adverse effects of ADT was examined, confirmed the role of
exercise in managing many of these adverse effects and highlighted where more
research is needed. Cost-effectiveness analysis of two RCTs identified limitations of
within-trial CEA of published exercise interventions due to small sample size,
insensitivity of currently available QoL instruments and short-term follow-up. These
CEAs showed there was a low probability (30-40%) that supervised exercise is costeffective in the short term (3-6 months), highlighting the need for collaboration between
health economists and AEPs at the research design stage to ensure the required data
is collected over longer time frames, reducing uncertainty in health economic
outcomes. Application of VOI analysis in a preliminary RCT was used to estimate the
value of additional evidence to reduce uncertainty, showing the benefit of early
economic evaluation using this approach.
A modelled CUA demonstrated that exercise is cost saving in preventing falls and
fractures in PCa patients receiving ADT for localized and locally advanced disease.
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There is potential for this model to be developed further, improved by incorporating
more PCa specific data, extrapolated over a longer time horizon and applied to other
cancers, diseases or healthy populations.
The cost-effectiveness of exercise medicine in PCa is a nascent area of research
with much scope for further research. There is potential to improve economic
evaluation in this field and reduce uncertainty, methods which can be applied to the
economic evaluation of exercise in other fields and for other diseases. Importantly,
these findings provide strong evidence that exercise medicine should be more
accessible for men with PCa, contributing to slower disease progression, less
morbidity, increased survival and improved quality of life for PCa patients and
survivors, their partners and families. Efforts should be focused on conducting more
economic evaluation of exercise medicine for PCa, collecting more data specific to this
population and incorporating methods of economic analysis suited to these
interventions. Decision making based on rigorous economic evaluation is more likely to
contribute to research translation and the implementation of effective and cost-effective
public health exercise programs.

105

References
1. Australian Institute Of Health and Welfare (AIHW). Burden of cancer in Australia:
Australian Burden of Disease Study 2011. Canberra 2017.
2. Australian Institute of Health and Welfare. Cancer Data in Australia: prostate
cancer. Canberra: Australian Government; 2020 [Cat. no: CAN 122:[Available
from:https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/cancersummary-data-visualisation.
3. Karikios DJ, Schofield D, Salkeld G, Mann KP, Trotman J, Stockler MR. Rising cost
of anticancer drugs in Australia. Intern Med J. 2014;44(5):458-63.
4. Australian Institute of Health and Welfare (AIHW). Health System Expenditure on
Cancer and other Neoplasms in Australia:2008-09. Cat. no. 78. ed. Canberra: AIHW;
2013.
5. Global Cancer Observatory. Prostate. Lyons, France: International Agency for
Research on Cancer; 2019.
6. Darves-Bornoz A, Park J, Katz A. Prostate cancer epidemiology. In: Tewari A,
Whelan P, Graham J, editors. Prostate cancer: diagnosis and clinical management.
West Sussex, UK: John Wiley & Sons; 2014.
7. Watson R, Fitzpatrick J. Biology of prostate cancer. In: Dasgupta P, Kirby R,
editors. ABC of Prostate Cancer. BMJ Books. West Sussex, UK: Wiley Blackwell;
2012.
8. Rowlands M-A, Holly J, Gunnell D, Donovan J, Lane J, Hamdy F, et al. Circulating
insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer:
the large case-control study ProtecT. Cancer Res. 2012;72(2):503-15.
9. Boorjian S, Tindall D. Molecular progression of prostate cancer: androgens and
estrogens. In: Klein E, Jones J, editors. Management of Prostate Cancer. 3rd ed. New
York: Humana Press; 2013. p. 119-.
10. Huggins C, Hodges C. The effect of castration, of estrogen and of androgen
injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer
Journal for Clinicians. 1972;22:232-40.
11. Nesbit R, Plumb R. Prostatic carcinoma, follow-up on 795 patients treated prior to
endocrine era and comparison of survival rates between these and patients treated by
endocrine therapy. Surgery 1946;20:263-72.
12. Nesbit R, Baum W. Endocrine control of prostatic carcinoma, clinical and statistical
survey of 1,818 cases. JAMA. 1950;143:1317-20.
13. Chung E. Androgen deprivation therapy in men with prostate cancer: Rationale
between clinician and patient. European journal of Clinical and Medical Oncology.
2012;4(2):67-72.
14. Johnson MT, Lowe GJ, Bahnson RR. Androgen deprivation therapy: A primer on
concepts and therapeutic options. Journal of Men's Health. 2010;7(4):358-67.
15. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer.
Journal of the American Medical Association. 2005;294(2):238-44.
16. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in
Oncology (NCCN Guidelines) Prostate Cancer Version 2.2020. Pennsylvania: NCCN;
2020 [Available from:https://www.nccn.org/professionals/physician_gls/default.aspx.
17. National Institutes of Health and National Cancer Institute. Common Terminology
Criteria for Adverse Events (CTCAE) Version 5.0 2017 Accessed April 15, 2019;
Version 5. Available from:
https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_
Quick_Reference_8.5x11.pdf.
18. Lee D, Kildegaard Nielsen S, van Keep M, Andersson F, Greene D. Quality of life
improvement in patients treated with degartelix versus leuprorelin for advanced
prostate prostate cancer. The Journal of Urology. 2015;193:839-46.
106

19. Prostate Cancer Foundation of Australia (PCFA). Grading and staging of prostate
cancer. Prostate Cancer Foundation of Australia; 2017 [Available from:
https://www.prostate.org.au/awareness/for-recently-diagnosed-men-and-theirfamilies/partners-and-carers/diagnosis/grading-and-staging-of-prostate-cancer/.
20. Gordon L, Reinking S, Mervin C. The Financial Impact of Prostate Cancer in
Australia: Final Report August 2013. Meadowbank, Queensland: Centre for Applied
Health Economics, Griffith University; 2013.
21. Gordon LG, Walker SM, Mervin MC, Lowe A, Smith DP, Gardiner RA, et al.
Financial toxicity: a potential side effect of prostate cancer treatment among Australian
men. Eur J Cancer Care (Engl). 2015:n/a-n/a.
22. Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD. Bone and
metabolic health in patients with non-metastatic prostate cancer who are receiving
androgen deprivation therapy. Medical Journal of Australia. 2011;194(6):301-6.
23. Grossmann M, Zajac JD. Androgen deprivation therapy in men with prostate
cancer: How should the side effects be monitored and treated? Clin Endocrinol (Oxf).
2011;74(3):289-93.
24. Allan C, Collins V, Frydenberg M, McLachlan R. Androgen deprivation therapy
complications. Endocr Relat Cancer. 2014;21(4):T119-29.
25. Department of Health. The Pharmaceutical Benefits Scheme. Canberra:
Commonwealth of Australia; 2014 [updated December 1, 2014.Available
from:http://www.pbs.gov.au/pbs/home.
26. South Australian Prostate Cancer Clinical Outcomes Collaborative (SAPCCOC).
Prostate Health Website. Adelaide, SA: SAPCCOC; 2014 [Available
from:http://www.prostatehealth.org.au.
27. Australia M. Pharmaceutical Benefits Scheme. Australian government; 2014 [
28. Faunce T, Lofgren H. Drug price reforms: the new F1-F2 bifurcation. Australian
Prescriber. 2007;30(6):138-40.
29. Department of Health and Ageing - Medicines Australia. Trends in and drivers of
the Pharmaceutical Benefits Scheme expenditure: Report for the Access to Medicines
Working Group. 2013 May 2013.
30. Pharmaceutical Benefits Scheme. Pharmaceutical Benefits Schedule Item Reports
Australian Government, Canberra: Department of Human Services; 2019 [Available
from:http://medicarestatistics.humanservices.gov.au/statistics/pbs_item.jsp.
31. Kumar S, Shelley M, Harrison C, Coles B, Wilt T, Mason M. Neo-adjuvant and
adjuvant hormone therapy for localised and locally advanced prostate cancer (Review).
The Cochrane Library. 2006(4).
32. Newton RU, Galvão DA. Exercise medicine for prostate cancer. Eur Rev Aging
Phys Act. 2013;10:41-5.
33. Galvão D, Taaffe D, Spry N, Joseph D, Newton R. Combined resistance and
aerobic exercise program reverses muscle loss in men undergoing androgen
suppression therapy for prostate cancer without bone metastases: a randomized
controlled trial. J Clin Oncol. 2010;28(2):340-7.
34. Cormie P, Newton RU, Spry N, Joseph D, Taaffe DR, Galvão DA. Safety and
efficacy of resistance exercise in prostate cancer patients with bone metastases.
Prostate Cancer Prostatic Dis. 2013;16:328-35.
35. Cormie P, Galvão D, Spry N, Joseph D, Chee R, Taaffe D, et al. Can supervised
exercise prevent treatment toxicity in prostate cancer patients initiating androgen
deprivation therapy: a randomised control trial. BJU Int. 2015;115(2):256-66.
36. Galvão DA, Spry N, Denham J, Taaffe DR, Cormie P, Joseph D, et al. A
multicentre year-long randomised controlled trial of exercise training targeting physical
functioning in men with prostate cancer previously treated with androgen suppression
and radiation from TROG 03.04 RADAR. Eur Urol. 2014;65(5):856-64.
37. Kenfield S, Stampfer M, Giovannucci E, Chan J. Physical activity and survival after
prostate cancer diagnosis in the Health Professionals Follow-Up Study. J Clin Oncol.
2011;29:726-32.
107

38. Galvao DA, Newton RU. Review of exercise intervention studies in cancer patients.
J Clin Oncol. 2005;23(4):899-909.
39. Galvão D, Spry N, Taaffe D, Newton R, Stanley J, Shannon T, et al. Changes in
muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate
cancer. BJU Int. 2008;102:44-7.
40. Galvão D, Taaffe D, Spry N, Joseph D, Turner D, Newton R. Reduced muscle
strength and functional performance in men with prostate cancer undergoing androgen
suppression: a comprehensive cross-sectional investigation. Prostate Cancer and
Prostatic Diseases. 2009;12:198-203.
41. Galvao D, RU N, Taafe D, Spry N. Can exercise ameliorate the increased risk of
cardiovascular disease and diabetes associated with ADT? Nature Clinical Practice
Urology. 2008;5(6):306-7.
42. Galvao D, Nosaka K, Taaffe D, Spry N, Kristjanson L, McGuigan M, et al.
Resistance training and reduction of treatment side effects in prostate cancer patients.
Medicine and Science in Sports and Exercise. 2006;38(12):2045-52.
43. Galvao D, Nosaka K, Taaffe D, Peake J, Spry N, Suzuki K, et al. Endocrine and
immune responses to resistance training in prostate cancer patients. Prostate Cancer
and Prostatic Disease. 2008;11(2):160-5.
44. Galvao D, Taaffe D, Spry N, Joseph D, Newton R. Acute versus chronic exposure
to androgen suppression for prostate cancer: impact on the exercise response. J Urol.
2011;186(4):1291-7.
45. Newton RU, Taaffe DR, Spry N, Gardiner RA, Levin G, Wall B, et al. A phase III
clinical trial of exercise modalities on treatment side-effects in men receiving therapy
for prostate cancer. BMC Cancer. 2009;9:210.
46. Newton RU, Galvao DA. Exercise medicine for prostate cancer. European Review
of Aging and Physical Activity. 2013;10(1):41-5.
47. Hayes S, Spence R, Galvão D, Newton R. Australian Association for Exercise and
Sport Science position stand: optimising cancer outcomes through exercise. Journal of
Science and Medicine in Sport. 2009;12(4):428-34.
48. Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvão DA, Pinto
BM, et al. American College of Sports Medicine Roundtable on Exercise: Guidelines for
Cancer Survivors. Medicine and Science in Sports and Exercise. 2010;42(7):1407-26.
49. Gardner JR, Livingston PM, Fraser SF. Effects of exercise on treatment-related
adverse effects for patients with prostate cancer receiving androgen-deprivation
therapy: a systematic review. J Clin Oncol. 2014;32(4):335-46.
50. Hayes S, Newton R, Spence R, Galvão D. The Exercise and Sports Science
Australia position statement: exercise medicine in cancer management. Journal of
Science and Medicine in Sport. 2019;22(11):1175-99.
51. Campbell K, Winters-Stone K, Wiskemann J, May A, Schwartz A, Courneya K, et
al. Exercise Guidelines for Cancer Survivors: Consensus Statement from International
Multidisciplinary Roundtable. Medicine & Science in Sports & Exercise.
2019;51(11):2375-90.
52. ASCO Cancer Survivorship Committee. Providing high quality survivorship care in
practice: an ASCO guide. American Society of Clinical Oncology; 2014.
53. National Comprehensive Cancer Network (NCCN). NCCN Guidelines Version
1.2019: Survivorship 2019 Accessed May 24, 2019; 2019. Available from:
https://www.nccn.org/professionals/physician_gls/default.aspx#supportive.
54. National Institute for Health and Care Excellence (NICE). Prostate cancer:
diagnosis and management 2019; (Accessed May 24, 2019). Available from:
https://www.nice.org.uk/guidance/ng131.
55. Newton R, Galvao D, Taaffe D. Clinical Oncology Society of Australia position
statement on exercise in cancer care. Medical Journal of Australia. 2019;210(1):54.
56. Hart N, Galvão D, Newton R. Exercise medicine for advanced prostate cancer.
Current Opinion in Supportive and Palliative Care. 2017;11:247-57.
108

57. Greasely R, Turner R, Collins K, Brown J, Bourke L, Rosario D. Treatment in the
STAMPEDE for castrate resistant prostate cancer in the UK: ongoing challenges and
underappreciated clinical problems. BMC Cancer. 2018;18:667.
58. Kumar S, Shelley M, Harrison C, Coles B. Neo-adjuvant and adjuvant hormone
therapy for localised and locally advanced prostate cancer. The Cochrane
Collaboration [Internet]. 2006; (4):[1-71 pp.].
59. Shelley MD, Kumar S, Coles B, Wilt T, Staffurth J, Mason MD. Adjuvant hormone
therapy for localised and locally advanced prostate carcinoma: A systematic review
and meta-analysis of randomised trials. Cancer Treatment Reviews. 2009;35(7):540-6.
60. Sharifi N, Gulley JL, Dahut WL. An update on androgen deprivation therapy for
prostate cancer. Endocr Relat Cancer. 2010;17(4):R305-R15.
61. National Institute of Cancer. NCI Dictionary of Cancer Terms. Maryland: National
Institutes of Health, US Department of Health and Human Services; 2015 [Available
from:http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=444960.
62. Australian Institute of Health and Welfare (AIHW). Prostate cancer in Australia.
Canberra: AIHW; 2013.
63. Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M.
Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease
following androgen deprivation therapy for prostate cancer: a meta-analysis. European
Urology. 2015;68(3):386-96.
64. Bosco C, Crawley D, Adolfsson J, Rudman S, Van Hemelrijck M. Quantifying the
evidence for the risk of metabolic syndrome and its components following androgen
deprivation therapy for prostate cancer: a meta-analysis. PLoS ONE.
2015;10(3):e0117344.
65. Fagerlund A, Cormio L, Palangi L, Lewin R, Di Pompeo FS, Elander A, et al.
Gynecomastia in patients with prostate cancer: a systematic review. PLoS ONE.
2015;10(8).
66. Guo Z, Huang Y, Gong L, Gan S, Chan FL, Gu C, et al. Association of androgen
deprivation therapy with thromboembolic events in patients with prostate cancer: a
systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2018;21(4):45160.
67. Haseen F, Murray LJ, Cardwell CR, O’Sullivan JM, Cantwell MM. The effect of
androgen deprivation therapy on body composition in men with prostate cancer:
Systematic review and meta-analysis. Journal of Cancer Survivorship. 2010;4(2):12839.
68. Jin C, Fan Y, Meng Y, Shen C, Wang Y, Hu S, et al. A meta-analysis of
cardiovascular events in intermittent androgen-deprivation therapy versus continuous
androgen-deprivation therapy for prostate cancer patients. Prostate Cancer & Prostatic
Diseases. 2016;19(4):333-9.
69. Kim D, Lee J, Kim K, N H, Kim J, Hah Y, et al. Effect of Androgen-Deprivation
Therapy on Bone Mineral Density in Patients with Prostate Cancer: A Systematic
review and Meta-analysis. Journal of Clinical Medicine. 2019;8(113).
70. Kunath F, Grobe HR, Rucker G, Motschall E, Antes G, Dahm P, et al. Non-steroidal
antiandrogen monotherapy compared with luteinizing hormone-releasing hormone
agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane
systematic review. BJU Int. 2015;116(1):30-6.
71. Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E, et al.
Intermittent vs continuous androgen deprivation therapy for prostate cancer: a
systematic review and meta-analysis. JAMA Oncology. 2015;1(9):1261-9.
72. McGinty HL, Phillips KM, Jim HSL, Cessna JM, Asvat Y, Cases MG, et al.
Cognitive functioning in men receiving androgen deprivation therapy for prostate
cancer: A systematic review and meta-analysis. Support Care Cancer.
2014;22(8):2271-80.
109

73. Meng F, Zhu S, Zhao J, Vados L, Wang L, Zhao Y, et al. Stroke related to
androgen deprivation therapy for prostate cancer: a meta-analysis and systematic
review. BMC Cancer. 2016;16:180.
74. Nead K, Boldbaatar N, Yang D, Sinha S, Nguyen P. Association of androgen
deprivation therapy and thromboembolic events: a systematic review and metaanalysis. J Urol. 2018;114:155-62.
75. Nead KT, Sinha S, Nguyen PL. Androgen deprivation therapy for prostate cancer
and dementia risk: a systematic review and meta-analysis. Prostate Cancer & Prostatic
Diseases. 2017;20(3):259-64.
76. Nead KT, Sinha S, Yang DD, Nguyen PL. Association of androgen deprivation
therapy and depression in the treatment of prostate cancer: A systematic review and
meta-analysis. Urologic Oncology. 2017;35(11):664.e1-.e9.
77. Nguyen PL, Je Y, Schutz FA, Hoffman KE, Hu JC, Parekh A, et al. Association of
androgen deprivation therapy with cardiovascular death in patients with prostate
cancer: a meta-analysis of randomized trials. JAMA. 2011;306(21):2359-66.
78. Roviello G, Sigala S, Danesi R, Re MD, Bonetta A, Cappelletti MR, et al. Incidence
and relative risk of adverse events of special interest in patients with castration
resistant prostate cancer treated with CYP-17 inhibitors: a meta-analysis of published
trials. Crit Rev Oncol Hematol. 2016;101:12-20.
79. Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, et al. Adding
abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive
prostate cancer: a systematic review and meta-analysis. Eur J Cancer. 2017;84:88101.
80. Scailteux LM, Naudet F, Alimi Q, Vincendeau S, Oger E. Mortality, cardiovascular
risk, and androgen deprivation therapy for prostate cancer: A systematic review with
direct and network meta-analyses of randomized controlled trials and observational
studies. Medicine. 2016;95(24):e3873.
81. Sciarra A, Fasulo A, Ciardi A, Petrangeli E, Gentilucci A, Maggi M, et al. A metaanalysis and systematic review of randomized controlled trials with degarelix versus
gonadotropin-releasing hormone agonists for advanced prostate cancer. Medicine.
2016;95(27):e3845.
82. Sun M, Cole A, Hanna N, Mucci L, Berry D, Basaria S, et al. Cognitive impairment
in men with prostate cancer treated with androgen deprivation therapy: a systematic
review and meta-analysis. The Journal of Urology. 2018;199:1417-25.
83. Wang H, Sun X, Zhao L, Chen X, Zhao J. Androgen deprivation therapy is
associated with diabetes: Evidence from meta-analysis. Journal of Diabetes
Investigation. 2016;7(4):629-36.
84. Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, et al. Androgen deprivation therapy
for prostate cancer is associated with cardiovascular morbidity and mortality: a metaanalysis of population-based observational studies. PLoS ONE. 2014;9(9):e107516.
85. Zhu J, Liao R, Su C, Liang D, Wu J, Qiu K, et al. Toxicity profile characteristics of
novel androgen-deprivation therapy agents in patients with prostate cancer: a metaanalysis. Expert Review of Anticancer Therapy. 2018;18(2):193-8.
86. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions
Version 5.1.0 [updated March 2011]: The Cochrane Collaboration; 2011. Available
from: http://handbook.cochrane.org.
87. Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J, et al. The
PRISMA statement for reporting systematic reviews and meta-analyses of studies that
evaluate health care interventions: explanation and elaboration. Bmj. 2009;339:b2700.
88. Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence Working
Group. The Oxford 2011 Levels of Evidence 2016 Accessed November 21, 2018.
Available from: https://www.cebm.net/wp-content/uploads/2014/06/CEBM-Levels-ofEvidence-2.1.pdf.
89. Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, et al.
The 2011 Oxford CEBM Evidence Levels of Evidence (Introductory Document).
110

Oxford: Oxford Centre for Evidence-Based Medicine; 2016 [Available
from:http://www.cebm.net/index.aspx?o=5653.
90. Shea B, Reeves B, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a
critical appraisal tool for systematic reviews that include randomised or nonrandomised studies of healthcare interventions, or both. Bmj. 2017;358.
91. Higgins J, Sterne J, Savović J, Page M, Hróbjartsson A, Boutron I, et al. A revised
tool for assessing risk of bias in randomized trials. Cochrane Database of Systematic
Reviews. 2016;10.
92. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The
Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in
meta-analyses. Ottawa: The Ottawa Hospital Research Institute; 2019 [
93. Schunemann H, Cuello C, Akl E, Mustafa R, Meerpohl J, Thayer K, et al. GRADE
guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized
studies should be used to rate the certainty of a body of evidence. 2018.
94. Morgans AK, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, et al.
Bone complications among prostate cancer survivors: long-term follow-up from the
prostate cancer outcomes study. Prostate Cancer & Prostatic Diseases.
2014;17(4):338-42.
95. Wadhwa VK, Weston R, Mistry R, Parr NJ. Long-term changes in bone mineral
density and predicted fracture risk in patients receiving androgen-deprivation therapy
for prostate cancer, with stratification of treatment based on presenting values. BJU Int.
2009;104(6):800-5.
96. Greenspan SL, Nelson JB, Trump DL, Resnick NM, Miller M. Effect of once-weekly
oral alendronate on bone loss in men receiving androgen deprivation therapy for
prostate cancer: A randomized trial. Ann Intern Med. 2007;146(6):416-24.
97. Ng HS, Koczwara B, Roder D, Vitry A. Development of comorbidities in men with
prostate cancer treated with androgen deprivation therapy: an Australian populationbased cohort study. Prostate Cancer & Prostatic Diseases. 2018;21(3):403-10.
98. Shao YH, Moore DF, Shih W, Lin Y, Jang TL, Lu-Yao GL. Fracture after androgen
deprivation therapy among men with a high baseline risk of skeletal complications. BJU
Int. 2013;111(5):745-52.
99. Wallis C, Mahar A, Satkunasivam R, Hershorn S, Kodama R, Lee Y, et al.
Cardiovascular and skeletal-related events folowing localised prostate cancer
treatment: role of surgery, radiotherapy, and androgen deprivation. J Urol. 2016
97:145-52.
100. Alibhai SM, Duong-Hua M, Cheung AM, Sutradhar R, Warde P, Fleshner NE, et
al. Fracture types and risk factors in men with prostate cancer on androgen deprivation
therapy: a matched cohort study of 19,079 men. J Urol. 2010;184(3):918-23.
101. Sun M, Choueri T, Hamnvik O-P, Preston M, De Velasco G, Jiang W, et al.
Comparison of Gonadotrophin-Releasing Hormone Agonists and Orchiectomy. JAMA
Oncology. 2016;2(4):500-7.
102. Tsai HT, Pfeiffer RM, Philips GK, Barac A, Fu AZ, Penson DF, et al. Risks of
Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy
for Advanced Prostate Cancer: A Population Based Study. J Urol. 2017;197(5):1251-7.
103. Beebe-Dimmer JL, Cetin K, Shahinian V, Morgenstern H, Yee C, Schwartz KL,
et al. Timing of androgen deprivation therapy use and fracture risk among elderly men
with prostate cancer in the United States. Pharmacoepidemiology & Drug Safety.
2012;21(1):70-8.
104. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al.
Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med.
2018;378(15):1408-18.
105. Graff J, Baciarello G, Armstrong A, Higano C, Iversen PW, Flaig W, et al.
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapynaive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann
Oncol. 2016;27:286-94.
111

106. Morote J, Gomez-Caamano J, Alvarez-Ossorio J, Pesqueira D, Tabernero A,
Veiga F, et al. The metabolic syndrome and its components in patients with prostate
cancer on androgen deprivation therapy. The Journal of Urology. 2015;193(6):1963-9.
107. Smith M, Lee H, McGovern F, Fallon M, Goode M, Zeitman A. Metabolic
changes during gonadotrophin-releasing hormone agonist therapy for prostate cancer:
differences from the classic metabolic syndrome. Cancer. 2008;112:2188-94.
108. Keating N, O'Malley J, Smith M. Diabetes and cardiovascular disease during
androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448-56.
109. Taylor L, SE C, Du X. Review of major adverse effects of androgen-deprivation
therapy in men with prostate. Cancer. 2009;115(11):2388-99.
110. Iacovelli R, Ciccarese C, Bria E, Romano M, Fantinel E, Bimbatti D, et al. The
cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin
Genitourin Cancer. 2018;16(3):e645-e53.
111. van der Windt DJ, Sud V, Zhang H, Tsung A, Huang H. The effects of physical
exercise on fatty liver disease. Gene Expression. 2018;18:89-101.
112. Spratt DE, Dess RT, Zumsteg ZS, Lin DW, Tran PT, Morgan TM, et al. A
systematic review and framework for the use of hormone therapy with salvage
radiation therapy for recurrent prostate cancer. Eur Urol. 2018;73(2):156-65.
113. Gild P, Cole AP, Krasnova A, Dickerman BA, von Landenberg N, Sun M, et al.
Liver disease in men undergoing androgen deprivation therapy for prostate cancer. J
Urol. 2018;200(3):573-81.
114. National Institute for Health and Care Excellence (NICE). Clinical guideline
[CG175] Managing adverse effects of hormone therapy. UK: NICE; 2014 [updated
January 2014.
115. Daly PE, Dunne MT, O'Shea CM, Finn MA, Armstrong JG. The effect of short
term neo-adjuvant androgen deprivation on erectile function in patients treated with
external beam radiotherapy for localised prostate cancer: An analysis of the 4-versus
8-month randomised trial (Irish Clinical Oncology Research Group 97-01).
Radiotherapy and Oncology. 2012;104(1):96-102.
116. Jones C, Hunt D, McGowan D, Amin M, Chetner M, Bruner D, et al.
Radiotherapy and short-term androgen deprivation therapy for localized prostate
cancer. The New England Journal of Medicine. 2011;365(2).
117. Sharpley C. Actual change in anxiety and depression among Australian men
with prostate cancer. Journal of Men's Health and Gender. 2007;4(1):32-8.
118. Lee M, Jim HS, Fishman M, Zachariah B, Heysek R, Biagioli M, et al.
Depressive symptomatology in men receiving androgen deprivation therapy for
prostate cancer: A controlled comparison. Psycho-Oncology. 2015;24(4):472-7.
119. Himelhoch S, Weller W, Wu A, Anderson G, Cooper L. Chronic Medical Illness,
Depression, and Use of Acute Medical Services Among Medicare Beneficiaries. Med
Care. 2004;42:512-21.
120. Roviello G, Generali D. Is the fatigue an adverse event of the second
generation of hormonal therapy? Data from a literature-based meta-analysis. Medical
Oncology. 2018;35(3):29.
121. Alibhai SM, Breunis H, Timilshina N, Naglie G, Tannock I, Krahn M, et al. Longterm impact of androgen-deprivation therapy on physical function and quality of life.
Cancer. 2015;121(14):2350-7.
122. Gonzalez B, Jim H, Small B, Sutton S, Fishman M, Zachariah B, et al. Changes
in physical functioning and muscle strength in men receiving androgen deprivation
therapy for prostate cancer: a controlled comparison. Support Care Cancer.
2016;24:2201-7.
123. Hussain S, Breunis H, Timilshina N, Alibhai SMH. Falls in men on androgen
deprivation therapy for prostate cancer. Journal of Geriatric Oncology. 2010;1(1):32-9.
124. Graff J, Baciarello G, Armstrong A, Higano C, Iversen P, Flaig T, et al. Efficacy
and safety of enzalutamide in patients 75 years or older with chemotherapy-naive
112

metastatic castrate resistant prostate cancer: results from PREVAIL. Ann Oncol.
2016;27:286-94.
125. Carneiro A, Sasse AD, Wagner AA, Peixoto G, Kataguiri A, Neto AS, et al.
Cardiovascular events associated with androgen deprivation therapy in patients with
prostate cancer: a systematic review and meta-analysis. World Journal of Urology.
2015;33(9):1281-9.
126. Bourke L, Kirkbride P, Hooper R, Rosario A, Chico T, Rosario D. Endocrine
therapy in prostate cancer: time for reapprisal of risks, benefits and cost-effectiveness?
British Journal of Cancer. 2013;108:9-13.
127. Pearce A, Haas M, Viney R. Are the true impacts of adverse events considered
in economic models of antineoplastic drugs? A systematic review. Applied Health
Economics and Health Policy. 2013;11:619-37.
128. Australian Institute of Health and Welfare (AIHW). Cancer in Australia: an
overview 2014. Canberra: AIHW; 2014.
129. International Agency for Research on Cancer (IARC). Cancer Today: Prostate
Cancer. France: GLOBOCAN World Health Organisation; 2018 [updated Accessed
December 28, 2019.Available from:http://gco.iarc.fr/today/data/factsheets/cancers/27Prostate-fact-sheet.pdf.
130. Gordon L, Tuffaha H, James R, Keller A, Lowe A, Scuffham P, et al. Estimating
the healthcare costs of treating prostate cancer in Australia: a Markov modelling
analysis. Urologic Oncology: Seminars and Original Investigations. 2018;36.
131. Edmunds K, Tuffaha H, Galvão D, Scuffham P, Newton R. Incidence of the
adverse effects of androgen deprivation therapy for prostate cancer: a systematic
review. Support Care Cancer. 2020;28:2079-93.
132. Vina J, Sanchis-Gomar F, Martinez-Bello V, Gomez-Cabrera M. Exercise acts
as a drug; the pharmacological benefits of exercise. British Journal of Pharmacology.
2012;167:1-12.
133. Resnick MJ, Lacchetti C, Bergman J, Hauke RJ, Hoffman KE, Kungel TM, et al.
Prostate cancer survivorship care guideline: American society of clinical oncology
clinical practice guideline endorsement. J Clin Oncol. 2015;33(9):1078-85.
134. Joseph JS, Lam V, Patel MI. Preventing osteoporosis in men taking androgen
deprivation therapy for prostate cancer: a systematic review and meta-analysis. Eur
Urol Oncol. 2019;2(5):551-61.
135. Taaffe DR, Galvão DA, Spry N, Joseph D, Chambers SK, Gardiner RA, et al.
Immediate versus delayed exercise in men initiating androgen deprivation: effects on
bone density and soft tissue composition. BJU Int. 2018;123(2):261-9.
136. Uth J, Hornstrup T, Schmidt JF, Christensen JF, Frandsen C, Christensen KB,
et al. Football training improves lean body mass in men with prostate cancer
undergoing androgen deprivation therapy. Scandinavian Journal of Medicine and
Science in Sports. 2014;24(SUPPL.1):105-12.
137. Newton RU, Galvão DA, Spry N, Joseph D, Chambers SK, Gardiner RA, et al.
Exercise Mode Specificity for Preserving Spine and Hip Bone Mineral Density in
Prostate Cancer Patients. Medicine & Science in Sports & Exercise. 2018;51(4):60714.
138. Newton RU, Jeffery E, Galvão DA, Peddle‐McIntyre CJ, Spry N, Joseph D, et
al. Body composition, fatigue and exercise in patients with prostate cancer undergoing
androgen‐deprivation therapy. BJU Int. 2018;122(6):986-93.
139. Baumann FT, Zopf EM, Bloch W. Clinical exercise interventions in prostate
cancer patients: a systematic review of randomized controlled trials. Support Care
Cancer. 2012;20(2):221-33.
140. Hasenoehrl T, Keilani M, Sedghi Komanadj T, Mickel M, Margreiter M, Marhold
M, et al. The effects of resistance exercise on physical performance and health-related
quality of life in prostate cancer patients: a systematic review. Support Care Cancer.
2015;23(8):2479-97.
113

141. Bourke L, Smith D, Steed L, Hooper R, Carter A, Catto J, et al. Exercise for
men with prostate cancer: a systematic review and meta-analysis. European Urology.
2016;69(4):693-703.
142. Keilani M, Hasenoehrl T, Baumann L, Ristl R, Schwarz M, Marhold M, et al.
Effects of resistance exercise in prostate cancer patients: a meta-analysis. Support
Care Cancer. 2017;25:2953-68.
143. Yunfeng G, Weiyang H, Xueyang H, Yilong H, Xin G. Exercise overcome
adverse effects among prostate cancer patients receiving androgen deprivation
therapy. Medicine (United States). 2017;96(27).
144. Crawford-Williams F, March S, Goodwin BC, Ralph N, Galvão DA, Newton RU,
et al. Interventions fo prostate cancer survivorship: a systematic review of reviews.
Psychooncology. 2018;27:1339-2348.
145. O’Neill RF, Haseen F, Murray LJ, O’Sullivan JM, Cantwell MM. A randomised
controlled trial to evaluate the efficacy of a 6-month dietary and physical activity
intervention for patients receiving androgen deprivation therapy for prostate cancer. J
Cancer Surviv. 2015;9(3):431-40.
146. Gilbert SE, Tew GA, Fairhurst C, Bourke L, Saxton JM, Winter EM, et al. Effects
of a lifestyle intervention on endothelial function in men on long-term androgen
deprivation therapy for prostate cancer. British Journal of Cancer. 2016;114(4):401-8.
147. Galvão DA, Taaffe DR, Spry N, Cormie P, Joseph D, Chambers SK, et al.
Exercise Preserves Physical Function in Prostate Cancer Patients with Bone
Metastases. Medicine & Science in Sports & Exercise. 2018;50(3):393-9.
148. Grossmann M, Zajac J. Management of the side effects of androgen deprivation
therapy. Endocrinology and Metabolism Clinics of North America. 2011;40(4):655-71.
149. Arnett D, Blumenthal R, Albert M, Buroker A, Goldberger Z, Hahn E, et al. 2019
ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of
the American College of Cardiology/American Heart Association Task Force on Clinical
Practice Guidelines. Circulation. 2019;140:e596-e646.
150. Colberg S, Sigal R, Yardley J, Riddell M, Dunstan D, Dempsey P, et al.
Physical activity/exercise and diabetes: a position statement of the American Diabetes
Association. Diabetes Care. 2016;39(11):2065-79.
151. The Royal Australian College of General Practitioners & Diabetes Australia.
General practice management of type 2 diabetes 2016-2018 2016 Accessed
November 27, 2019. Available from:
https://www.racgp.org.au/FSDEDEV/media/documents/Clinical%20Resources/Guidelin
es/Diabetes/General-practice-management-of-type-2-diabetes_1.pdf.
152. Collins L, Mohammed N, Ahmad T, Basaria S. Androgen deprivation therapy for
prostate cancer: implications for cardiometabolic clinical care. J Endocrinol Invest.
2012;35(3):332-9.
153. Beaudry R, Liang Y, Boyton S, Tucker W, Brothers R, Daniel K, et al. Metaanalysis of exercise training on vascular endothelial function in cancer survivors.
Integrative Cancer Therapies. 2018;17(2):192-9.
154. Ahmadi H, Daneshmund S. Androgen deprivation therapy: evidence-based
management of side effects. BJU Int. 2013;111:543-8.
155. Hamilton K, Chambers SK, Legg M, Oliffe JL, Cormie P. Sexuality and exercise
in men undergoing androgen deprivation therapy for prostate cancer. Support Care
Cancer. 2015;23(1):133-42.
156. Cormie P, Newton R, Taaffe D, Saunders, Joseph D, Akhil Hamid M, et al.
Exercise maintains sexual activity in men undergoing androgen suppression for
prostate cancer: a randomized controlled trial. Prostate Cancer Prostatic Dis.
2013;16:170-5.
157. Chambers S, Dunn J, Lazenby M, Clutton S, Newton R, Cormie P, et al.
ProsCare: A psychological care model for men with prostate cancer. Prostate Cancer
Foundation of Australia (PCFA) and Griffith University, Australia; 2013.
114

158. Chipperfield K, Brooker J, Fletcher J, Burney S. The impact of physical activity
on psychosocial outcomes in men receiving androgen deprivation therapy for prostate
cancer: a systematic review. Health Psychol. 2014;33(11):1288-97.
159. Bourke L, Boorjian SA, Briganti A, Klotz L, Mucci L, Resnick MJ, et al.
Survivorship and Improving Quality of Life in Men with Prostate Cancer. European
Urology. 2015;68(3):374-83.
160. Keogh JWL, MacLeod RD. Body composition, physical fitness, functional
performance, quality of life, and fatigue benefits of exercise for prostate cancer
patients: a systematic review. Journal Pain Symptom Manage. 2012;43(1):96-110.
161. Baguley BJ, Bolam KA, Wright ORL, Skinner TL. The effect of nutrition therapy
and exercise on cancer-related fatigue and quality of life in men with prostate cancer.
Nutrients. 2017;9.
162. Larkin D, Lopez V, Aromataris E. Managing cancer-related fatigue in men with
prostate cancer: a systematic review of non-pharmacological interventions. Int J Nurs
Pract. 2014;20(5):549-60.
163. Moe E, Chadd J, McDonagh M, Valtonen M, Horner-Johnson W, Eden K, et al.
Exercise Interventions for Prostate Cancer Survivors Receiving Hormone Therapy:
Systematic Review. Translational Journal of the ACSM. 2017;2(1):1-9.
164. Vashistha V, Singh B, Kaura S, Prokop L, Kaushik D. The Effects of Exercise
on Fatigue, Quality of Life, and Psychological Function for Men with Prostate Cancer:
Systematic Review and Meta-analyses. European Urology Focus. 2016;2:284-95.
165. Taaffe DR, Newton RU, Spry N, Joseph D, Chambers SK, Gardiner RA, et al.
Effects of different exercise modalities on fatigue in prostate cancer patients
undergoing androgen deprivation therapy: a year-long randomised controlled trial. Eur
Urol. 2017;72(2):293-9.
166. Segal R. Physical functioning for prostate health. Can Urol Assoc J. 2014;8(7-8
Supplement 5):S162-3.
167. Sherrington C, Fairhall N, Wallbank G, Tiedemann A, Michaleff Z, Howard K, et
al. Exercise for preventing falls in older people living in the community (Review).
Cochrane Database Sys Rev. 2019;Art No.: CD012424(1).
168. Lin X, Zhang X, Guo J, Roberts C, McKenzie S, Wu W, et al. Effects of exercise
training on cardiorespiratory fitness and biomarkers of cardiometabolic health: a
systematic review and meta-analysis of randomized controlled trials. Journal of the
American Heart Association. 2015;4(7).
169. Pan B, Ge L, Xun YQ, Chen YJ, Gao CY, Han X, et al. Exercise training
modalities in patients with type 2 diabetes mellitus: a systematic review and network
meta-analysis. Int J Behav Nutr Phys Act. 2018;15(1):72.
170. Schellenberg E, Dryden D, Vandermeer B, Ha C, Korownyk C. Lifestyle
interventions for patients with and at risk for type 2 diabetes: a systematic review and
meta-analysis. Ann Intern Med. 2013;159:543-51.
171. Zanuso S, Sacchetti M, Sundberg CJ, Orlando G, Benvenuti P, Balducci S.
Exercise in type 2 diabetes: genetic, metabolic and neuromuscular adaptations. A
review of the evidence. Br J Sports Med. 2017;51(21):1533-8.
172. Scott J, Nilsen T, Gupta D, Jones L. Exercise therapy and cardiovascular
toxicity in cancer. Circulation. 2018;137:1176-91.
173. Green DJ, Hopman MT, Padilla J, Laughlin MH, Thijssen DH. Vascular
adaptation to exercise in humans: role of hemodynamic stimuli. Physiological reviews.
2017;97(2):495-528.
174. Janssen V, De Gucht V, Dusseldorp E, Maes S. Lifestyle modification
programmes for patients with coronary heart diease: a systematic review and metaanalysis of randomized controlled trials. European Journal of Preventive Cardiology.
2013;20:620-40.
175. Northey J, Cherbuin N, Pumpa K, Smee D, Rattray B. Exercise interventions for
cognitive function in adults older than 50: a systematic review with meta-analysis. Br J
Sports Med. 2018;52(3):154-60.
115

176. Blondell S, Hammersley-Mather R, Veerman J. Does physical activity prevent
cognitive decline and dementia?: a systematic review and meta-analysis of longitudinal
studies. BMC Public Health. 2014;14.
177. Meschia J, Bushnell CB, Boden-Albala B, Braun L, Dawn M. Bravata D,
Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a statement for
healthcare professionals from the American Heart Association/American Stroke
Association. Stroke. 2014;45:3754-832.
178. Tsivgoulis G, Safouris A, Kim D-E, Alexandrovb A. Recent advances in primary
and secondary prevention of artherosclerotic stroke. Journal of Stroke. 2018;20(2):14566.
179. Carlson D, Dieberg G, Hess N, Millar P, Smart N. Isometric exercise training for
blood pressure management: a systematic review and meta-analysis. Mayo Clin Proc.
2014;89(3):327-4.
180. Carpio-Rivera E, Moncada-Jiménez J, Salazar-Rojas W, Solera-Herrera A.
Acute effects of exercise on blood pressure: a meta-analytic investigation. Arq Bras
Cardiol. 2016;106(5):422-33.
181. Cornelissen V, Smart N. Exercise training for blood pressure: a systematic
review and meta‐analysis. Journal of the American Heart Association.
2013;2(1):e004473.
182. Nelson MR, Doust JA. Primary prevention of cardiovascular disease: new
guidelines, technologies and therapies. Med J Aust. 2013;198(11):606-10.
183. National Vascular Disease Prevention Alliance (NVDPA). Guidelines for the
management of absolute cardiovascular disease risk. NVDPA; 2012. p. 124.
184. Brook R, Appel L, Rubenfire M, Ogedegbe G, Bisognano J, Elliott W, et al.
Beyond medications and diet: alternative approaches to lowering blood pressure: a
scientific statement from the American Heart Association. Hypertension. 2013;61:136083.
185. Key N, Khorana A, Kuderer N, Bohlke K, Lee A, Arcelus J, et al. Venous
thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical
practice guideline update. J Clin Oncol. 2019;38(5):496-520.
186. Kahn SR, Shrier I, Kearon C. Physical activity in patients with deep venous
thromboembolism: a systematic review. Thrombosis Research. 2008;122:763-73.
187. Lambiase MJ, Thurston RC. Physical activity and sleep among midlife women
with vasomotor symptoms. Menopause (New York, NY). 2013;20(9):946-52.
188. Moilanen J, Aalto AM, Hemminki E, Aro AR, Raitanen J, Luoto R. Prevalence of
menopause symptoms and their association with lifestyle among Finnish middle-aged
women. Maturitas. 2010;67:368-74.
189. Golabi P, Locklear C, Austin P, Afdhal S, Byrns M, Gerber L, et al.
Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease:
Systematic review. . World Journal of Gastroenterology. 2016;22(27):6318-27.
190. Whitsett M, van Wagner L. Physical activity as a treatment of non-alcoholic fatty
liver disease: A systematic review. World Journal of Hepatology. 2015;7(16):2041-52.
191. Schuch F, Vancampfort D, Richards J, Rosenbaum S, Ward P, Stubbs B.
Exercise as a treatment for depression: A meta-analysis adjusting for publication bias.
Journal of Psychiatric Research. 2016;77:42-51.
192. Craft L, Vaniterson E, Helenowski I, Rademaker A, Courneya K. Exercise
effects on depressive symptoms in cancer survivors: a systematic review and metaanalysis. Cancer Epidemiol Biomarkers Prev. 2012;21(1):3-19.
193. Brown A, Huedo-Medina T, Pescatello L, Ryan S, Pescatello S, Moker E, et al.
The efficacy of exercise in reducing depressive symptoms among cancer survivors: a
meta-analysis. PLoS ONE. 2012;7(1):e30955.
194. Mishra S, Scherer R, Geigle P, Berlanstein D, Topaloglu O, Gotay C, et al.
Exercise interventions on health-related quality of life for cancer survivors. Cochrane
Database Sys Rev. 2012;8.
116

195. Mishra S, Scherer R, Snyder C, Geigle P, Berlanstein D, Topaloglu O. Exercise
interventions on health-related quality of life for people with cancer during active
treatment. Cochrane Database Sys Rev. 2012;8.
196. Fong D, Ho J, Hui B, Lee A, Macfarlane D, Leung S, et al. Physical activity for
cancer survivors: meta-analysis of randomised controlled trials. BMJ (Online).
2012;344(e70).
197. Winters-Stone KM, Dobek JC, Bennett JA, Maddalozzo GF, Ryan CW, Beer
TM. Skeletal response to resistance and impact training in prostate cancer survivors.
Medicine and Science in Sports and Exercise. 2014;46(8):1482-8.
198. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate
cancer. CSH Perspectives in Medicine 2018;8.
199. Bourke L, Turner R, Greasley R, Sutton E, Steed L, Smith D, et al. A multicentre investigation of delivering national guidelines on exercise training for men with
advanced prostate cancer undergoing androgen deprivation therapy in UK NHS. PLoS
ONE. 2018;13(7):e0197606.
200. Schmidt M, Østergren P, Cormie P, Ragle A, Sønksen J, Midtgaard J. “Kicked
out into the real world": prostate cancer patients' experiences with transitioning from
hospital-based supervised exercise to unsupervised exercise in the community.
Support Care Cancer. 2019;27(1):199-208.
201. Australian Institute of Health and Welfare (AIHW). Health Expenditure Australia
2017-18. Canberra: AIHW; 2019.
202. Drummond MF, Sculpher MJ, Klaxton K, Stoddart GL, Torrance GW. Methods
for the Economic Evaluation of Health Care Programmes. Fourth ed. Oxford: Oxford
University Press; 2015.
203. Briggs A, O'Brien B. The death of cost minimisation analysis? Health
Economics. 2001;10(2):179-84.
204. Norman R, Viney R. CREST Health related quality of life for economic
evaluations in cancer. Sydney: The Centre for Health Economics Research and
Evaluation: University of Technology (UTS); 2011.
205. Gray A, Clarke P, Wolstenholme J, Wordsworth S. Applied Methods of Costeffectiveness Analysis in Health Care. Oxford: Oxford University Press; 2011.
206. McCabe C, Claxton K, Culyer A. The NICE cost-effectiveness threshold: what it
is and what it means. Pharmacoeconomics. 2008;29(9):733-44.
207. Henry D, Hill S, Harris A. Drug prices and value for money. JAMA.
2005;294(20):2630-2.
208. Edney L, Afzali H, Cheng T, Karnon J. Estimating the reference incremental
cost-effectiveness ratio for the Australian health system. Pharmacoeconomics.
2018;36:239-52.
209. York Health Economics Consortium. Net Monetary Benefit [online]. York2016
[Available from:https://yhec.co.uk/glossary/net-monetary-benefit/.
210. Stinnett A, Mullahy J. Net health benefits: a new framework for the analysis of
uncertainty in cost-effectiveness analysis. Medical Decision Making. 1998;1998:S68S80.
211. Janssen M, Pickard A, Golicki D, Gudex C, Niewada M, Scalone L, et al.
Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight
patient groups: a multi-country study. Quality of Life research. 2013;22(7):1717-27.
212. Horsman J, Furlong W, Feeny D, Torrance G. The Health Utilities Index (HUI®):
concepts, measurement properties and applications. Health and Quality of Life
Outcomes. 2003;1(54).
213. Richardson J, Sinha K, Iezzi A, Khan M. Modelling the Utility of Health States
with the Assessment of Quality of Life (AQoL) 8D Instrument: Overview and Utility
Scoring Algorithm 2011.
214. Brazier J, Roberts JD, Deverill M. The estimation of a preference-based
measure of health from the SF-36 J Health Econ. 2002;21:271-92.
117

215. Glick H, Doshi J, Sonnad S, Polsky D. Economic evaluation in clinical trials.
Second ed. Briggs AGaA, editor. Oxford: Oxford University Press; 2015.
216. Mihaylova B, Briggs A, O'Hagan A, Thompson S. Review of statistical methods
for analysing healthcare resources and costs. Health Economics. 2011;20:897-916.
217. Nixon R, Wonderling D, Grieve R. Non-parametric methods for costeffectiveness analysis: the central limit theorem and bootsrap compared. Health
Economics. 2010;19:316-33.
218. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good
research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR
RCT-CEA Task Force Report. Value in Health. 2005;8(5):521-33.
219. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic
evaluation. Oxford: Oxford University Press; 2006.
220. Roberts M, Russell L, Paltiel D, Chambers M, McEwan P, Krahn M, et al.
Conceptualizing a Model: a report of the ISPOR-SMDM Modeling Good Research
Practices Task Force-2. Value in Health. 2012;16(6).
221. Caro J, Briggs A, Siebert U, Kuntz K, Force oBotI-SMGRPT. Modeling good
research practices-overview: a report of the ISPOR-SMDM Modeling Good research
Practices Task Force-1. Value in Health. 2012;15(6):796-803.
222. Petrou S, Gray A. Economic evaluation using decision analytical modelling:
design, conduct, analysis, and reporting. Bmj. 2011;442.
223. Briggs A, Weinstein M, Fenwick E, Karnon J, Sculpher M, Paltiel A, et al. Model
parameter estimation and uncertainty: a report of the ISPOR-SMDM modeling Good
Research Practices Task Force-6. Value in Health. 2012;15(6):835-42.
224. Edith Cowan University (ECU). Exercise Medicine Research Institute. Edith
Cowan University; 2019 [updated 22 October 2019.Available
from:https://www.exercisemedicine.org.au/research-activity.
225. Menzies Health Institute Queensland (MHIQ). NHMRC Centre for Research
Excellence: Prostrate Cancer Survivorship. Menzies Health Institute Queensland:
Griffith University; 2019 [
226. Optum. SF Health Surveys. 2017 [Available
from:https://www.optum.com/solutions/life-sciences/answer-research/patientinsights/sf-health-surveys.html.
227. School of Health and Related Research (ScHaRR). Measuring and Valuing
Health. School of Health and Related Research: The University of Sheffield; 2017
[Available from:https://www.sheffield.ac.uk/scharr/sections/heds/mvh/sf-6d.
228. Tuffaha HW, Gordon LG, Scuffham PA. Value of information analysis in
healthcare: a review of principles and applications. Journal of Medical Economics.
2014;17(6):377-83.
229. Tuffaha HW, Reynolds H, Gordon LG, Rickard CM, Scuffham PA. Value of
information analysis optimizing future trial design from a pilot study on catheter
securement devices. Clinical Trials. 2014;11(6):648-56.
230. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg DJ, et
al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)
statement. British Medical Journal. 2013;346 (25 March).
231. Ramsey S, Willke R, Glick H, Reed S, Augustovski F, Jonsson B, et al. CostEffectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research
Practices Task Force Report. Value in Health. 2015;18:161-72.
232. Organization for Economic Co-operation and Development (OECD). GDP
Implicit Price Deflator. St Louis: FRED, Federal Reserve Bank of St Louis; 2018
[Available from:https://fred.stlouisfed.org/series/.
233. Yu XQ, Luo Q, Smith DP, Clements M, O'Connell DL. Prostate cancer
prevalence in New South Wales Australia: a population-based study. Cancer
Epidemiology. 2015;39(1):29-36.
234. Australian Institute of Health and Welfare. Cancer in Australia 2019.
Canberra2019.
118

235. Buffart LM, Kalter J, Sweegers MG, Courneya KS, Newton RU, Aaronson NK,
et al. Effects and moderators of exercise on quality of life and physical function in
patients with cancer: an individual patient data meta-analysis of 34 RCTs. Cancer
Treatment Reviews. 2017;52:91-104.
236. Fuller JT, Hartland MC, Maloney LT, Davison K. Therapeutic effects of aerobic
and resistance exercises for cancer survivors: a systematic review of meta-analyses of
clinical trials. British Journal of Sports Medicine. 2018;52:1311.
237. Turner RR, Steed L, Quirk H, Greasley RU, Saxton JM, Taylor SJC, et al.
Interventions for promoting habitual exercise in people living with and beyond cancer.
Cochrane Database of Systematic Reviews. 2018(9).
238. Ha D, Kerr J, Ries ALF, M.M., Lippman SM, Murphy JD. A model-based costeffectiveness analysis of an exercise program for lung cancer survivors following
curative-intent treatment. American Journal of Physical Medicine & Rehabilitation.
2019;Published ahead of print.
239. Haines TP, Sinnamon P, Wetzig NG, Lehman M, Walpole E, Pratt T, et al.
Multimodal exercise improves quality of life of women being treated for breast cancer,
but at what cost? Randomized trial with economic evaluation. Breast Cancer Research
and Treatment. 2010;124:163-75.
240. Kampshoff CS, van Dongen JM, Van Mechelen W, Schep G, Vreugdenhil A,
Twisk JWR, et al. Long-term effectiveness and cost-effectiveness of high versus lowto-moderate intensity resistance and endurance exercise interventions among cancer
survivors. Journal of Cancer Survivorship. 2018;12:417-29.
241. May AM, Bosch MJC, Velthius MJ, van der Wall E, Steins Bisschop CN, Los M,
et al. Cost-effectiveness analysis of an 18-week exercise programme for patients with
breast and colon cancer undergoing adjuvant chemotherapy: the randomised PACT
study. BMJ Open. 2017;7:e012187.
242. Mewes JC, Steuten LMG, Duijts SFA, Oldenberg HSA, van Beurden M, Stuiver
MM, et al. Cost-effectiveness of cognitive behavioral therapy and physical exercise for
alleviating treatment-induced menopausal symptoms in breast cancer patients. Journal
of Cancer Survivorship. 2015;9:126-35.
243. van Waart H, van Dongen JM, van Harten WH, Stuiver MM, Huijsmans R,
Hellendoorn-van Vreeswijk JAJH, et al. Cost-utility and cost-effectiveness of physical
exercise during adjuvant chemotherapy. European Journal of Health Economics.
2018;19:893-904.
244. Gordon LG, DiSipio T, Battistutta D, Yates P, Bashford J, Pyke C, et al. Costeffectiveness of a pragmatic exercise intervention for women with breast cancer:
results from a randomized controlled trial. Psycho-Oncology. 2017;26:649-55.
245. Gordon LG, Scuffham P, Battistutta D, Graves N, Tweeddale M, Newman B. A
cost-effectiveness analysis of two rehabilitation support services for women with breast
cancer. Breats Cancer Research and Treatment. 2005;94:123-33.
246. Sansano-Nadal O, Giné-Garriga M, Brach J, Wert D, Jerez-Roig J, Guerra-Balic
M, et al. Exercise-based Interventions to Enhance Long-term Sustainability of Physical
Activity in Older Adults: A Systematic Review and Meta-analysis of Randomized
Clinical Trials. International journal of Environmental Research and Public Health.
2019;16.
247. Henderson R, Miller M, Fielding R, Gill T, Glynn N, Guralnik J, et al.
Maintenance of Physical Function 1 Year After Exercise Intervention in At-risk Older
Adults: Follow-up from the LIFE Study. Journals of Gerontology: Medical Sciences.
2018;73(5):688-94.
248. Geirsdottir O, Arnarson A, Ramel A, Briem K, Jonsson P, Thorsdottir I.
Muscular Strength and Physical Function in elderly adults 6-18 months after 12-week
Resistance Exercise Program. Scandinavian Journal of Public Health. 2015;43:76-82.
249. Gudlaugson J, Gudnason V, Aspelund T, Siggeirsdottir K, Olafsdottir A,
Jonsson P, et al. Effects of a 6-month multimodal training intervention on retention of
119

functional fitness in older adults: a randomized-controlled cross-over design.
International Journal of Behavioural Nutrition and Physical Activity. 2012;9.
250. Rejeski W, Marsh A, Chmelo E, Prescott A, Dobrosielski M, Walkup M, et al.
The Lifestyle Interventions and Independence for Elders Pilot (LIFE-P): 2-Year Followup. Journal of Gerontology: Medical Sciences. 2009;64A(4):462-7.
251. Davies C, Colon G, Geyer H, Pfalzer L, Fisher M. Oncology EDGE task force
on prostate cancer outcomes: a systematic review of outcome measures for functional
mobility. Physical Therapy Faculty Publications. 2016.
252. Newman A, Simonsick E, Naydeck B, Boudreau R, Kritchevsky S, Nevitt M, et
al. Association of Long-Distance Corridor Walk Performance with Mortality,
Cardiovascular Disease, Mobility Limitation, and Disability. JAMA. 2006;296(17):201826.
253. Sanders G, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al.
Recommendations for conduct, methodological practices, and reporting of costeffectiveness analyses. Journal of the American Medical Association.
2016;316(10):1093-103.
254. Edith Cowan University. Academic and Professional Staff Union Collective
Agreement. Perth, WA: Edith Cowan University; 2013.
255. Edith Cowan University (ECU). Salary rates and allowances. 2019 [Available
from:https://intranet.ecu.edu.au/staff/centres/human-resources-service/ourservices/salary-and-superannuation/salary-rates-and-allowances.
256. Department of Health. MBS Online: Medicare Benefits Schedule Canberra:
Australian Government; 2017 [Available
from:http://www.mbsonline.gov.au/internet/mbsonline/publishing.nsf/Content/Home.
257. Australian Tax Office. Car Expenses. Canberra: Australian government; 2016
[Available from:https://www.ato.gov.au/Individuals/Income-and-deductions/Deductionsyou-can-claim/Vehicle-and-travel-expenses/Carexpenses/#Calculating_your_deduction.
258. Transperth. Transperth Smartrider. 2016 [Available
from:http://www.transperth.wa.gov.au/SmartRider/Types-of-SmartRider/SeniorsSmartRider.
259. Jones M, Oldmeadow C. RADAR SF36 Imputation. New Lambton: Hunter
Medical Research Institute; 2017.
260. Abu-Omar K, Rütten A, Burlacu I, Schätzlein V, Messing S, Suhrcke M. The
cost-effectiveness of physical activity interventions: a systematic review of reviews.
Preventive Medicine Reports. 2017;8:72-8.
261. Campbell F, Holmes M, Everson-Hock E, Davis S, Buckley Woods H, Anokye
A, et al. A systematic review and economic evaluation of exercise referral schemes in
primary care: a short report. Health Technology Assessment. 2015;19(60).
262. Wu S, Cohen D, Shi Y, Pearson M, Sturm R. Economic analysis of physical
activity interventions. American Journal of Preventive Medicine. 2011;40(2):149-58.
263. Davis JC, Verhagen E, Bryan S, Liu-Ambrose T, Borland J, Buchner D, et al.
2014 consensus statement from the first Economics of Physical Inactivity Consensus
(EPIC) conference (Vancouver). British Journal of Sports Medicine. 2014;48(12):94751.
264. Milte CM, Walker R, Luszcz MA, Lancsar E, Kaambwa B, Ratcliffe J. How
important is health status in defining quality of life for older people? An exploratory
study of the views of older people. Applied Health Economics and Health Policy.
2014;12:73-84.
265. Windle G, Hughes D, Linck P, Russell I, Woods B. Is exercise effective in
promoting mental well-being in older age? A systematic review. Aging and Mental
Health. 2010;14(6):652-69.
266. Fisher KJ, Li F. A community-based walking trial to improve neighborhood
quality of life in older adults: A multilevel analysis. Annals of Behavioral Medicine.
2004;28(3):186-94.
120

267. Fairhall N, Sherrington C, Kurrle SE, Lord SR, Lockwood K, Howard K, et al.
Economic evaluation of a multifactorial, interdisciplinary intervention versus usual care
to reduce frailty in frail older people. Journal of the American Medical Directors
Association. 2015;16:41-8.
268. Davis JC, Robertson MC, Ashe MC, Liu-Ambrose T, Khan KM, Marra CA. Does
a home-based strength and balance programme in people aged >80 years provide the
best value for money to prevent falls? A systematic review of economic evaluations of
falls prevention interventions. British Journal of Sports Medicine. 2010;44:80-9.
269. Cobiac LJ, Vos T, Barendregt JJ. Cost-effectiveness of interventions to promote
physical activity: a modelling study. PLoS Medicine. 2009;6(7):e1000110
270. King MT, Viney R, Pickard AS, Rowen D, Aaronson NK, Brazier JE, et al.
Australian Utility Weights for the EORTC QLU-C10D, a MultiAttribute Utility Instrument
Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30.
Pharmacoeconomics. 2018;36:225-38.
271. School of Health and Related Research (ScHaRR). Extending the QALY.
Sheffield: The University of Sheffield; 2017 [Available
from:https://scharr.dept.shef.ac.uk/e-qaly/about-the-/project.
272. Iacovelli R, Verri E, Cossu Rocca M, Aurilio G, Cullurà D, De Cobelli O, et al.
The incidence and relative risk of cardiovascular toxicity in patients treated with new
hormonal agents for castration-resistant prostate cancer. European Journal of Cancer.
2015;51(14):1970-7.
273. Warburton DER, Bredin SSD. Health benefits of physical activity: a systematic
review of current systematic reviews. Current opinion in cardiology. 2017;32(5):541-56.
274. Ruegsegger GN, Booth FW. Health benefits of exercise. Cold Spring Harbor
perspectives in medicine. 2018;8:a029694.
275. Fiuza-Luces C, Santos-Lozano A, Joyner M, Carrera-Bastos P, Picazo O,
Zugaza J, et al. Exercise benefits in cardiovascular disease: beyond attenuation of
traditional risk factors. Nature Reviews Cardiology. 2018;15:731-43.
276. Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU. Cardiovascular and
metabolic complications during androgen deprivation: exercise as a potential
countermeasure. Prostate Cancer and Prostatic Diseases. 2009;12(3):233-40.
277. Green DJ, Smith KJ. Effects of exercise on vascular function, structure, and
health in humans. Cold Spring Harbor perspectives in medicine. 2018;8(4).
278. Helmrich S, Ragland D, Leung R, Paffenbarger JR R. Physical activity and
reduced occurence of non-insulin-dependent diabetes mellitus. New England Journal
of Medicine. 1991;325(3):147-52.
279. Joyner M, Green D. Exercise protects the cardiovasular system: effects beyond
traditional factors. Journal of Physiology. 2009;587(23):5551-8.
280. Marwick T, Hordern M, Miller T, Chyun D, Bertoni A, Blumenthal R, et al.
Exercise training for type 2 diabetes mellitus: impact on Cardiovascular Risk. A
scientific statement from the American Heart Association. Circulation. 2009;119:324462.
281. Mora S, Cook N, Buring J, Ridker P, Lee I-M. Physical activity and reduced risk
of cardiovascular events: potential mediating mechanisms. Circulation.
2007;116(19):2110-8.
282. Ruiz JR, Sui X, Lobelo F, Morrow JR, Jackson AW, Sjöström M, et al.
Association between muscular strength and mortality in men: prospective cohort study.
BMJ : British Medical Journal (Online). 2008;337.
283. Smith M, Saad F, Egerdie B, Sieber P, Tammela T, Ke C, et al. Sarcopenia
during androgen-deprivation therapy for prostate cancer. J Clin Oncol.
2012;30(26):3271-6.
284. Winters-Stone K, Moe E, Graff J, Dieckmann N, Stoyles S, Borsch C, et al.
Falls and frailty in prostate cancer survivors: current, past and never users of androgen
therapy. Journal of American Geriatric Society. 2017;65(7):1414-9.
121

285. Lassemillante A, Doi S, Hooper J, Prins J, Wright O. Prevalence of
osteoporosis in prostate cancer survivors: a meta-analysis. Endocrine. 2014;45(3):37081.
286. Wallander M, Axelsson K, Lundh D, Lorentzon M. Patients wth prostate cancer
and androgen deprivation therapy have increased risk of fractures-a study from the
fractures and fall injuries in the elderly cohort (FRAILCO). Osteoporos Int.
2019;30:115-25.
287. Kreisfeld R, Pointer S, Bradley C. Trends in hospitalisations due to falls by older
people, Australia: 2002-03 to 2012-13. Canberra: Australian Institute of Health and
Welfare; 2017.
288. Kanis J, Johnell O, Oden A, Johansson H, McKloskey E. FRAX and the
assessment of fracture probability in men and women from the UKFracture Risk
Assessment Tool. Osteoporos Int. 2008;19:385-97.
289. Burns E, Stevens J, Lee R. The direct costs of fatal and non-fatal falls among
older adults - United States. Journal of Safety Research. 2016;58:99-103.
290. Edmunds K, Tuffaha H, Scuffham P, Galvão D, Newton R. The role of exercise
in the management of adverse effects of androgen deprivation therapy for prostate
cancer: a rapid review. Journal of Supportive Care in Cancer. 2020;28:5661-71.
291. Kendrick D, Kumar A, Carpenter H, Zijlstra G, Skelton D, Cook J, et al. Exercise
for reducing fear of falling in older people living in the community. Cochrane Database
of Systematic Reviews 2014(11).
292. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al.
Consolidated health economic evaluation reporting standards (CHEERS)-explanation
and elaboration: A report of the ISPOR health economic evaluation publication
guidelines good reporting practices task force. Value in Health. 2013;16:231-50.
293. Davis J, Robertson M, Comans T, Scuffham P. Guidelines for conducting and
reporting economic evaluation of fall prevention strategies. Osteoporos Int.
2011;22:2449-59.
294. Finnegan S, Seers K, Bruce J. Long-term follow-up of exercise interventions
aimed at preventing falls in older peopleliving in the community: a systematic review
and meta-analysis. Physiotherapy. 2019;105:187-99.
295. Abimanyi-Ochom J, Watts J, Borgström F, Nicholson G, Shore-Lorenti C, Stuart
A, et al. Changes in quality of life associated with fragility fractures: Australian arm of
the International Cost and Utility Related to Osteoporotic Fractures Study (ICUROS).
Osteoporos Int. 2015;26:1781-90.
296. Scuffham P, Chaplin S, Legood R. Incidence and costs of unintentional falls in
older people in the United Kingdom. Journal of Epidemiology and Community Health.
2003;57:740-4.
297. Australian Bureau of Statistics. Life Tables. States, Territories and Australia,
2016-2018, cat. no. 3302.0.55.001. In: Statistics ABo, editor. Canberra: Australian
Bureau of Statistics; 2018.
298. El-Khoury F, Cassou B, Charles M-A, Dargent-Molina P. The effect of fall
prevention exercise programmes on fall induced injuries in community dwelling older
adults: systematic review and meta-analysis of randomised controlled trials. BMJ
(Online). 2013;347.
299. Krahn MD, Bremner KE, Tomlinson G, Naglie G. Utility and health-related
quality of life in prostate cancer patients 12 months after radical prostatectomy or
radiation therapy. Prostate Cancer & Prostatic Diseases. 2009;12(4):361-8.
300. Shahinian V, Kuo Y, Freeman J, Goodwin J. Risk of fracture after androgen
deprivation for prostate cancer. The New England Journal of Medicine.
2005;352(2):154-64.
301. Dijkers M. Quality of life after traumatic brain injury: a review of research
approaches and findings. Arch Phys Med Rehabil. 2004;85:S21-S35.
302. Thiem U, Klaaßen-Mielke R, Trampisch U, Moschny A, Pientka L, Hinrichs T.
Falls and EQ-5D rated quality of life in community-dwelling seniors with concurrent
122

chronic diseases: a cross-sectional study. Health and Quality of Life Outcomes.
2014;12(2).
303. Kumar A, Delbaere K, Zijlstra G, Carpenter H, Iliffe S, Masud T, et al. Exercise
for reducing fear of falling in older people living in the community: Cochrane systematic
review and meta-analysis. Age and Ageing. 2016;45:345-52.
304. Watts J, Abimanyi-Ochom J, Sanders K. Osteoporosis costing all Australians A
new burden of disease analysis – 2012 to 2022. Glebe, NSW: Osteoporosis Australia;
2013.
305. Pavlov V, Thompson-Leduc P, Zimmer L, Wren J, Shea J, Beyhaghi H, et al.
Mild traumatic brain injury in the United States: demographics, brain imaging
procedures, health-care utilization and costs. Brain Injury. 2019;33(9):1151-7.
306. Hall S, Hendrie D. A prospective study of the costs of falls in older adults living
in the community. Australian and New Zealand Journal of Public Health.
2003;27(3):343-51.
307. Stevens J, Ballesteros M, Macl K, Rudd R, DeCaro E, Adler G. Gender
differences in seeking care for falls in the aged medicare population. American Journal
Of Preventive Medicine. 2012;43(1):59-62.
308. Edmunds K, Reeves P, Scuffham P, Galvão D, Newton R, Jones M, et al. CostEffectiveness Analysis of Supervised Exercise Training in Men with Prostate Cancer
Previously Treated with Radiation Therapy and Androgen-Deprivation Therapy.
Applied Health Economics and Health Policy. 2020;18(5):727-37.
309. Pharmaceutical Benefits Advisory Committe (PBAC). Guidelines for preparing
submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) Version 5.
Canberra: Department of Health; 2016 [Available from:https://pbac.pbs.gov.au/.
310. Independent Hospital Pricing Authority IHPA. National Efficient Price
Determination 2019-20. Sydney: IHPA; 2019 [Available
from:https://www.ihpa.gov.au/publications/national-efficient-price-determination-201920.
311. Medicare. Medicare Benefits Schedule. Canberra: Department of Health; 2017 [
312. Irvine L, Conroy S, Sach T, Gladman J, Harwood R, Kendrick D, et al. Costeffectiveness of a day hospital falls prevention programme for screened communitydwelling older people at high risk of falls. Age and Ageing. 2010;39(6):710-6.
313. Robertson M, Gardner M, Devlin N, McGee R, Campbell J. Effectiveness and
economic evaluation of a nurse delivered home exercise programme to prevent falls. 2:
Controlled trial in multiple centres. British Medical Journal. 2001;322:701-4.
314. Church J, Goodall S, Norman R, Haas M. The cost-effectivenes of falls
prevention interventions for older community-dwelling Australians. Australian and New
Zealand Journal of Public Health. 2011;36:241-8.
315. Farag I, Howard K, Ferreira M, Sherrington C. Economic modelling of a public
health programme for fall prevention. Age and Ageing. 2015;44:409-14.
316. Franklin M, Hunter R. A modelling-based economic evaluation of primary-carebased fall-risk screening followed by fall-prevention intervention: a cohort-based
Markov model stratified by older age groups. Age and Ageing. 2020;49:57-66.
317. McLean K, Day L, Dalton A. Economic evaluation of a group-based exercise
program for falls prevention among the older community-dwelling population. BMC
Geriatrics. 2015;15.
318. Cormie P, Oliffe JL, Wootten AC, Galvão DA, Newton RU, Chambers SK.
Improving psychosocial health in men with prostate cancer through an intervention that
reinforces masculine values – exercise. Psycho-Oncology. 2016;25:232-5.
319. McDougall JA, Bansal A, Goulart BHL, McCune JS, Karnopp A, Fedorenko C,
et al. The clinical and economic impacts of skeletal-related events among Medicare
enrollees with prostate cancer metastatic to bone. The Oncologist. 2016;21:320-6.
320. Cancer Australia. National cancer stage at diagnosis data. Cancer Australia:
Australian Government; 2018 [Available
from:https://ncci.canceraustralia.gov.au/features/national-cancer-stage-diagnosis-data.
123

321. O'Sullivan A, Thompson D, Drummonsd M. Collection of health-economic data
alongside clinical trials: is there a future for piggyback evaluations? Value in Health.
2005;8(1):67-79.
322. Greenberg D, Earle C, Chi-Hui F, Eldar-Lissai A, Neumann PJ. When is Cancer
Care Cost-Effective? A Systematic Overview of Cost–Utility Analyses in Oncology.
JNCI: Journal of the National Cancer Institute. 2010;102(2):82-8.
323. Soares MO. Is the QALY blind, deaf and dumb to equity? NICE's considerations
over equity. British Medical Bulletin. 2012;101(1):17-31.
324. Cookson R, Mirelman AJ, Griffin S, Asaria M, Dawkins B, Norheim OF, et al.
Using Cost-Effectiveness Analysis to Address Health Equity Concerns. Value in
Health. 2017;20:206-12.
325. Devlin NJ, Lorgelly PK. QALYs as a measure of value in cancer. Journal of
Cancer Policy. 2017;11:19-25.
326. Tuffaha H, El-Saifi N, Chambers S, Scuffham P. New challenges in psychooncology: Economic evaluation of psychosocial services in cancer: Challenges and
best practice recommendations. Psycho-Oncology. 2019;28:3-10.
327. Brazier J, Mulhern B, Bjorner J, Gandek B, Rowen D, Alonso J, et al.
Developing a new version of the SF-6D health state classification system from the SF36v2:SF-6dv2. Medial Care. 2020;58(6):557-65.
328. King AJL, Evans M, Moore THM, Paterson C, Sharp D, Persad R, et al.
Prostate cancer and supportive care: a systematic review and qualitative synthesis of
men's experiences and unmet needs. Eur J Cancer Care (Engl). 2015;24(5):618-34.
329. Dieperink KB, Wagner L, Hansen S, Hansen O. Embracing life after prostate
cancer. A male perspective on treatment and rehabilitation. Eur J Cancer Care (Engl).
2013;22(4):549-58.
330. Kirsch B. World Report: Many US cancer survivors still lost in transition. The
Lancet. 2012;379:1865-6.
331. Nekhlyudov L, Ganz P, Arora N, Rowland J. Going Beyond Being Lost in
Transition: A Decade of Progress in Cancer Survivorship. J Clin Oncol.
2017;35(18):1978-82.
332. Nekhlyudov L, O’Malley D, Hudson S. Integrating primary care providers in the
care of cancer survivors: gaps in evidence and future opportunities. Lancet Oncology.
2017;18:e30-8.
333. Recklitis C, Syrjala K. Provision of integrated psychosocial services for cancer
survivors post-treatment. Lancet Oncology 2017;18(1):e39-50.
334. Jacobs L, Shulman L. Follow-up care of cancer survivors: challenges and
solutions. Lancet Oncology. 2012;18(1):e19-29.
335. Cormie P, Turner B, Kaczmarek E, Drake D, Chambers SK. A qualitative
exploration of the experience of men with prostate cancer involved in supervised
exercise programs. Oncol Nurs Forum. 2015;42(1):24-32.
336. Crombie I, Irvine L, Williams B, McGinnis A, Slane P, Alder E, et al. Why older
people do not participate in leisure time physical activity: a survey of activity levels,
beliefs and deterrents. Age and Ageing 2004;33(3):287-92.
337. Lees F, Clark P, Nigg C, Newman P. Barriers to exercise behavior among older
adults: a focus-group study. Journal of Aging & Physical Activity. 2005;13:13-23.
338. Mathews A, Laditka S, Laditka J, Wilcox S, Corwin S, Liu R, et al. Older adults’
perceived physical activity enablers and barriers: a multicultural perspective. . Journal
of Aging & Physical Activity. 2010;18:119-40.
339. IJsbrandy C, Ottevanger P, Tsekou Diogeni M, Gerritsen W, van Harten W,
Hermens R. Review: Effectiveness of implementation strategies to increase physical
activity uptake during and after cancer treatment. Critical Reviews in Oncology /
Hematology. 2018;122:157-63.
340. Reeves P, Edmunds K, Searles A, Wiggers J. Economic evaluations of public
health implementation-interventions: a systematic review and guideline for practice.
Public Health. 2019;169:101-13.
124

341. Kennedy M, Bayes S, Galvão D, Singh F, Spry N, Davis M, et al. If you build it,
will they come? Evaluation of a co-located exercise clinic and cancer treatment centre
using RE-AIM framework. Eur J Cancer Care (Engl). 2020.

125

Appendix 1 Systematic search (Chapter 2)
Search strings and databases utilised in search strategy
Ovid (Medline; PsycInfo); Elsevier (Embase)
Prostatic Neoplasms/
(androgen adj (deprivation or ablation or suppression)).mp. OR Gonadotropin-Releasing
Hormone/ag, ai [Agonists, Antagonists & Inhibitors] OR Luteinizing Hormone/ag, ai [Agonists,
Antagonists & Inhibitors] OR Androgen Antagonists/ or anti-androgens.mp. OR androgen
receptor inhibitors OR adrenal androgen inhibitors.mp. OR goserelin OR leuprorelin OR
triptorelin OR degarelix OR cyproterone acetate OR enzalutamide OR bicalutamide OR
flutamide OR nilutamide OR apalutamide OR abiraterone acetate
((side or adverse) adj (event* or effect*)).mp. OR complication*.mp. OR toxicity.mp.
incidence.mp. OR rate.mp OR risk.mp
limit to (english language and humans and yr = 2010 - Current [February 2019])
“systematic review”.mp OR meta-analysis.mp
Cochrane Library (Reviews, Protocols, Trials)
"androgen deprivation": ti,ab,kw
"prostate cancer": ti,ab,kw
("adverse effects" OR “side effects” OR complication* OR toxicity): Search All Text
Limits: Publication Year from 2010 to February 2019, in Cochrane Reviews, Other
Reviews and Trials (Word variations have been searched)

1226

27
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Appendix 2 Summary of findings (Chapter 2)
First author, Year,
Country
Kim 2019 Korea (69)

Study type

Cancer stage & treatment

Systematic review &
meta-analysis:
includes prospective
cohort studies

Stage: Localised or
advanced PCa
Treatment: orchiectomy,
LHRH agonist, alone or
combined (LHRH agonist +
antiandrogen)
6-36 months ADT duration

Ng 2018 Australia (97)

Retrospective
cohort study using
PBS data

Stage: Localised or
advanced PCa
Treatment: Any ADT
ADT duration stratified into
>1 & <1 year (For details
see Table S3 in Ng et al.)

Smith 2018 USA (104)

Phase III doubleblind RCT

Stage: Non-metastatic
CRPCa
Treatment: Apalutamide

Graff 2016 USA (105)

Multinational
double-blind RCT

Stage: Chemotherapy
naïve mCRPCa
Treatment: Enzalutamide
Median duration of
treatment: <75 years16.7
(Enzalutamide) & 4.4
months (placebo); >75
years 16.6 (enzalutamide)
& 5.0 months (placebo)

Sample size
(control group)
Pooled analysis of 5 studies n=533 ADT:
orchiectomy, LHRH agonist, antiandrogen
Follow-up 1 year in 1 study; 2 years in 2
studies; 3 years in 2 studies.
Men taking bone sparing agents not
mentioned in 1 study, excluded in 4
studies (censored if initiated during trial in
one study or allowed if osteoporotic in a
second study).
Random 10% sample of population 20032014
3689 men receiving first ADT between
2004 – 2010
Age: 92% osteoporosis cohort ≥65 years
at ADT initiation
Follow-up to 2014
Control: Age & sex matched cohort not
receiving anti-neoplastic agents or having
none of 9 comorbidities at baseline
n=1207 men receiving ADT; (n=806) Age:
48-94
Median follow-up 20.3 months
Control: placebo (n=401) Age: 52-97
Bone sparing agent 10% vs 9.7%
(placebo)
n=1717
1.
<75 (n=1108); (42-74 years)
2.
≥75 (n=609) (75-93 years)
Follow-up: varied dependent on disease
progression or death
Control: placebo
No clear differences between
treatment groups regarding concomitant
use of systemic
corticosteroids, denosumab, &
bisphosphonates.

Outcomes/Incidence
%, RR, HR, OR (95% CI)
Mean difference in % change in BMD
Lumbar spine:
4 studies n=483
-3.60 (-6.72—0.47, P =0.02)
Femoral neck:
5 studies n=515
-3.11 (-4.73—1.48, P =0.0002)
Total hip:
4 studies n=483
-1.59 (-2.99—0.19, P=0.03)
Osteoporosis: aHR 1.65 (1.48-1.85)
Sub analysis of ADT duration: Higher risk
>1 year aHR 1.77
≤1 year aHR 1.38
The PCa cohort had a significant, higher risk of developing most
comorbidities, i.e. cardiovascular conditions, depression, diabetes, gastric
acid disorders, hyperlipidaemia, osteoporosis & pain/pain-inflammation vs
control groups

Quality assessment/ Risk of
bias
AMSTAR 2 rating: Low

Fracture 11.7% (apalutamide) vs 6.5% (placebo)

ROB 2 rating: Some concerns

Incidence rate of any fracture: Enzalutamide vs control by age group (<75
9.9% vs 3.6%) (≥75 15.8% vs 7.9%) & non-pathological fractures (<75
6.5% vs 1.8%) (≥75 10.1% vs 5.1%)
Higher than placebo group for both age groups.
1. Enzalutamide <75 vs control; 2. Enzalutamide ≥75 vs control
Fracture: 1. 9.9% vs 3.6% (RR 2.75); 2. 15.8% vs 7.9% (RR 2.0); nonpathological fracture 1. 6.2% vs 2.8% (RR 2.2); 2. 8.7% vs 9.6% (RR
0.91)
Fall any grade: 1. 7.2% vs 4.0% (RR 1.8); 2. 19.2% vs 7.9% (RR 2.43);
older vs younger 13.8% vs 5.6% (RR 2.5)
Fall requiring hospitalization: 1. 0.9% vs 0.5% (RR 1.8); 2. 2.2% vs
1.0% (RR 2.2)

ROB 2 rating: Some concerns

NOS rating: Good
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Shao 2013 USA (98)

Population-based
linked data SEERMedicare data

Stage: Localised PCa
Treatment: ADT only; ADT
+ curative therapy;
orchiectomy

n= 75 994
Age ≥66
1992-2007
Follow-up: 12 years
Bisphosphonate use during follow-up
(4.3%)
Control: no ADT

Alibhai 2010 Canada
(100)

Matched cohort
study using linked
admin. data

n=19,079
≥66 years
1995-2005
Control/reference: Propensity score
matched population non-ADT PaC
Mean 6.47 years follow-up

Wallis 2016 Canada
(99)

Retrospective
cohort study SEER
& Medicare linked
data

Sun 2016 USA (101)

Population-based
cohort study SEERMedicare linked
data

Stage: Non-metastatic PCa
Treatment: LHRH
agonists, non- steroidal or
steroidal anti-androgens
alone or in combination &
orchiectomy
ADT duration: at least 6
months continuous ADT
Stage: Localised PCa
Treatment: Radical
Prostatectomy +/-ADT;
Radiotherapy +/- ADT
ADT duration stratified for
sub analysis: 6, 12 & 18
months
Stage: Metastatic PCa
Treatment: GnRHa

Beebe-Dimmer 2012
USA (103)

Population-based
cohort study SEERMedicare linked
data

Stage: Advanced PCa
Treatment: GnRH agonist
ADT duration stratified for
sub-analysis:1-5 doses, 617 doses, ≥18 doses

n=80,844
Age ≥66 years diagnosed 1996-2003
Follow-up to December 2006
Control/reference: non-ADT PCa

n=60,156 (14,403 RP; 45,753 RT); Age
≥65 years
Median follow-up 6 years
Control/reference: radical prostatectomy

n=3295 (1995-2009)
Age ≥66 years
Follow-up 12 months
Control/reference: Orchiectomy

26.83% developed at least one fracture; 8.8% required hospitalisation
Risk group: > 58% of men in the high-risk group and 38% of men in the
low-risk group sustained fracture; 31% of men in low-risk group No-ADT
sustained fracture.
Treatment group: For ADT only, fracture risk of men receiving 18 doses
of GnRH agonist was HR 1.53 (1.44–1.62) for low-risk group and 1.27
(1.20–1.35) for the high-risk group compared to No-ADT. ADT + other
curative treatments, fracture risk was 1.37 (1.27–1.49) for the low-risk
group; 1.20 (1.09–1.33) for high-risk group.
22.3% of fractures in this study were hip fractures (assoc. with increased
risk of mortality)
ADT 9% vs non-ADT 5.9% had fragility fracture of spine, lower arm,
hip/femur
(aHR 1.65, 1.53-1.78, p<0.0001) (RR 1.52); Any fracture 17.2% vs 12.7%
(aHR 1.46, 1.39-1.54, p<0.0001) (RR 1.35)
ADT/non-ADT
Elevated risk associated with age, prior osteoporosis, prior fragility
fracture, prior dementia and prior bone thinning medication

NOS rating: Good

aHR (95% CI) Primary treatment + ADT (adjusted for age, grade, race,
marital status, comorbidity index, pre-diagnosis osteoporosis)
Any Fracture 1.28 (1.16, 1.41; P<0.0001)
Fracture requiring hospitalisation 1.32 (1.19-1.46; P<0.0001)
No difference in risk of skeletal related events for patients receiving
shorter durations of ADT whether threshold was 6, 12 or 18 months
(Supplementary Table S8)
Any fractures incidence
GnRHa 37.7% vs Orchiectomy 31.4%
HR (95% CI) 0.77 (0.62, 0.94; P=0.01)
sub analysis GnRHa duration
18-34 months 1.48 (1.17, 1.97; <P 0.001)
≥35 months 1.80 (1.45, 2.24; <P 0.001)
M0 + GnRHa 31% increase (HR 1.31; 1.29-1.39) +ve relation between
cumulative dose & fracture incidence. Higher increase in incidence of
fractures for M1 (aHR 1.52; 1.36-1.67) HRs adjusted for recency of
exposure & dose of ADT. Orchiectomy associated with 62% increase in
risk of any fracture (aHR 1.62; 1.42-1.84) among M0 & 54% increase in
M1 (aHR 1.54; 1.26-1.88). Fracture risk highest for men currently
receiving or within 6 months (aHR 1.67; 1.56-1.78). Fracture risk for M0
men who had received fewer than 6 doses discontinued ADT more than
18 months ago (aHR 1.06; 0.99-1.14). Similar for M1 men. Mortality risks
within 6 & 12 months or experiencing any fracture 8.3% & 12.2%,
respectively. Fracture associated with two-fold increase in rate of death

NOS rating: Good

NOS rating: Good

NOS rating: Good

NOS rating: Good
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Tsai 2017 USA (102)

Population-based
cohort study

Stage: Advanced PCa
Treatment: IADT

Haseen 2010
Ireland (67)

Systematic review:
includes RCTs &
cohort studies

Stage: Localised, locally
advanced, advanced,
metastatic
Treatment: LHRH, GnRH,
anti-androgen, orchiectomy

Bosco 2015a UK (64)

Systematic review
and meta-analysis

Stage: All
Treatment: Any ADT

Wang 2016 China (83)

Systematic review
and meta-analysis

Stage: mCRPCa
Treatment: GnRH,
combined androgen
blockade, orchiectomy

Bosco 2015 UK (63)

Systematic review
and meta-analysis

Stage: not reported
Treatment:
GnRH agonist,
orchiectomy, anti-androgen

Pooled analysis of 8 observational studies
n=414,657
Control: No ADT

Jin 2016 China (68)

Systematic review
and meta-analysis

Magnan 2015 Canada
(71)

Systematic review
and meta-analysis

Stage: Locally advanced,
metastatic or recurrent
hormone sensitive PCa
(HSPCa) Treatment: IADT
Stage: Locally advanced,
recurrent, metastatic,
mCRPCa Treatment:
IADT

Pooled analysis of 6 RCTs
(n=4810)
n=4,810 men with HSPCa
Control: CADT
Pooled analysis of 15 RCTs
n=6586
Control: CADT

n=9772 men ≥66 years
Follow-up: 5 years post ADT initiation
Control/reference: CADT
Pooled analysis 14 studies
n=573
Baseline to last follow up; varied from 12
weeks to 96 weeks but more than 50% of
studies had 12 months follow up
Sub group analyses of ADT duration ≤3
months, ≤6 months, >6 months

9 studies: Pooled analysis of 4 cross
sectional studies for MetS; 4 cohort & 1
cross sectional study for Diabetes
ADT n=335
Control: No ADT n=594
8 studies n=157,588
follow up varied in cohort studies from 1
year to 6.47 years Control: No ADT,
watchful waiting/active surveillance
Sub group analysis: short duration ≥6
months; long duration >6 months

(aHR 2.05; 1.98-2.12) & aHR 2.82 (2.68-2.97) for fracture requiring
hospitalisation.
Use of bisphosphonates overall prior to fracture 2.3%; 0.6% in nonmetastatic patients and 18.2% in metastatic patients.
IADT lower risk of fracture than CADT (HR 0.52; 0.38-0.70, p<0.0001)

NOS rating: Good

% change body weight:
2.14 (1.35-2.94, P<0.00001);
% change BMI (95% CI): 2.15 (1.16-3.14, P<0.0001); Increases in body
weight and BMI more pronounced for treatment duration >6 months.
% change fat mass (95% CI): 7.71 (4.27-11.15, P<0.00001); treatment
duration varied from 3-12 months; all (7 studies) showed significant gains
regardless of duration or treatment type.
% change lean mass (95% CI): -2.82 (-3.64- -2.01), P<0.00001
Treatment duration varied from 3-24 months; loss reported in all studies
(n=6)
RR 1.75 (1.27-2.41) MetS;
RR 1.36 (1.17-1.58) Diabetes
Need for further research on impact of type and duration of ADT.

AMSTAR 2 rating: Low

10.9% developed diabetes
Diabetes RR 1.39 (1.27-1.53, P<0.001)
sub group analyses show that GnRH (P<0.01), GnRH + anti-androgen
(P=0.04), & orchiectomy (P<0.01), are significantly associated with risk of
diabetes
Longer duration significantly associated with risk of diabetes RR 1.39
(1.27, 1.53) P<0.00001
GnRH agonists: i. any type CVD: RR 1.38 (1.29-1.48); ii. Non-fatal IHD:
RR 1.39 (1.26-1.54); iii. non-fatal MI or stroke: RR 1.57 (1.26-1.94); iv.
fatal MI or stroke: RR 1.51 (1.24-1.84);
Orchiectomy: i. any non-fatal CVD: RR 1.44 (1.28-162);
Antiandrogen: i. Any non-fatal CVD: RR 1.21 (1.07-1.37)
No significant diff for CV events: RR=0.95 (0.83-1.08)
Association between low CV mortality & IADT: 0.85 (0.71-1.00) (n=4170)

AMSTAR 2 rating: High

CVD death HR 0.86 (0.73-1.02) 4 studies
Fatigue HR 0.94 (0.60-1.48) 2 studies
Gynaecomastia HR 0.63 (0.36-1.10) 6 studies
Hot flashes HR 0.76 (0.57-1.00) 6 studies
Erectile dysfunction 1.03 (0.74-1.43) - 4 studies Decreased libido 1.01
(0.95-1.07) - 2 studies

AMSTAR 2 rating: Moderate

AMSTAR 2 rating: Moderate

AMSTAR 2 rating: Moderate

AMSTAR 2 rating: Moderate
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Zhao 2014 China (84)

Systematic review
and meta-analysis

Stage: All/any Treatment:
GnRHa
GnRHa + AA
Orchiectomy

7 observational studies
129802 vs 165,605 control
ADT & AMI:
6 studies, 129,802 ADT vs 165,605
control
Control: No ADT or watchful waiting/active
surveillance

Nguyen 2011 USA
(77)

Systematic review
and meta-analysis

Pooled analysis of 8 RCTS n=4141
Control: no ADT

Scailteux 2016 France
(80)

Systematic review
and meta-analysis

Meng 2016 China (73)

Systematic review
and meta-analysis

Stage: unfavourable risk,
non-metastatic Treatment:
GnRHa
Stage: Any
Treatment:
CPT vs AA
CAB vs GnRH agonist,
CAB vs Orchiectomy,
GnRH vs Orchiectomy,
Orchiectomy vs
Orchiectomy + AA, GnRH
agonist vs GnRH
antagonist, OT, Intermittent
CAB vs continuous CAB,
Orchiectomy vs AA,
Stage: Any
Treatment: All ADT, GnRH
alone, GnRH + AA,
orchiectomy, AA alone

Spratt 2018 USA (112)

Systematic review
and meta-analysis

Stage: Recurrent
Treatment: Salvage RT +
GnRH

Sciarra 2016 Italy (81)

Systematic review
and meta-analysis

Stage: Advanced PCa
Treatment: Degarelix

Pooled analysis of 2 RCTs: GETUG
n=743, ADT duration GnRH agonist -6
months; RTOG n=760, ADT duration AA 24 months
Control: Salvage RT + AA
5 clinical trials n=1719 Pooled analysis
where possible (1061 degarelix vs 658
GnRHa)
Control: GnRH agonists

Pooled analysis of 11 observational
studies (n=193,620); 57 RCTs (n=31,037)

Pooled analysis 6 observational studies
n=74,538 ADT users vs 85,947 non-ADT
users
Control: All ADT, GnRH alone, GnRH +
antiandrogen, orchiectomy, AA alone

Depression 0.91 (0.39-2.13) - 3 studies
ADT & CVD (6 studies)
1.10 (1.00, 1.21, P=0.06)
ADT & CVM (6 studies)
1.17 (1.04, 1.32, P=0.01)
ADT monotherapy vs WW/AS for CVD
(3 studies) & CVM (4 studies)
CVD 1.19 (1.08, 1.30, P=0.0004)
CVM 1.30 (1.13, 1.50)
ADT & MI
1.10 (0.97-1.26, P=0.14)
subgroup analyses for ADT type: positive association for GnRH (RR
1.20, 1.05-1.38, P=0.008); AA alone (RR 0.88 0.81-0.96, P=0.002)
CVM Experimental group: incidence 11% (8.3-14.5); Control group: 11.2%
RR 0.93 (7.9-1.10) no significant difference. Sub group analysis showed
no association with CVM and ADT duration (≥3 years or ≤6 months)
MYOCARDIAL INFARCTION
Observational: RR(95% CI)
Orchiectomy vs AA 2.04 (0.66, 8.33); GnRHa vs Orchiectomy 0.61 (0.30,
0.92); CAB vs OT 0.49 (0.19, 0.89); CAB vs GnRHa 0.97 (0.63, 1.47);
GnRHa vs AA 1.43 (1.10, 1.85); CAB vs AA 1.34 (0.87, 2.06)
RCT: CPT vs AA 0.49 (0.04, 5.39); GnRHant vs GnRHa 0.42 (0.23, 0.77)
STROKE
Observational: OT vs AA 1.14 (0.83, 1.56);
GnRHa vs OT 1.00 (0.58, 1.72); CAB vs OT 0.71 (0.52, 0.97); CAB vs
GnRHa 0.82 (0.66, 1.02); GnRHa vs AA 1.22 (0.93, 1.61); CAB vs AA
1.10 (1.02, 1.19)
RCT: GnRHant vs GnRHa 0.42 (0.23, 0.77) 3.44 (0.22, 1.32)
Incidence of stroke across all types of ADT (HR 1.12; 0.95-1.32) not
significant;
Sub analyses:
GnRHa alone (HR 1.20; 1.12-1.28, p<0.001);
GnRHa + AA (HR 1.23; 1.13-1.34, p<0.001);
Orchiectomy (1.37; 1.33-1.46, p<0.001);
AA alone (1.06; 0.71-1.57, p=0.078)
Long term hypertension (GnRHa) 12% vs (AA) 4%
Gynaecomastia (GnRHa) 11% vs (AA) 70%
Vasomotor flushing (GnRHa) 45% vs (AA) 1%
Severe cardiovascular adverse effects (3 trials) Deg 1.6%; GnRHa
3.6% (OR 0.55; 0.26-1.14, P>0.1)
Vasomotor flushing Deg. 29%; GnRHa 27% (OR 1.06 95% CI 0.84-1.33,
P=>0.1)

AMSTAR 2 rating: Moderate

AMSTAR 2 rating: Low
AMSTAR 2 rating: High

AMSTAR 2 rating: Moderate

AMSTAR 2 rating: Low

AMSTAR 2 rating: Low
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Rydzewska 2017 UK
(79)

Systematic review
and meta-analysis

Iacovelli 2018 Italy
(110)

Systematic review
and meta-analysis

Roviello 2016 Italy (78)

Systematic review
and meta-analysis

Follow-up duration heterogeneous but did
not exceed 364 days

erectile dysfunction Deg. 9.5%; GnRHa 10%
OR 0.94 (0.700-1.26, P=0.686)

Stage: Metastatic HSPCa
Treatment: ADT +
abiraterone acetate +
prednisone/ prednisolone
Stage: HSPCa & CRPCa
Treatment: Abiraterone
acetate & Enzalutamide

Pooled analysis of 2 trials: LATITUDE
n=597 & 602; STAMPEDE n = 500 + 502
Control: ADT alone

CV events: Grade III acute cardiac events Peto OR: 2.93 (1.74, 4.93,
p<0.001); Grade III-IV vascular events 2.28 (1.71, 3.03, p<0.001)
hepatic disorder: 3.09 (2.12, 4.50, p<0.001)

AMSTAR 2 rating: High

Pooled analysis of 7 Phase II & III clinical
trials
n=8660
Enzalutamide vs Placebo; Abiraterone
acetate + prednisone vs placebo +
prednisone;
Enzalutamide vs bicalutamide
Median treatment duration for
experimental group: 8-24 months (control
duration 3-14 months)

AMSTAR 2 rating: Low

Stage: CRPCa Treatment:
Abiraterone acetate +
prednisone; Orteronel +
prednisone (NA in
Australia)

4 RCTs n=2849, 2067 control; 2 prechemotherapy, 2 post-chemotherapy
Control: placebo + prednisone
Median treatment duration: AA 8-13.8
months; Enzalutamide 11.7-16.6 months.

CV events: All grade 11.7% vs 8.6% RR 95% CI 1.36 (1.13-1.64,
p=0.001); high grade 3.7% vs 2.0% RR 1.84 (1.21-2.80, p=0.004);
Abiraterone acetate: all grade 13.7% & high grade 4.5% RR 1.41 (1.211.64 p<0.001) & 2.22 (1.60-3.07, p<0.001); Enzalutamide: all grade 8.6%
& high grade 2.5% RR 1.25 (0.99-1.59 p=0.3) & 1.28 (0.45-3.66, p=0.7);
comparison between abiraterone acetate & enzalutamide: no differences
in RR.
HYPERTENSION: All grade 19.6% vs 10.9% RR (95% CI) RR 1.98 (1.622.13, p=0.006); high grade 6.1% vs 3.1% RR 2.26 (1.84-2.77, p<0.001);
Abiraterone acetate: all grade 26.2% & high grade 6.9% RR 1.79 (1.452.21, p<0.001) & RR 2.19 (1.73-2.78, p<0.001); Enzalutamide: all grade
10.5% & high grade 4.8% RR 2.66 (1.96-3.66 p<0.001) & RR 2.44 (1.64 3.63, p<0.001). Significant difference in RR for all grade, but not highgrade hypertension between Abiraterone acetate & Enzalutamide.
Sub analysis based on stage of PCa
HSPCa vs CRPaC for CV outcomes:
CRPCa receiving Abiraterone acetate
High-grade CV events (2.85% vs 6.45%, P<0.001). Same result for
placebo (1.09% vs 3.43%, P<0.001). HSPCa receiving Abiraterone
acetate
Hypertension Higher incidence high & low grade events, but not
significant.
Abiraterone acetate compared to placebo:
HSPCa High grade (4.6% vs 1.9%; P<0.001); all grade (1.9% vs 11.3%’=;
P<0.001)
Increased incidence of cardiac toxicity in patients treated for CRPCa
related to longer duration of ADT.
Within trial incidence
Abiraterone acetate + prednisone vs control (COU-AA-301 %all, %high;
COU-AA 302 %all, %high):
Hypertension
301 12 vs 8, 1 vs <1; 302 24 vs 14, 5 vs 3
Cardiac disorders
301 21 vs 15, 5 vs 3; 302 302-23 vs 18; 8 vs 5.
Hepatotoxicity
301 15 vs 5; 302 25 vs 8
Across all studies

AMSTAR 2 rating: Moderate
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Zhu 2018 China (85)

Systematic review
and meta-analysis

Stage: Metastatic CRPCa
Treatment: Enzalutamide,
Abiraterone acetate

Pooled analysis 10 RCTs
(5 Enzalutamide + 5 Abiraterone acetate)
n=9520
Control: Placebo/ADT/
Prednisone/ Abiraterone + placebo
/Bicalutamide

Gild 2018 US (113)

Population-based
cohort study SEERMedicare linked
data

Stage: localised
Treatment: GnRH
agonists/antagonists

n=82,938
Age ≥66 years diagnosed 1992-2009
Median follow-up was 6.1 years (IQR 3.6
to 9.0)
Control: non-ADT PCa

Guo 2018 China (66)

Systematic review
and meta-analysis

Stage: Any
Treatment: GnRHa alone,
GnRHa + AA, AA alone,
orchiectomy

5 cohort studies n=170,851 ADT users &
256,704 non-ADT users n=170,851 ADT
users & 256,704 non-ADT users
Control: No ADT

Nead 2018 USA (74)

Systematic review
and meta-analysis

Stage: locally advanced,
advanced
Treatment: Estrogens,
GnRH + anti-androgen,

18 studies in pooled meta-analysis
n=>250000
Control (lesser exposed group): no
ADT, short-term ADT, intermittent ADT

All grade AEs relative risk (95% CI)
Hypertension: RR 1.53 (1.30, 1.80, p<0.00001);
Cardiac disorders: RR 1.47 (1.27, 1.70, p<0.00001);
Hepatotoxicity: RR 1.93 (1.15, 3.24, p=0.001)
High grade AEs (≥ grade 3)
Hypertension: RR 1.36 (0.97, 1.92, p=0.08)
Cardiac disorders: RR 1.55 (1.18, 2.05, p=0.02)
Hepatotoxicity: RR 2.94 (0.95-9.08, p=0.06)
Significant AE events relative risk (95% CI)
Abiraterone acetate: all grade AEs
cardiac events RR 1.40, (1.22–1.62);
hypertension (RR 1.70, 1.36–2.12);
High grade AEs (≥ grade 3)
cardiac events RR 1.93 (1.42–2.61), hypertension RR 2.16 (1.43–3.26)
Enzalutamide: all grade AEs
fatigue RR 1.29 (1.17–1.42);
vasomotor flushing RR 1.94 (1.55-2.42);
hypertension RR 2.62 (1.05–3.34);
High grade AES (≥ grade 3)
fatigue RR 1.50 (1.08-2.08)
hypertension RR 2.66 (1.76–4.02)
vasomotor flushing RR 1.94 (1.55–2.42)
Hepatotoxicity hazard risk (95% CI)
any liver disease HR 1.47 (1.35, 1.60), NAFLD HR 1.54 (1.40, 1.68), liver
cirrhosis HR 1.35 (1.12, 1.60), and liver necrosis HR 1.41 (1.15, 1.72)
Dose-response relationship observed between no. of ADT doses and
NAFL and any liver disease
Compared to no ADT, risk of NAFLD increased
with no. of monthly equivalent doses of ADT: fewer than 7 vs more than
11 - HR 1.47 (1.31, 1.63) vs HR 1.72, (1.47, 2.02).
Risk of any liver disease: fewer than 7 vs more than 11 HR 1.40 (1.26, 1.55) vs HR 1.64 (1.43, 1.88)
Thrombolytic embolisms hazard risk (95%CI)
Deep Vein Thrombosis: GnRH agonist alone HR 1.47 (1.07-2.03); GnRH
agonist + AA HR 2.55 (2.1-2.94); AA alone HR 1.49(1.13- 1.96);
orchiectomy HR 1.80 (0.93-3.47) not statistically significant differences.
Pulmonary embolism: GnRH agonist alone HR 2.26 (1.78-2.26);
orchiectomy HR 2.12 (1.44-3.11)
relative risk (95% CI)
ADT without estrogen RR 1.43 (1.78, 7.80, p<0.001) - 10 studies;
estrogen only RR 3.72 (1.78-7.80, p<0.001) - 9 studies. Increased risk of

AMSTAR 2 rating: Moderate

NOS rating: Good

AMSTAR 2 rating: Low

AMSTAR 2 rating: Moderate
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anti-androgen alone,
orchiectomy
Roviello 2018 Italy
(120)

Systematic review
and meta-analysis

Stage: Metastatic CRPCa
Treatment:
Enzalutamide, Abiraterone
acetate + prednisone

11 studies n=11,751 Pooled analysis and
sub analyses to address heterogeneity
Control: placebo, bicalutamide

Alibhai 2015 Canada
(121)

Three-armed
matched cohort
study

Stage: Non-metastatic PCa
Treatment: ADT any

Hussain 2010 Canada
(123)

Matched cohort
study using linked
administration data

Kunath 2015 Germany
(70)

Systematic review
and meta-analysis

Stage: Non-metastatic PCa
Treatment: LHRH
agonists, non- steroidal or
steroidal anti-androgens
alone or in combination &
orchiectomy
Stage: Advanced HSPCa
Treatment: Non- steroidal
anti-androgen monotherapy

n=87, median age 69.8 years
36-month follow-up
Controls: PCa controls (no ADT) n=86,
median age 69.8; healthy controls n=86,
median age 67.8 (2004 – 2007)
n=87, median age 69.8 years
12-month follow-up
Controls: PCa controls (no ADT) n=86,
median age 69.8; healthy controls n=86,
median age 67.8 (2004 – 2007)

Daly (2012) Ireland
(115)

RCT (ICORG 97-01)

Jones (2011) USA
(116)

RCT Radiation
Therapy Oncology
Group (RTOG)

Nead 2017 USA (76)

Systematic review
and meta-analysis

Stage: Localised PCa
Treatment: Neoadjuvant
ADT (NADT) &
Radiotherapy (RT) 4
months (n=109)
Stage: Localised PCa
Treatment:
4 months Neoadjuvant ADT
(NADT) & Radiotherapy
(RT) (n=987)
Stage: Any Treatment:
Primary ADT, anti-

thromboembolic events ADT without estrogen for localised disease RR
1.10 (1.05-1.16, p=<0.001)
ADT duration: >12 months ADT conferred statistically significant
increased risk (RR 1.72 95% CI 1.30-2.28. p<0.001)
relative risk (95% CI)
Any grade of fatigue ranged from 28-47% in experimental group & 844% in control group
Any grade fatigue RR 1.27 (1.13-1.43); grade 3-4 fatigue RR 1.25 (0.921.71)
Sub analyses: pre-chemotherapy fatigue statistically significant RR 1.47
(P=0.09); post chemotherapy no increase in RR; drug type no statistically
significant difference in RR.
Grip strength stable in control groups but declined sharply in ADT group
by 3 months and remained stable to 36 months (P=.0041). TUG scores
declined gradually in ADT group over 36 months; unchanged in control
groups (P=.0008). Aggregate physical QOL declined in ADT users over
time; remained stable in control groups (P=0.0001).
35% of ADT users sustained falls over 12 months prospective follow up vs
18.1% PCa controls & 21.7% healthy controls (P=0.08)

AMSTAR 2 rating: Moderate

NOS rating: Good

NOS rating: Good

Pooled analysis of studies reporting
adverse events: Gynaecomastia 9 studies
n = 2774; Mastalgia 8 studies n=2670;
Vasomotor Flashing 9 studies n = 2774
Control: LHRH agonists or orchiectomy

relative risk (95% CI)
Non-steroidal AA
Significantly higher rates of occurrence for: Mastalgia RR 22.97 (14.7935.67);
Gynaecomastia RR 8.43 (3.19-22.28)
Significantly decreased rates of occurrence for: Vasomotor flashing: RR
0.23 (0.10-0.27)

AMSTAR 2 rating: High

n=276 eligible patients (Feb. 1997-Dec.
2001) Median age 67 years
Median follow-up 80 months
Control: Neoadjuvant ADT (NADT) &
Radiotherapy (RT) 8 months (n=121)
n=1979 eligible patients (1994-2001)
Experimental: RT + ADT (n=987) Median
age 70 years (47-91)
Control: RT alone (n=992) Median age
71 years (47-88)
Median follow-up 9.1 years
Pooled analysis 168,756 total population

No significant difference between 4-month & 8-month NADT arms (48%
vs 61% decrease in sexual potency)
26% men can expect to retain sexual function at 5 years

ROB 2 rating: Some concerns

potency rate
ADT + RT: Baseline 48%; 1 year 21%
RT alone: Baseline 54%; 1 year 31%
(P=0.004)

ROB 2 rating: High

relative risk (95% CI)
Depression RR 1.41 (1.18, 1.70; p<0.001);

AMSTAR 2 rating: Moderate
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androgen, RT/RP + ADT,
orchiectomy

Sun 2018 USA (82)

Systematic review
and meta-analysis

Stage: Any Treatment:
Primary ADT, antiandrogen, RT/RP + ADT,
orchiectomy

Nead 2017 USA (75)

Systematic review
and meta-analysis

Stage: Any ADT, any
LHRHa, continuous LHRHa
+AA
Treatment: ADT &
dementia risk vs a lesser
exposed comparison group
(no ADT, short term ADT,
intermittent ADT)
Stage: Any Treatment:
GnRH agonists, short- &
long-term ADT, active
surveillance

Primary 18 studies meta-analysed
(n=77,017 ADT users);
Sub analyses
Prospective (6 studies), Retrospective (11
studies), cross sectional (1 study)
Control: lesser exposed comparison
group (any ADT vs no ADT, short term
ADT, intermittent ADT)
Pooled analysis in two sub groups –
prospective and retrospective. High
heterogeneity
6 cohort studies n=68,086 (2 prospective;
4 retrospective)
Control: No ADT

Sub analyses
Localised PCa
RR 1.85 (1.20, 2.85; P=0.005)
Studies using clinical diagnosis of depression RR 1.19 (1.08, 1.32,
P=0.001)
No statistically significant differences between IADT & CADT RR 1.00
(0.50, 1.99; P=0.992)
Odds ratio (95% CI)
Prospective:
Cognitive impairment definition-1.5 or more SDs below norms on 2+ tests:
OR 1.56 (0.50, 4.91, p=0.441).
Cognitive impairment definition-2 or more SDs below norms on 2+ tests:
OR 1.75 (0.49, 6.25, p=0.389).
Retrospective:
OR 1.28 (0.93, 1.76, p=0.130)
Dementia
hazard ratio (95% CI)
1. HR 1.47 (1.08-2.00)
2. HR 1.46 (1.05-2.02)
3. HR 1.25 (0.99-1.57)

AMSTAR 2 rating: Low

9 cohort studies n=50,541
AMSTAR 2 rating: Moderate
Primary analysis
1. 6 studies - risk of dementia from ADT;
Sub analyses
2. 5 studies - risk of all cause dementia;
3. 3 studies - Alzheimer’s disease
Control: No ADT, intermittent LHRHa +
AA
McGinty 2014 USA
Systematic review
Pooled meta-analysis across all study
Weighted average effect (95% CI)
AMSTAR 2 rating: Low
(72)
and meta-analysis
designs
visuomotor skills
-0.67 (-1.17, -0.17; P=0.008)
Mean ADT duration: 23 -31 months
Meta-regression indicated that time on ADT was significantly associated
(cross-sectional studies; n=3)
with effect of ADT on visuomotor ability (P=0.04).
ADT duration 1-9 months after ADT
initiation (longitudinal studies; n=11)
Key: BMI body mass index; BMD bone mineral density; RCT randomised controlled trial; LHRH luteinising hormone replacing hormone; GnRH gonadotrophin releasing hormone; AA anti-androgen; RT radiotherapy; RP radical prostatectomy;
M0 non-metastatic; M1 metastatic; IADT intermittent androgen deprivation therapy; CADT continuous androgen deprivation therapy; HSPCa hormone sensitive prostate cancer; CRPCa castrate resistant prostate cancer; mCRPCa metastatic
castrate resistant prostate cancer; MI myocardial infarction; IHD ischaemic heart disease; CV cardiovascular; CVD cardiovascular disease; CVM cardiovascular mortality; TUG timed up & go; aHR adjusted hazard ratio; HR hazard ratio; RR
relative risk; OR odds ratio; SD standard deviation; AMSTAR 2 tool for assessing the methodological quality of systematic reviews version 2; ROB 2 risk of bias instrument version 2; NOS Newcastle Ottawa Scale to assess quality of
observational studies.
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Appendix 3 Quality assessment tools (Chapter 2)
AMSTAR 2 Critical appraisal tool for systematic reviews
PICO Y/N

Protocol
Partial Y/Y/No

Choice of study designs Y/N

Comp. literature search Partial Y/Y/N

Duplicate study selection
& consensus Y/N

Duplicate data extraction Y/N

Exclusions list with reasons PY/Y/N

Adequate study detail PY/Y/N

Satisfactory RoB -RCTs PY/Y/N/only NRSI

Satisfactory RoB -NRSI PY/Y/N/ only RCTs

Sources of funding reported for included
studies Y/N

Appropriate meta-analysis RCTs Y/N No
meta-analysis

Appropriate meta-analysis NRSI Y/N No
meta-analysis

Impact of RoB on results of evidence
synthesis Y/N/No meta-analysis

Individual study RoB accounted for in results
of review Y/N

Heterogeneity addressed Y/N

Impact of publication bias on results of review
Y/N/No meta-analysis

Sources of conflict reported Y/N

Confidence in overall results of review rating

N
Y
PY
PY
N
PY
PY
PY
N
Y
PY
N
N
Y

N
N
Y
N
Y
N
N
Y
N
Y
N
N
Y
Y

Y
Y
Y
Y
Y
Y
Y
Y
PY
Y
PY
PY
PY
Y

Y
Y
N
Y
N
N
Y
N
N
Y
Y
Y
Y
Y

Y
Y
N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

PY
PY
PY
Y
PY
N
PY
PY
N
PY
Y
N
N
N

Y
Y
Y
Y
Y
PY
Y
Y
Y
Y
Y
Y
Y
Y

N
NRSI
NRSI
NRSI
NRSI
Y
Y
NRSI
Y
Y
Y
N
N
Y

N
Y
Y
Y
Y
RCT
RCT
Y
RCT
Y
Y
RCT
RCT
RCT

N
N
N
Y
Y
N
N
N
N
N
N
N
N
N

N
NRSI
NRSI
NRSI
NRSI
Y
Y
NRSI
Y
Y
Y
No Met
Y
Y

N
Y
Y
Y
Y
RCT
RCT
Y
RCT
Y
Y
RCT
RCT
RCT

N
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
N
N
Y

N
Y
Y
Y
Y
Y
Y
Y
N
Y
Y
N
N
Y

PY
Y
Y
Y
Y
Y
N
Y
Y
Y
Y
N
Y
Y

Y
N
N
Y
Y
Y
Y
Y
Y
Y
Y
No Met
N
Y

N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

low
low
low
high
mod
mod
mod
mod
low
high
mod
low
low
high
Haseen 2010
Kim 2019
Bosco 2015a
Wang 2016
Bosco 2015
Jin 2016
Magnan 2015
Zhao 2014
Nguyen 2011
Scailteux 2016
Meng 2016
Spratt 2018
Sciarra 2016
Rydzewska 2017

Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y
Systematic
Review
First author, year

RESULT
16
15
14
11ii

12

13
11i
10
9ii
9i
8
7
6
5
4
3
2
1
AMSTAR 2
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Iacovelli 2018
Roviello 2016
Zhu 2018
Guo 2018
Nead 2018
Roviello 2018
Kunath 2015
Nead 2017
Sun 2018
Nead 2017a
McGinty 2014

N
Y
Y
Y
Y
Y
Y
Y
Y
Y
Y

Y
Y
PY
PY
PY
PY
PY
PY
Y
PY
PY

N
Y
N
N
Y
Y
Y
N
Y
N
Y
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Y
Y
PY
Y
Y
Y
Y
Y

Y
Y
Y
NRSI
NRSI
Y
Y
NRSI
NRSI
NRSI
NRSI

RCT
RCT
RCT
Y
Y
RCT
RCT
Y
PY
Y
N

Abbreviations: Y yes, PY; partial yes; N no; RCT randomised controlled trial; NRSI non-randomised study of intervention; Met meta-analysis
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high
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Risk of Bias (ROB 2) tool for RCTs
Risk of Bias
Domain

Randomisation process

First Author
Year

Deviations from
intended intervention
(effect of adhering to
intervention)

Missing outcome data

Measurement of
outcome

Selection of reported
result

Daly 2012

High

Low

Low

Low

Low

Graff 2016

Low

Low

Low

Low

Low

Jones 2011

Low

High

Low

High

Low

Smith 2018

Low

Low

Low

Low

Low

Risk of Bias judgement

Low - However some concerns
regarding conflicts of interest on
the part of some authors with
pharmaceutical companies
Low - However, some regarding
authors who have conflicts of
interest with pharmaceutical
companies in the form of funding,
honorariums, consultancy,
employment, speaker fees, etc.
High – two authors had conflicts of
interest with pharmaceutical
companies as advisors, recipients
of speaking fees, etc.
Low - However potential conflicts of
interest for a number of authors
with pharmaceutical companies
(employees, recipients of funding,
honorariums, travel grants, etc.)
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Newcastle-Ottawa Scale for Cohort Studies
Selection -1 Representativeness
exposed cohort (maximum 1 star)

Selection -2 Non-exposed cohort
(maximum 1 star)

Selection -3 Ascertainment of
exposure
(maximum 1 star)

Selection - 4 Outcome of interest
not present at start of study
(maximum 1 star)

Comparability cohorts by design
or control for confounders
(Maximum 2 stars based on factors
controlled for)

Outcome -1 Assessment
(maximum 1 star)

Outcome - 2
Length of follow-up
(maximum 1 star)

Outcome - 3 Adequacy of follow-up
(maximum 1 star)

Score
(Good, Fair, Poor)

*
*
*
*
*
*
*
*
*
*

*
*
*
*
*
*
*
*
*
*

*
*
*
*
*
*
*
*
*
*

*
**
**
**
**
**
**
**
**
*

*
*
*
*
*
*
*
*
*
*

*
*
*
*
*
*
*
*
*
*

*
*
*
*
*
*
*
*

Good
Good
Good
Good
Good
Good
Good
Good
Good
Good
Ng 2018
Shao 2013
Alibhai 2010
Wallis 2016
Sun 2016
Beebe-Dimmer 2012
Tsai 2017
Gild 2018
Alibhai 2015
Hussain 2010

*
*
*
*
*
*
*
*
*
*

First Author year
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Appendix 4: Sensitivity and scenario analyses (Chapter 6)
Test to be modelled
Sensitivity analyses (SA)
SA1: Variation in the magnitude of effect size
using the upper and lower confidence interval
limits
SA2: Societal perspective based on patient
out-of-pocket costs

SA3: Variation in the intervention cost/
number of participants
SA4: Maintenance of HRQoL outcomes after
the 6-month home-based exercise program

Detailed assumptions

Justification

Assumes benefit of the intervention varies between the
calculated confidence interval of the effect size in all outcome
measures.
In order to participate in the exercise intervention, participants
would need to access an exercise facility and thus have a
membership. They would also need to travel to exercise
facility. No productivity losses included due to mean age of
population (72 years); only seven participants in sample
engaged in employment - 4 part time & 3 full time).
Variation in number of participants attending one session –
more people reduces cost
Maintenance of benefit beyond the supervised intervention
based on evidence in the literature1.

Plausible variation in effect size.

Scenario analyses (S) (healthcare perspective)
S1 Scalability of intervention
MBS AEP item numbers and admin staff wages used to scale
to a community-based intervention; increasing participants per
session and reducing implementation costs.
S2 Private cancer clinic located in multiple
Use of in-house exercise clinic included as part of the business
locations provide access to exercise clinic &
model (Team care arrangements provided as part of Chronic
AEP.
Disease Management Plan [CDMP] – 1 GP, 1 consulting
physician + allied health practitioners [AEP](MBS item 10953))
(MBS items 721 & 723). Exercise equipment & maintenance
included as opportunity cost in payment to cancer clinic as part
of patient fees.

Plausible costs incurred by participants.
Societal perspective not included as a base case due to lack of data
regarding societal benefits.

Plausible variation in cost when more participants can attend one
session
Plausible maintenance of HRQoL based on follow-up data after 6month home-based intervention immediately following 6-month
supervised program.
Plausible variation in cost, particularly if run as a community/clinical
intervention, with set time frames.
Potential alternative model of care. Cost reallocation that impacts on
uptake & attendance, improving impact & reducing overheads. Patients
more likely to attend if little perceivable added cost burden, co-located
with oncology services, quieter, more personal space shared with
people in similar circumstances2,3. Private cancer clinics are currently
operating using this model, where exercise clinic costs are absorbed
as part of a business model designed to improve market share.

Abbreviations: SA sensitivity analysis; S scenario analysis; GP general practitioner; MBS Medicare benefits schedule; PCa prostate cancer; AEP accredited exercise physiologist; CDMP chronic disease management plan
Notes: 1Henderson, RM, Miller, ME, Fielding, RA, Gill, TM, Glynn, NW et al. Maintenance of physical function 1 year after exercise intervention in at-risk older adults: Follow-up from the LIFE study. Journals of Gerontology: Medical Sciences.
2018, 73(5):688-95.
2Cormie P, Oliffe JL, Wootten AC, Galvão DA, Newton RU, Chambers SK. Improving psychosocial health in men with prostate cancer through an intervention that reinforces masculine values – exercise. Psycho-Oncology. 2016; 25:232-5.
3Cormie P, Turner B, Kaczmarek E, Drake D, Chambers SK. A qualitative exploration of the experience of men with prostate cancer involved in supervised exercise programs. Oncol Nurs Forum. 2015;42(1):24-32.
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Appendix 5 Supplementary Information (Chapter 7)
Supplementary file 1 Cost of exercise intervention (AU$2019)
Intervention cost
component
GP consent

Cost description

Unit of measure

MBS Item 23: Level B GP consultation
lasting less than 20 minutes (2019)
Clerks private sector award 2010 level
3 $911/week ($23.97/hour) + 20% on
costs (2019)
MBS Item no. 81115

1 consultation ($38.20)

Registration of
intervention participants
& administration
AEP pre-program
consultation
Subtotal
50-week exercise
1-hour exercise session AEP MBS Item
intervention
no. 10932
Total per participant (healthcare perspective)

Cost per
participant
$38

30 mins clerk time +
phone calls

$15

1 consultation

$81
$134
$633

Up to 10 participants per
session

$767

Abbreviations: GP general practitioner; MBS Medicare benefits schedule; RCT randomised controlled trial; AEP accredited exercise physiologist

Supplementary file 2 Univariate sensitivity analysis

Variable

Strategy

Cost

Base C_exercise
$767 Base - 12mos AEP
(MBS no. 10953)-health
service
SA1a C_exercise
$1917 Base - 12mos AEP
(MBS no. 10953)-part societal

Exercise
intervention
(10 persons)

$2,952

Exercise
intervention
(10 persons) +
OOP costs
Exercise
intervention (6
persons)
Exercise
intervention (6
persons) +
OOP costs
Exercise
intervention
6mos + 6mos
home-based
(10 persons)
Exercise
intervention
6mos + 6mos
+ OOP costs
(10 persons)
Exercise
intervention
diabetes (10
persons)
Exercise
intervention
diabetes +

SA2 C_exercise
$1188 - 12mos AEP
(MBS no. 10953)-health
service
SA2a C_exercise
$2338 - 12mos AEP
(MBS no. 10953)-part societal
SA3 C_exercise
$450 6mos AEP
(MBS no. 10953) + 6mos
home-based-health service
SA3a C_exercise
$709 - 6mos AEP
(MBS no. 10953) + 6mos
home-based-part societal
SA4 C_exercise
$2154 12mos AEP group
diabetes (MBS no. 81110)health service
SA4a C_exercise
$3304 12mos AEP group
diabetes (MBS no. 81110)-part
societal

Effectiveness ICER
(QALYs)

NMB

C/E

2.10

Cost
saving

$102,112

1.40K

$4,102

2.10

Cost
saving

$100,962

1.95K

$3,373

2.10

Cost
saving

$101,691

1.61K

$4,523

2.10

10.61K

$99,101

2.00K

$2,635

2.10

Cost
saving

$102,429

1.25K

$2,894

2.10

Cost
saving

$101,691

1.38K

$4,339

2.10

5.58K

$100,725

2.06K

$5,489

2.10

37.05K

$99,575

2.61K
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OOP costs (10
persons)
SA5 C_majfracture
Mean -50% +50% ($10K-$30K)
SA6-C_mininjury
Mean -50% +50% ($0.55K$1.65K)
SA7 P_Risk_Fall_Reduction
Mean -0.2 +0.2 (RR 0.56-0.96)
SA8
P_Risk_Fracture_Reduction
Mean -0.2 +0.2 (RR 0.24-0.64)
SA9 P_firstfall
Mean -/+50% (0.0525-0.1575)
SA10 P_recurfall
Mean -/+50% (0.1145-0.3435)
SA11-P_fracture
Mean -/+50% (0.06-0.18)
SA12 U_atriskfall
Mean -0.1 QALY +0.1 QALY
(0.69-0.89)
SA13 StartingAge
Mean -8 yrs +8 yrs (60-76)
SA14 Time horizon (total
cycles) 6 yrs (24)

Exercise
intervention
(10 persons)
Exercise
intervention
(10 persons)
Exercise
intervention
(10 persons)
Exercise
intervention
(10 persons)
Exercise
intervention
(10 persons)
Exercise
intervention
(10 persons)
Exercise
intervention
(10 persons)
Exercise
intervention
(10 persons)
Exercise
intervention
(10 persons)
Exercise
intervention
(10 persons)

$2,631
$3,230

2.10

Cost
saving

$102,433
$101,834

1.25K
1.54K

$2,470
$3,409

2.10

Cost
saving

$102,594
$101,655

1.18K
1.62K

$2,338
$3,571

2.11
2.09

Cost
saving

$103,391
$100,896

1.11K
1.71K

$2,630
$3,274

2.10

Cost
saving

$102,504
$101,720

1.25K
1.56K

$2,031
$3,615

2.13
2.08

Cost
saving

$104,271
$100,552

0.96K
1.74K

$2,530
$3,326

2.10
2.08

Cost
saving

$102,692
$101,600

1.20K
1.58K

$2,608
$3,337

2.10

Cost
saving

$102,530
$101,643

1.24K
1.59K

$2952

1.93
2.28

Cost
saving

$ 93,329
$110,894

1.53K
1.30K

$2976
$2911

2.12
2.06

Cost
saving

$103,145
$100,335

1.40K
1.41K

$5600

3.78

Cost
saving

$183,647

1.48K

Abbreviations: QALYs quality adjusted life years ICER incremental cost-effectiveness ratio NMB net monetary benefit C/E cost divided by effect
SA-C sensitivity analysis cost SA-P sensitivity analysis probability SA-U sensitivity analysis utility yrs years
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